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ABSTRACT
S-nitrosothiols are effective NO-donating drugs which can elicit vasodilation of 
vascular tissue and disaggregate or inhibit the aggregation of platelets in blood. The 
chemistries of two S-nitrosothiols, S-nitroso-N-acetyl-DL-penicillamine (SNAP) and 
S-nitrosoglutathione (GSNO) have been investigated in an attempt to identify the 
chemical and physiological mechanisms which underlie their biological actions as 
vasodilators and modulators of platelet behaviour. Although SNAP and GSNO have 
been found to be susceptible to decomposition by similar chemical mechanisms, such 
as by thermal and photochemical means, evidence is presented to suggest that they are 
both capable of NO transfer to other thiol containing compounds such as cysteine. This 
produces a very unstable S-nitrosothiol, S-nitrosocysteine, which readily produces 
NO. However, they can both be decomposed by different, distinctive mechanisms.
Metal ion catalysis by copper is shown to greatly accelerate the decomposition of 
SNAP, but has little effect on GSNO. Instead, NO release from GSNO is effected by 
enzymatic cleavage of the glutamyl-cysteinyl peptide bond by the enzyme y-glutamyl 
transpeptidase (y-GT). The resulting S-nitrosothiol, S-nitrosocysteinylglycine, would 
be expected to be more susceptible to release of NO by metal (copper) ion catalysis.
It is concluded that transnitrosation (NO-transfer) between thiol groups, or enzymatic 
cleavage are obligatory steps in the mechanism of NO release from GSNO, whereas 
SNAP requires only the presence of trace amounts of metal ions like copper to effect 
this process. The different modes of NO production may go some way towards 
explaining the different physiological effectiveness of these S-nitrosothiols as 
vasodilators and inhibitors of platelet aggregation.
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ABBREVIATIONS
The following abbreviations are used in the text and are defined on initial use. The 
following list is for ease of reference.
Oxides o f Nitrogen 
NO 
N0+
NO-
NO2"
NO3-
NO2
N2O3
Nitric oxide 
Nitrosonium ion 
Nitroxide ion 
Nitrite 
Nitrate
Nitrogen dioxide 
Dinitrogen trioxide
SNAP S-Nitroso-N-acetyl-DL-penicillamine
NAP N-acetyl-DL-penicillamine
(NAP-)2 N-acetyl-DL-penichlamine disulphide
SNFP S-Nitroso-N-formyl-DL-penicülamine
SNpen S-Nitroso-DL-peniciUamine
GSNO S-Nitrosoglutathione
SNAG S-Nitroso-N-acetylglutathione
SNFG S-Nitroso-N-formylglutathione
SNC S-Nitroso-DL-cysteine
SNAC S-Nitroso-N-acetyl-DL-cysteine
SNBC S-Nitroso-N-Boc cysteine
SNP Sodium nitroprusside
ISMN Isosorbide-5-mononitrate
RBS Roussins Black Salt
GTN Glycerol trinitrate
PE Phenylephrine
oxyHb Oxyhaemoglobin
metHb Methaemoglobin
Hb Ferro-haemoglobin
SOD Superoxide Dismutase
Cys Cysteine
EDTA Ethylenediaminetetraacetic acid, disodium salt dihydrate
EA Ethacrynic Acid
V I
ACh
DMGA
CD
Acetylcholine 
Dimethylglutaric acid 
Cyclodextrm
Biologically-Derived
EDRF
AA
PGI2
t-PA
O2-
H 2O2
OH
ONOO-
ACE
NANC
FAD
FMN
NADPH
BH4
cGMP
cAMP
ADP
ATP
GTP
Compounds
Endothelium-derived relaxing factor
Arachidonic acid
Prostacyclin
Tissue-type plasminogen activator
Superoxide anions
Hydrogen peroxide
Hydroxyl radical
Peroxynitrite anion
Angiotensin converting enzyme
Non-adrenergic, non-cholinergic
Flavin adenine dinucleotide
Flavin mononucleotide
Nicotinamide adenine dinucleotide phosphate
Tetrahydrobiopterin
Cyclic guanosine monophosphate
Cyclic adenosine monophosphate
Adenosine diphosphate
Adenosine triphosphate
Guanosine triphosphate
NO-Synthase Inhibitors 
L-NMMA 
L-NNA 
L-NAME 
L-NIO 
D-ADMA
N® monomethyl-L-arginine 
N® nitro-L-arginine 
N® nitro-L-arginine methyl ester 
N® iminoethyl-L-ornithine 
N® N® dimethyl-L-arginine
NO-Synthases
iNOS
eNOS
nNOS
Inducible NO synthase 
Endothelial NO synthase 
Neuronal NO synthase
Analytical Techniques 
HPLC High Performance Liquid Chromatography
V I I
GCMS
GCIRMS
CZE
ESR
Gas chromatography mass spectrometry 
Gas chromatography combustion isotope mass spec. 
Capillary zone electrophoresis 
Electron spin resonance
Miscellaneous
PRP
WP
LL
PNS
E D 50
IC50
Platelet rich plasma 
Washed platelet suspensions 
Luciferin-Luciferase 
Peripheral nervous system 
Equivalent dose for 50% response 
Concentration required to inhibit by 50%
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CHAPTER 1 
INTRODUCTION
1.1 BACKGROUND
The demonstration in 1987 (Palmer et al.) that formation of nitric oxide (NO) from 
vascular endothelial cells accounted for the physiological effect of the endothelial 
derived relaxing factor (EDRF), as described by Furchgott and Zawadzki in 1980, has 
resulted in a dramatic escalation of research into the biological roles of this 'gaseous' 
messenger molecule. It has become a rapidly growing area of biological research, and 
one in which the established modes of action of biological messengers are challenged. 
Its trafficking is independent of specific transporters or channels used by other chemical 
messengers. Instead, NO appears to diffuse freely in all directions from its site of 
origin (Moncada & Leone et al., 1994, unpublished pictures), making control of its 
synthesis the key to regulating its activity. Due to its small size, its radical nature and 
its diffusibility, NO more than any other biological messenger depends on its chemical 
properties, rather than its molecular shape to govern its biological action.
This inorganic gas is synthesised by a wide variety of animals ranging from barnacles, 
fruit flies and blood sucking insects, to horse shoe crabs, chickens, trout and humans 
(Feldman et al., 1993a, Moncada et al., 1993).
The discovery of NO as a biological mediator resulted from years of intense research on 
the functional significance of the endothelium, a monolayer of cells which lines the 
lumen wall of blood vessels throughout the vascular network. These unique cells play 
a crucial role in the contioi of local blood pressure and blood platelet adhesion and 
aggregation. An important breakthrough came with the discovery that prostacyclin 
(POl2 ), a prostaglandin synthesised from arachidonic acid (AA), was released by 
endothelial cells and acted as a vasodilator of certain tissues and an anti-aggregating 
agent (Moncada et al., 1976). It became clear that this was one of a plethora of 
biologically active substances that are synthesised in, and released from, vascular 
endothelial cells. Prostacyclin, a peptide (tissue-type plasminogen activator (t-PA),
Collen et a i, 1986) and more importantly EDRF constitute the most eminent triad of 
these.
1.2 THE DISCOVERY OF ENDOTHELIUM DERIVED RELAXING
FACTOR
In 1980 Furchgott and his co-workers investigating the effect of acetylcholine (ACh) on 
rabbit aorta showed that different responses were obtained when the endothelial cell 
layer was present or removed. They showed that precontracted aortic rings relaxed on 
exposure to ACh when the endothelium was intact, but failed to relax (or even 
contracted) when it was removed. They concluded that there was an 'endothelium 
derived relaxing factor' produced by ACh which was then termed an endothelium 
dependent vasodilator. Many other endothelium dependent vasodilators have since 
been identified including bradykinin, histamine, calcium ionophore A23187, substance 
P, thrombin and adenine nucleotides (for review see Furchgott, 1984).
Endothelium dependent relaxations have also been found to be elicited by changes in 
the physical nature of the blood vessels such as hypoxia, electrical stimulation and 
changes in 'shear stress' resulting from increased luminal flow (Furchgott, 1984; 
Moncada et al., 1986a; Busse et a l, 1985).
1.3 PROPERTIES OF EDRF
The humoral nature of EDRF was first demonstrated using a variety of pharmacological 
preparations based on a donor-detector bioassay in which the biologically active 
substance is transferred. One such anangement designed by Furchgott used an aortic 
strip with an intact endothelium as the donor 'sandwiched' against a similar strip 
without its endothelium acting as the detector (intimai surface facing intimai surface) 
(Furchgott & Zawadski, 1980). Other workers used a similar principle in their
systems, one of which involved perfusing the lumen of an isolated intact rabbit aorta 
and using the effluent to superfuse endothelium denuded vascular rings (Griffith et ai, 
1984; Rubanyi et a i, 1985). Stimulation of the donor aorta with ACh caused 
relaxation of the detector tissue.
It was later shown that endothelial cells cultured on microcarriers packed in 
chromatography columns were capable of bradykinin-stimulated relaxation of detector 
tissues when superfused with the column effluent (Cocks et ai, 1985; Gryglewski et 
al., 1986a).
Bioassay systems such as these allowed the chemical and biological characteristics of 
the EDRF to be investigated. The short half life of EDRF in physiological solutions 
was the first property to be noticed and subsequently investigated. Cocks et a i (1985) 
and Griffith et a i (1984) claimed that the half-life of EDRF was a matter of seconds, 
and Griffith along with other researchers showed that it could be released under basal 
conditions as well as after stimulation by ACh (Griffith et a i, 1984; Rubanyi et a i, 
1985; Martin et a i, ,1985). Other properties of EDRF were shown to include 
inhibition of its biological effects by haemoglobin and methylene blue (Martin et a i, 
1985), as well as dithiothreitol and hydroquinone (Griffith et a i, 1984). It was also 
demonstrated that the effect of EDRF was mediated by stimulation of soluble guanylate 
cyclase in vascular smooth muscle, resulting in the elevation of intracellular cyclic GMP 
(but not cAMP) levels (Rapoport & Murad, 1983a). Superoxide anions (02") were 
shown to have a dramatic effect on the biological half life of EDRF, as superoxide 
dismutase (SOD), the endogenous enzyme which scavenges O2" ions, converting them 
to H2O2, substantially stabilised EDRF (Rubanyi & Vanhoutte, 1986). Subsequent 
work by Moncada et a i  (1986b) showed that certain inhibitors of EDRF acted by 
generating O2" in solution as a result of their redox properties and more recent work 
has shown that haemoglobin and methylene blue inhibit EDRF, at least in part, by this 
process (Steele et ai, 1991; Marczin et ai, 1992). However, the main cause of EDRF
inhibition by haemoglobin is attributed to its ability to bind EDRF (Maitin et a l 1985; 
Hutchinson et a i, 1987).
Armed with these observations regarding the properties of EDRF, Furchgott (1988) 
and Ignarro (1987) both proposed at the same conference, that it could be NO or a 
closely related compound. It was only a few months later that Palmer^ Ferrige and 
Moncada (1987) provided crucial evidence strongly supporting the theory that EDRF 
was indeed NO, using the reaction between NO and ozone (O3 ) to yield a 
chemiluminescent product (Downes et al., 1976). They showed that bradykinin was 
capable of generating enough NO from cultured endothelial cells to account for the 
physiological effects of EDRF and in comparative experiments using a cascade system, 
demonstrated that NO and EDRF had very similar biological properties. In subsequent 
experiments, NO was also shown to be susceptible to the same inhibitors as EDRF 
(Fe^+, methylene blue, other redox reagents and haemoglobin) and its half-life was 
prolonged by agents such as SOD and cytochiome C (which oxidises 02“ to O2). Like 
EDRF, NO also elevated intracellular cGMP levels mediated by stimulation of 
guanylate cyclase.
In addition, an intensive study by Radomski and co-workers showed that EDRF and 
NO inhibited blood platelet aggregation (1987a), caused disaggregation of aggregated 
platelets (1987b) and also inhibited platelet adhesion to endothelial monolayers 
(1987c&d). Radomski also showed that there was synergistic activity between EDRF 
and prostacyclin (PGI2) in the inhibition of platelet aggregation (Radomski et 
fl/.,1987a&b).
1.4 THE CHEMICAL IDENTITY OF EDRF
The evidence for EDRF being NO is compelling, but not conclusive and this has been 
an issue of intense speculation and controversy. The main argument surrounds the
wide variation in half-life of EDRF (from 3 to 50s, Palmer et al, 1987; Griffith et al., 
1984; Forstermann et al., 1984; Cocks et a i, 1985; Rubanyi et al., 1985; Gryglewski 
et al., 1986b; Ignarro et al., 1987), although this discrepancy is thought to be due to 
differing experimental conditions with regard to relative 0 %" and 0 % concentrations. 
Other points of contention are: differential binding of EDRF and NO to anion exchange 
columns; differential activity of EDRF and NO on smooth muscle preparations and 
poor correlation between biological activity and amounts of NO detectable by chemical 
methods (Cocks et al., 1985; Myers et al., 1990; Long et a i, 1987). Most of these 
factors can be explained by the different experimental methodologies implemented and 
side reactions of NO in the 'artificial' surroundings that these methodologies employ. 
For instance, in experiments using anion exchange columns (Cocks et al., 1985; Long 
et a i, 1987;), EDRF has been reported to bind to columns, whereas NO (which is not 
anionic) binds to a lesser extent (Khan et al., 1987). It is possible that EDRF 
undergoes a reaction with amines when passing down the column as NO is known to 
be a nitrosating agent under certain conditions (Williams et al., 1985). Also, the 
response of the bioassay tissues to bolus administration of an agonist differs 
quantitatively from that to an infusion, therefore the comparison between NO released 
from cells or tissues and bolus injections of NO may be misleading.
Evidence from electron paramagnetic resonance (EPR) studies also raises a question 
mark concerning the exact identity of EDRF, since NO, but not EDRF, can form 
paramagnetic nitrosyl-haem (Greenberg & Rubanyi et al., 1990). It has been proposed 
that an S-nitrosothiol, such as S-nitrosocysteine, more closely mimicks EDRF than NO 
(Rubanyi et al., 1991; Myers et al., 1990). Further experiments showed that like 
EDRF, S-nitrosocysteine did not produce an EPR signal of nitrosyl-haem when a 
solution of the nitrosothiol is passed down a reduced haemoglobin-agarose column 
(Rubanyi et al., 1991). Furthermore, in concentrations necessary to produce vascular 
relaxation, S-nitrosocysteine did not spontaneously release NO (Rubanyi et al., 1991). 
Further (indirect) evidence supporting the theory that an S-nitrosothiol could be EDRF
is provided by bradykinin-induced ^5s efflux studies using endothelial cells previously 
loaded with cysteine containing the isotope. This experiment showed a similar time 
course of EDRF release and suggested that EDRF carried the label. More recent 
work by Fukuto et ai, (1992b) has proposed a possible role of nitroxyl (HNO) as 
having similar biological activity to EDRF and NO. Hydroxyguanidines, one of 
which, N®-hydroxyarginine, is a biosynthetic intermediate in the endogenous 
enzymatic production of NO (see section 1.3), have been shown to generate NO or 
nitroxyl (Fukuto gf a/., 1992a).
It has also been postulated that there is more than one EDRF (De Mey et a i, 1982) and 
the existence of mechanisms other than NO synthesis which play a role in endothelium- 
dependent relaxations cannot be excluded. For example, stimulation of the endothelium 
of some arteries by ACh or histamine results in hyperpolarisation of the adjacent 
smooth muscle cells which contributes to their relaxation and this has been attributed to 
the release of a factor, termed endothelium derived hyperpolarising factor. (Feletou et 
ai, 1988; Chen et a i, 1989; Taylor et al., 1988). The existence of other endothelium- 
dependent vasodilator mechanisms would not be suprising, because mechanisms 
subserving a biological function are usually multiple. It is important to stress however, 
that endothelium-dependent relaxations susceptible to inhibition by haemoglobin and 
methylene blue, which indicate the involvement of NO and cyclic GMP, have been 
demonstrated in many different vascular preparations, whereas evidence for other 
mechanisms is scant. Furthermore, a recent work by Feelisch and Moncada sides 
heavily with the view that NO is the EDRF (Feelisch & Moncada et al., 1994). Using a 
bioassay cascade, comprising three precontracted de-endothelialised rabbit aortic strips, 
and infusing cysteine over the detector tissues they found that only NO and EDRF had 
analogous vasodilator profiles unlike all the other possible EDRF candidates examined.
The underlying problem when trying to identify the nature of EDRF as NO, which is 
evident from most of the studies conducted, is the determination of what happens to it
between its production and release from the endothelium and its stimulation of 
guanylate cyclase. This could involve a number of chemical reactions to allow its 
transport to the active site of guanylate cyclase, or this whole process could be 
conducted by simple diffusion of NO. Whatever the exact chemical nature of EDRF 
and the way by which it is transported, it is generally agreed that its actions are 
mediated ultimately by NO.
1.5 SYNTHESIS OF EDRF
The enzymes responsible for the synthesis of NO from L-arginine in mammalian 
tissues are known as NO synthases. These enzymes are remarkable for three different 
reasons: the rapidity with which they have been characterised, purified and cloned 
(first described in 1989, Palmer et al.\ first purified in 1990, Bredt et al.; and first 
cloned in 1991, Bredt et al.); the complexity and number of reactions carried out by a 
medium-sized subunit of 125-155 KDa (probably as a homodimer) to produce EDRF; 
and for the number and range of physiological and pathological roles in which they are 
involved (Moncada et al., 1991).
The first description of NO synthases demonstrated that the synthesis of EDRF 
required L-arginine. Mass spectiometry studies showed that ^^NO was produced when 
endothelial cells containing labelled L-arginine (on the terminal guanidino nitrogen 
atom(s)) were stimulated by bradykinin (Palmer et al., 1988a&b).
Two distinct types of NO synthase have been purified; a constitutive, Ca^’^ /calmodulin 
dependent enzyme (Bredt et al„ 1990; Mayer et al., 1989) first shown to be present in 
endothelial and brain cells (Palmer et al., 1989; Garthwaite et al., 1989); and an 
inducible Ca2'+ independent enzyme initially found in macrophages (Stuehr et al., 
1989). Both enzymes are flavoproteins containing bound flavin mononucleotide 
(FMN) and flavin adenine dinucleotide (FAD) (Mayer et al., 1991; Stuehr et al., 1991;
Yui et a i, 1991). Furtheniiore they are both dependent on an e" donor, nicotinamide 
adenine dinucleotide phosphate (NADPH; Moncada and Palmer, 1990; Palmer et a i, 
1989; Bredt et al,, 1990) as a cofactor and tetrahydrobiopterin (BH4) which enhances 
the enzymes activity and may stabilise or help assemble the active enzyme (Mayer et al., 
1991; Yui era/., 1991).
Subsequent work on the mechanism of NO production from L-arginine by NO 
synthases demonstrated that molecular oxygen is also a substrate, being incorporated 
into both NO and citrulline (Kwon et al., 1990, Leone et al., 1991). This discovery 
has shed some light on the mechanism, which appears to involve 2 separate mono­
oxygenation steps with N ^ -hydroxyai’ginine as an intermediate species formed by a 
reaction requiring one O2 and one NADPH molecule (Leone et al., 1991) and the 
presence of tetrahydrobiopterin (BH4). The second step in the mechanism appears to 
result in the oxidation of N®-hydroxyarginine to fonu citrulline and NO (Figure 1.1). 
The detailed mechanism of this reaction remains to be determined.
The NO synthase enzymes have close homology with Bacillus megaterium cytochrome 
P-450bM-3- The presence of FMN and FAD (see Figure 1.1), the striking sequence 
similarity with cytochrome P-450 reductase (Bredt et al., 1991) and the presence of a 
haem centre, which exhibits similar spectral properties (Stuehr et a i, 1992a; White et 
al., 1992) infer that NO synthase is the first self-sufficient mammalian P-450 enzyme 
to be identified.
There are at least 6 isoforms of NO synthase which have been purified (Table 1.1) 
based on 3 isoenzymes: nNOS originally identified as constitutive in neuronal tissue 
synthesising NO in response to glutamate; eNOS originally identified as constitutive in 
vascular endothelial cells synthesising NO in response to ACh; and iNOS originally 
identified as inducible by cytokines in macrophages and hepatocytes.
L-arginine + 0%NADPH
L-ci(rulUne + N©*NADP+
reductase domain
Fig 1,1 (inset) Schematic view of NOS
haem domain
ÇO2
,N.©  . N B
NADPH+ H
NADPL-Arginine
BB
BH
ÇQ
FAD Cytochrome 
FMN -  P450 N“~Hydroxyarginine NH<Q)H
0=01/2 NADP
CO2
NH
L-Citrulline
Figure 1,1 The proposed NO synthase reaction (adapted from Knowles & Moncada^ 1994; 
Marietta, 1993)Jn brain NO synthase the flavin coenzymes have been shown to be involved 
in the production o f NO & citrulline from hydroxyarginine with analogy to cytochrome P450 
reductase enzymes.
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Type/source Type Cell type Ca2+- CaM- Constitutive Cytosolic/
isoenzyme dependent dependent particulate
Constit.VascularEndothelial eNOS
Platelets,Endothelium Yes Yes Yes Both
Constit.nepronal nNOS cerebellum,NANOnerves. Yes Yes Yes Cytosolic
Macrophage iNOS immune cell. VSM, endothelial, Kupfer,
No No No Cytosolic
Liver iNOS hepatocytes No Yes/No No Cytosolic
Rabbitchondrocyte iNOS Yes No No Cytosolic
Humanchondrocyte iNOS No No No Cytosolic
Table 1.1 Isoforms o f NO synthase (adapted from Knowles & Moncada, 1994). All 
isoforms use L-arginine as a substrate and are inhibited by LNMMA and LNIO (see 
section 1.6). CaM-dependent -  calmodulin dependent.
1.6 INHIBITORS OF NO SYNTHESIS
The study of NO synthesis in mammalian systems has been aided by the early 
identification of competitive inhibitors of NO synthase. Palmer and coworkers (1988a) 
discovered that N® monomethyl-L-ai'ginine (L-NMMA) was a substrate-competitive 
inhibitor, and it has since been shown that it inhibits all NO synthases so far examined 
with a Ki of -ImM. This inhibition is enantiomer-specific. In the vasculature, the 
diminished blood flow resulting from administration of L-NMMA shown by infusion 
into the human brachial ai tery, (Vallance et al. y 1989) confirmed the proposal that NO 
is the endogenous vasodilator responsible for maintaining a 'dilator tone’ of vessels 
(Moncada etal.y 1991).
L-NMMA and asymmetric N®-N®-dimethyl-L-arginine (L-ADMA), another NO 
synthase inhibitor, are both naturally occuring compounds (Vallance et al.y 1992) that 
can be derived from methylated protein arginine residues during protein turnover.
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However, symmetrical N®-N®-dimethylarginine, which is present in the same 
concentration as L-ADMA, is not an inhibitor of NO-synthase. Normally the 
concentrations of these compounds are low (ImM), but with patients suffering from 
renal failure L-NMMA and L-ADMA accumulate in sufficient quantities to inhibit NO 
synthesis (Vallance et al,y 1992). It is possible that under certain conditions these two 
inhibitors can be metabolised to L-citruUine and/or L-arginine in some cells and tissues 
(Hecker et a/., 1990) and so reduce their inhibitory effects, possibly leading to a 
paradoxical stimulation of NO synthesis.
A range of structurally related compounds has been synthesised (Figure 1.2) and 
found to inhibit NO synthase. Like L-NMMA these compounds are competitive 
inhibitors. However, there are some differences between them. L-NMMA is a non- 
selective inhibitor of the various NO synthase enzymes and its action is reversible 
unless incubation with the enzyme is prolonged (Olken et al.y 1991; Feldman et al., 
1993b). N®-nitro-L-arginine (L-NNA) and its methyl ester (L-NAME) show 
progressive and irreversible, or only slowly reversible, inhibition of brain NO 
synthase, but weaker and reversible inhibition of macrophage NO synthase, following 
the initial binding (Dwyer et al.y 1991). Furthermore, amidine N®-iminoethyl-L- 
omithine (L-NIO), L-canavanine and N®-amino-L-arginine show some selective 
behaviour by inhibiting the inducible macrophage NO synthase more potently than the 
constitutive brain and endothelial NO synthases (Knowles et al.y 1989; Stuehr et al 
1992b; Rees et al., 1990). Selective behaviour has also been found with other N® 
substituted arginine analogues which have been shown to be competitive inhibitors of 
macrophage NO synthase (Olken et al. y 1992). Furthermore, different types of 
inhibitor having no structural similarity to arginine have been developed, one of which 
named Ebselen is a nontoxic selenoorganic compound known to break a cysteine 
thiolate/ferric iron bond of some P-450 enzymes. It is a relatively selective inhibitor of 
the endothelial isoform of NO synthase (Zembowicz et a/., 1993).
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Figure 1,2 The structure of arginine and of the arginine analogues most frequently used as inhibitors of NO synthases, (adapted from Knowles et al., 1994).
The charge differences between the arginine analogue inhibitors also plays a part in the 
differing ways and strengths, in which they exert their effect. L-NNA and L-NAME 
are neutral at physiological pH (due to their low pKa-0) and would not be expected to 
be taken up by the y+ amino acid transport system, responsible for a high proportion of 
the cellular uptake of positively charged amino acids, such as L-arginine (White, 1985). 
L-NMMA, together with other positively chaiged inhibitors, competes with L-arginine 
for transport (Bogle et a i, 1992). Furthermore, both L-NMMA and L-NAME have 
been shown to be orally active in rats (Gardiner et al., 1990).
There are ways in which NO synthases can be inhibited other than substrate- 
competitive inhibition. Calmodulin antagonists have been shown to inhibit some NO 
synthase isoenzymes and indirect inhibition of NO synthase by depletion of one of its 
cofactors BH4 , has proven to limit NO synthesis (Gross et al., 1991). It has recently 
been demonstrated that NO synthase is subject to feedback inhibition by NO itself. 
Brain (constitutive) and macrophage (inducible) isoforms, were shown to be inhibited 
by NO from the enzyme itself, or NO donors, possibly by interaction with the haem of 
NO synthase (Assreney et al., 1993; Rogers et al., 1992). This claim is substantiated 
by work showing that CO and methylene blue which interact with haem, also inhibit 
NO synthase (Stuehr et ai, 1992a; White et al., 1992).
1.7 STIMULATION OF GUANYLATE CYCLASE: THE ROLE OF
PORPHYRINS AND THE REGULATORY EFFECTS OF THIOLS
Guanylate cyclase has been described in vhtually all cell types examined. In most cells 
the enzyme exists as a polymorphic protein with both cytosolic (soluble) and membrane 
associated (particulate) forms existing in the same cell. It has been shown to be the 
target enzyme for NO (whether endothelium derived or from an exogenous source). 
However, NO has its main site of action on the cytoplasmic isoenzyme (Waldman and 
Murad, 1987). The presence of multiple isoenzyme forms of guanylate cyclase has
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made the determination of the exact constitution of soluble guanylate cyclase difficult, 
but it is thought to be a heterodimer with Mr 82,000 and 70,000 subunits (Waldman 
and Murad, 1987). In bovine lung the enzyme contains haem and perhaps copper and 
when purified, enzyme extracts exhibit 3 absorption maxima at 433, 550 and 565nm 
which are shifted on exposure to either CO or NO (Gerzer et al., 1981). This is 
consistent with binding of these species to the haem moiety of the enzyme.
A range of 'nitrovasodilators' (compounds containing NO in some form) including 
glycerol trinitrate (GTN), sodium nitropmsside, and amyl nitrite, have been shown to 
activate soluble guanylate cyclase (Katsuki et ai, 1977a). All of these compounds are 
potential sources of NO under the appropriate conditions (Katsuki et al., 1977a). 
However haem-deficient guanylate cyclase demonstrated modest or little activation by 
these agents (Ignarro et a i, 1982a). The involvement of the haem group in stimulation 
of the enzyme was clarified by the inhibitory effect of adding ferro (Fe^" )^ metallo- 
proteins (but not ferric (Fe^+) forms) such as haemoglobin or myoglobin, to highly 
purified extracts of the enzyme. Application of NO-donor drugs to the purified enzyme 
in the presence of Fe^’^ metallo-proteins was no longer capable of activating cyclic 
guanosine monophosphate (cGMP) production (Mittal et al., 1978; Murad et al., 
1978). This was thought to be due to the efficient scavenging ability for NO of the 
Fe^+metallo-proteins.
It was also found that oxidising agents such as hydrogen peroxide, methylene blue, 
superoxide and ferrocyanide inhibited the activity of the enzyme, whilst reducing agents 
(ascorbate, cysteine, glutathione, dithiothreitol) promoted the activation of the enzyme 
by NO-donor drugs (Braughler, 1983; Craven et al., 1978). The inhibitory effect of 
oxidising agents is likely to be due to a number of reasons; NO may be converted to 
higher oxides of nitrogen (NO%) before it reaches the active site of the enzyme; the iron 
of the recipient haem group at the active site may be oxidised to its ferric form; or, an as 
yet unexplained 'overoxidation' of key regulatory thiol groups can cause irreversible
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loss of both basal and nitro-activated cGMP production by the enzyme (Waldman and 
Murad, 1987). Consequently, reducing agents may potentiate activation by preventing 
these oxidations.
Partial purification of hepatic soluble guanylate cyclase results in loss of responsiveness 
to NO-donor drugs, as well as to nitric oxide (Craven et al., 1978). Responses were 
partially restored by the addition of free haematin, haemoglobin and other 
haemoproteins, but the activity was potentiated by the addition of reducing agents into 
the incubations, which facilitate the generation of nitrosyl heme by maintaining the 
heme iron in the ferrous form (Katsuki et al,, 1977b; Craven et a l, 1978). Preformed 
nitrosyl-haemoglobin was found to be 10-fold more effective in activating guanylate 
cyclase than certain nitrovasodilators (Craven et aL, 1978). Activation of partially 
purified guanylate cyclase by preformed nitrosyl-haemoglobin was not potentiated by 
reducing agents, supporting the suggestion that reducing agents affect the conversion of 
the parent nitrovasodilator to nitrosyl-haem complexes (Craven et aL, 1978). These 
data imply that activation of guanylate cyclase by nitrovasodilators occurs through 
reductant-dependent formation of nitrosyl-haem porphyrin complexes.
Thiols such as cysteine, glutathione, and dithiothreitol are capable of releasing NO from 
a range of nitrovasodilators, although intermediates in this process, such as S- 
nitrosothiol derivatives, have been found to be 100-fold more effective than certain 
nitrovasodilators in activating guanylate cyclase (Ignarro et a i, 1980a,b &c). As 
sulphydryl groups can undergo oxidation/reduction reactions and thiol disulphide 
conversions have been demonstrated to regulate protein structure and function, it is 
reasonable to suggest that they may also be involved in the regulation of guanylate 
cyclase. Early studies using alkylating agents which modify free thiol groups (eg. 
ethacrynic acid) were shown to alter basal and nitro-activated cGMP production 
(Katsuki et al., 1977a). Similarly, mixed disulphide formation on addition of cysteine 
or cystamine, also inhibited enzyme activity (Ignarro et aU, 1981b; Waldman et aL,
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1983). Studies with p^S] cystamine resulted in incorporation of the radioactive label 
into the enzyme along a time course which paralleled inhibition of the enzyme. This 
effect was reversed by dithiothreitol which reforms the thiols (Brandwein et al.y 1981). 
It has been proposed that guanylate cyclase possesses multiple sulphydryl sites, one of 
which is responsible for regulation of basal cGMP production and another for 
regulation of nitro-activated cGMP production (Braughler et al.y 1983). At least one, 
but probably two, sulphydryl groups are located at or near the catalytic site of the 
enzyme, as preincubation with the activating agent (nitrovasodilators) or excess 
substrate (Mg^+-GTP) protected the enzyme against inactivation (Ignarro et al., 
1981a).
Although the mechanism by which the nitrosyl-haem complex activates guanylate 
cyclase remains unknown, a model has been presented which could explain this 
phenomenon.
HaemPorphyrin
/ / / / / / / / / / / V / / / / / / / / ,
/?////<//<//////
Soluble Guanylate 
Cyclase
Figure 1.3 A simplified diagram showing the out-of~plane movement o f the 
porphyrin iron centre of guanylate cyclase when activated by NO.
Conformational change in enzymes is widely believed to be a regulatory phenomenon 
in regulating its action as envisioned by D.Koshland Jr. in his induced-fit model of
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enzyme action (Stryer, 1988). If these changes occur at, or near, the active site, the 
conformational change may influence function. Based on the findings that free 
protoporphyrin IX gave the same activation effect as NO-haem, and that free haem 
inhibits (not activates) the enzyme (Ignarro e ta l .y  1982b), Ignarro proposed that a haem 
structural change is caused by NO binding. He suggested that once bound the haem- 
NO complex elicits an out-of-plane movement of the centre iron, to produce a haem 
core size similar to that of a free porphyrin (Ignarro, 1992).
Traylor et al. (1993) support this theory with work on model haem systems. Based on 
the finding that NO binds preferentially to the haem lacking a proximal ligand, they 
proposed that when NO binds haem, there is a tendency to expel the basic ligand on the 
proximal side of the haem. This mechanism liberates a free base to catalyse the 
hydrolysis of the phosphate diester bond of guanosine triphosphate (GTP). This 
theory was tested using NO to release 1-methylimidazole from a 5-coordinated model 
haem. This promoted hydrolysis of p-nitrophenolate in the aqueous medium used. 
However there are important aspects of the proposed mechanism which remain to be 
explained. It is not known whether haem is present in the ferric form in the native 
enzyme, because reductants such as dithiothreitol are used during enzyme purification. 
Furthermore, the strong binding of NO to ferrous haem and possible dissociation of 
haem from proteins due to this binding would tend to severely limit the number of 
turnovers of the enzyme and make for a very inefficient biocatalyst.
1.8 THE PHYSIOLOGICAL PROCESSES UNDERLYING 
ENDOTHELIUM- DEPENDENT AND INDEPENDENT VASCULAR 
SMOOTH MUSCLE RELAXATION
The production of cGMP from activation of guanylate cyclase was shown to 
correspond to a relaxation of certain smooth muscles and this activation was markedly 
enhanced by free radicals such as NO and hydroxyl radical (Murad et al.y 1979).
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Murad and his colleagues proposed that many potent vasodilators, such as sodium 
nitropmsside (SNP), organic nitrates and inorganic nitrite, activated guanylate cyclase 
indirectly via NO, which they release as a reaction product (Murad et aly 1979). 
Speculation that EDRF would stimulate an increase in intracellular cGMP in arterial 
smooth muscle cells was confirmed by experiments carried out by Rapoport & Murad 
(1983a) and Furchgott & Jothianandan (1983) on the rat and rabbit aorta. Stimulation 
of the tissues with intact endotheliums produced elevated levels of cGMP in the smooth 
muscle which was not present if the endothelium had been removed. This led to 
speculation that EDRF was a free radical. It has since been shown that the production 
of EDRF from NO synthase requires intracellular calcium to initiate its release (Palmer 
et al.y 1988b). This calcium appears to be released from intracellular stores as there is 
no evidence of calcium channels in endothelial cells (Zheng et al.y 1994). Endothelium 
dependent vasodilators such as ACh stimulate membrane-bound muscarinic receptors 
on endothelial cells initiating the release of calcium. This is required for the constitutive 
NO synthase for EDRF production (see Table 1.1), and leads to stimulation of 
guanylate cyclase in arterial smooth muscle in a similar way to nitrovasodilators.
Rapoport and co workers (1983) have shown that increases in cGMP in rat aorta due to 
this process are accompanied by a change in the pattern of phosphorylated proteins. 
This finding was particularly interesting as this change of pattern of phosphorylated 
proteins was identical to that previously found after exposure to the endothelium 
independent vasodilator, SNP, fuelling the hypothesis that the EDRF and the activating 
agent released by the nitrovasodilators (NO) were the same. They hypothesised that this 
processes was mediated through cyclic GMP production. In addition, the entry of 
calcium into the smooth muscle cells, which is necessary for contraction, diminished. 
Figure 1.4 summarises the endothelium-dependent and endothelium independent 
mechanisms of vascular smooth muscle relaxation which bring about vasodilation.
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1.9 THE PROPERTIES OF NITRIC OXIDE AND ITS REDOX FORMS: 
THE NITROSONIUM ION (N0+) AND THE NITROXIDE ION (NO")
i) NO
NO is one of the 10 smallest molecules known. It is a colourless gas at room 
temperature with Bp. -151.8'C and Mp. -163.6“C. It is also colourless in the solid and 
liquid states. At 25°C and 1 atmosphere pressure it has a solubility of 1.8mM (Feelisch 
et al.y 1991a) which remains unchanged within the pH range 2-13. The small amount 
of NO required for its physiological action means that it is always soluble in aqueous 
solution and therefore it is the aqueous chemistiy of NO that should be referred to.
NO is a relatively unreactive free radical and due to its odd electron it is paramagnetic. 
Its structure can be represented by a number of canonical foims shown below.
© © © © ___N O ► • N = 0  ^ — ► N = 0  • — ► N = 0
The general distiibiition of the odd electroip^ogether with a bond order which remains 
the same if NO were to dimerise, probably explain why dimérisation of NO does not 
occur (Butler & Williams, 1993).
NO can be prepared by a number of methods: the action of sodium nitiite or nitrous 
acid on ascorbic acid (vitamin C) (I) and the reduction of nitric acid using copper (2). 
On the industiial scale it is made by the catalytic oxidation of ammonia as an 
inteimediate in the synthesis of nitiic acid (3). The direct formation of nitiic oxide from 
nitrogen and oxygen is thermodynamically unfavourable, but does occur at high 
temperatures in lightning discharges and in the internal combustion engine (4).
2  1
OH OH
R=CH20H.CH(0H)-
+ 2NO + 2H2O (1) (Bunton et al., 1959)
8HNO3 + 3Cu 3Cu(N03)2 + 4H2O + 2NO (2)
4NH3 + 5O2 — 4N0 + 6H2O (3)
N2 + O2 2NO AG" = 173kJmol‘ (4)
NO is rapidly oxidised to niti'ogen dioxide (NO2) in the gas phase. This is a classic 
example of a third order reaction, second order in NO (5).
2NO + O' 2NO2 Rate = k3[N0 ]^[0 2 ] (5)
In aqueous solution, the final product of this reaction is nitrite ion (NO2") or nitrous 
acid (HNO2) depending on the pH, but no nitrate is seen. The rate law is the same as 
in the gas phase, but in aqueous media it would seem that NO is oxidised to NO2 which 
reacts with more NO to yield N2O3, the anhydride of nitrous acid (6 -8).
NO + I/2O2
NO2 + NO 
N2O3 + H2O
NO2
N2O3
2HNO2
(6)
(7)
(8)
This process has a third order rate constant of -5 x 10^ dm^mol'^s"^ (Wink et al.y 
1993; A wad et al.y 1993) and holds when either O2 or NO are in excess. Calculations
2 2
based on these results show that even in aqueous media saturated with oxygen, 
physiological concentrations of NO have long half lives. For example a lOnM solution 
of NO has a half life of approximately 3 hours (Butler & Williams, 1993).
It seems suprising that NO2 " is the sole product from NO in an aerobic aqueous 
solution given that its oxidation product NO2 produces an equimolar mixture of NO2" 
and nitrate ion (NO3") (9-10).
2NO2 N2O4 (9)
N2O4 + H2O ------► NO2 + NO3 + 2 H+ (10)
The conclusion must be that NO2 reacts much faster with NO than it does with H2O, 
whereas in the gas phase the reverse is the case. Pulse radiolysis studies have shown 
this to be true and Feelisch et al. (1991a) stated that NO2 hydrolysis is about 10 fold 
slower than reactions of NO with NO2 and eventual production of NO2"
ii) NO+ AND NO'
Recent papers have suggested that the redox forms of NO, the nitrosonium ion (N0+; 
Lipton et al. ,  1993) and the nitroxide ion (NO"; Fukuto et al.y 1992a,b & 1993) have 
physiological roles which up until recently have been confused with that of NO itself. 
Nitrosothiols have been implicated as molecules which possess the ability to release NO 
or NO+ depending on chemical environment (11 & 12) (Lipton et al.y 1993). They 
can produce NO photolytically (see Chapter 4), or by a metal ion catalysed process 
(see Chapter 3) and the NO group can be transferred between the nitrosothiol and 
other molecules (eg thiols) in the form of N0+ (see Chapter 5).
RSNO ------► RS + NO (11)
RSNO + X  RS“ + XNO X= eg.R'S (12)
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However, at no time can N0+ exist freely in an aqueous environment such as in the cell 
as there will be reaction at a diffusion controlled rate to give nitrous acid or the nitrite 
ion depending on the pH.
H2O + N0+  HNO2 + H+
(13)tH+ + NO2
Work is also being undertaken to investigate whether the complicated physiological 
action of SNP, a relatively long serving vasodilator for surgical operations is mediated 
by the dual action of NO and NO^ (Liptongf al.y 1993).
The possibility that the anion NO" has a physiological role has been little explained. 
Fukuto et al.  (1992a) have shown that under certain conditions nitroxyl (HNO) can be 
released from N-hydroxyguanidine compounds such as N® hydroxy-L-arginine an 
intermediate in the L-arginine to NO biosynthetic pathway. He also proposed that 
some, if not all, the physiological action of EDRF could be accounted for by nitroxyl 
(Fukuto et al.y 1992b). A pKa of 4.7 means that at physiological pH, HNO is 
dissociated to NO" and H+ and at physiological concentrations the rapid bimolecular 
reaction to form nitrous oxide (N2O) and water will be very slow (14). These factors 
make it feasible that NO" could well have a physiological role. However, if this is the 
case, a biosynthetic mechanism for its formation must be found.
2HNO  ► HgO + N2O (14)
Interestingly, if the interaction of the redox forms of NO with their most important 
target, the haem moiety of guanylate cyclase (or other haem containing proteins), is 
studied, there are a number of differences. The redox state of the haem iron is 
important. At physiological pH ferric haem has a net unitary positive charge (+3 from 
Fe^"  ^ and -2 from the pyrrole nitrogens) whereas ferrous haem is neutral (+2 from
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and -2 from the pyiTole nitrogens). Tiierefore, ferric haem will tend to react more 
strongly with anionic ligands such as NO" because of electrostatic interaction, whereas 
(neutial) NO will be preferentially bound by ferrous haem due to the increased orbital 
interactions of the exti'a d-orbital election. In fact looking at the binding of the redox 
forms of NO to fenous haem, it is likely tliat the ligand field strength follows the order 
NO>NO+>NO", as the isoelectronic compounds CO (=N0"^) and O2 (=NO") follow 
this order (Figure 1.5).
NO
a*
10
N0+ -le C 
NO +le C
Figure 1.5 An energy diagram of NO. Orbital hybridisation and energy promotion of 
the nitrogen atom relative to oxygen is shown. (Adapted from Huheey et al., 1983)
O2 binds differently to ferrous haem than CO, using a sp^ hybridised orbital rather than 
an sp orbital for binding. This results in a bent Fe-0-0 aiTangement compared with the 
linear Fe-C-0. Therefore, the stronger bonding and the shorter bond length, coupled 
with the presence of 2 electrons in the antibonding orbitals of O2 prohibiting 
backbonding Aom the iron, explain why CO binds to ferrous haem more strongly than 
O2 . Whether N0+ and NO" are analogous to CO and O2 respectively in their binding
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affinities for the ferrous haem remains to be determined. However, the protein 
environment of the rest of the enzyme must also be examined when looking at the 
relative ligand binding strengths of the redox forms of NO. Steric effects, solubility 
effects and other specific structural characteristics of the protein must be taken into 
account (Tsai, 1994).
1.10 NO; ITS TARGET MOLECULES AND INTRACELLULAR
INTERACTIONS.
As previously mentioned in section 1.7, the principal target for NO action is its 
binding to the haem group of guanylate cyclase, the subsequent activation of the 
enzyme and production of the second messenger cGMP. There are, however, many 
other haemoproteins to which NO can be bound and thereby inactivate. Among the 
most important is its interaction with the 0 2 " ligand of oxyhaemoglobin to produce the 
ferric form of haemoglobin, called methaemoglobin, and nitrate (Feelisch & Noack et 
al., 1987). Since most cells are close to capillaries carrying erythrocytes loaded with 
Hb, NO cannot diffuse far without encountering oxyhaemoglobin. NO has a much 
lower affinity for methaemoglobin and other ferric (Fe3+) compounds than to ferrous 
(Fe2+) haemoglobin (see section 1.9). However, a nitrosyl haemoprotein adduct 
will form (metHbNO) which slowly converts to HbNO (Ignarro et al., 1987, Chien, 
1968).
Another aspect of NO metabolism in vivo is the formation of a variety of high and low 
molecular weight nitrosothiols. These species can be envisioned as arising via formal 
oxidation of NO to an NO+ donor, followed by reaction with a thiol group. S- 
nitrosocysteine and S-nitrosoglutathione are among the biologically derived S- 
nitrosothiols that are postulated (Myers et al., 1990), or known (Stamler et al., 1992b), 
to be carriers of NO in animals. More recently, extensive work by Stamler et al., 
(1992a&b) has shown that protein thiols such as serum albumin, cathepsin B, and
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tissue-type plasminogen activator (t-PA) react with NO to form very stable S-nitroso 
proteins. These S-nitrosoproteins have half-lives of over 24 hours in phosphate buffer 
and about 40 minutes in plasma. Stamler et a i  (1992a) have shown that S-nitroso 
serum albumin is the major carrier of NO in blood plasma ('^5.5pM) and has postulated 
that NO is stored by proteins such as this until required to aid vasodilator tone. His 
group has also shown that the S-nitroso protein can bring about vasodilation, as well 
as inhibition of platelet aggregation (Simon et al, 1993).
It has been proposed that NO may be rapidly bound and stabilised by low and high 
molecular weight iron-sulphur complexes (Vanin et al., 1991). Dinitrosyl-iron (II)-L- 
cysteine has been shown to form a stable complex with protein thiols, which can act as 
an NO store in tissue and, by reaction with intracellular low molecular weight thiols, 
decompose and release low molecular weight dinitrosyl-iron (II)-dithiolate complexes 
into the extracellular space (Mulsch et al., 1991). These compounds exhibit biological 
properties similar to EDRF. At the same time the interaction of NO produced by 
activated macrophages with iron-sulphur containing enzymes, such as aconitase and 
complex I &n, which are involved in the mitochondrial electron transport chain and the 
pathway for the synthesis of DNA, results in inhibition of the activity of these enzymes 
and resultant NO-mediated cytotoxicity (Hibbs et al., 1990).
Superoxide (02") is an endogenous toxic species generated by several metabolic 
processes. It is implicated as a cause of acute cell injury in a variety of pathological 
conditions (Moncada et al., 1991). Rubanyi and Vanhoutte (1986) have shown that 
exogenous addition of a superoxide generating system (eg pyrogallol or 
xanthine/xanthine oxidase) inactivated EDRF but in the presence of superoxide 
dismutase (SOD), a scavenger of O2" anions, the half-life of EDRF was substantially 
prolonged. Normal levels of oxygen radicals are controlled by enzymes such as SOD, 
minimising their cytotoxic effect. SOD converts superoxide into hydrogen peroxide 
(H2O2) and oxygen.
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SOD
2O2' + 2H+  ► H2O2 + O2 (1)
Likewise, cataiase and peroxidase control the levels of hydrogen peroxide and hence 
the formation of hydroxyl (HO ) an extremely reactive and potentially the most harmful 
radical, formed by the action of superoxide on H2O2 (Hogg et al., 1992).
2 H A  2% 0 + O2 (2)cataiase
Despite the rapid activity of these enzymes, it is well documented that sufficient O2" 
exists in the intracellular environment to reduce NO stimulation of guanylate cyclase 
(Rubanyi & Vanhoutte., 1986; Gryglewski et al., 1986b). Recent studies have 
suggested that NO reacts rapidly with superoxide anion to form peroxynitrite anion 
(0 N 0 0 “) which, at physiological pH, is mainly in its protonated form, peroxynitrous 
acid (ONOOH; Beckman et al., 1990).
NO + O2  ONOO (3)
ONOO + H+ ------► ONOOH (4)
Evidence has been presented to suggest that peroxynitrous acid can undergo homolydc 
cleavage to produce HO- and nitrogen dioxide (NO2) (Beckman et al., 1990; Hogg et 
al., 1992), and it is thought that this reaction produces the toxic species (HO ) which 
may account for the pathological role evident when O2" is produced in reasonable 
concentrations. However, recombination of NO2 and OH- to form nitrate (NO3") and 
hydrogen ion (H+) is likely. Theoretical and empirical calculations indicate that while 
hydroxyl radical formation is energetically allowed it is kineticaUy disfavoured. Thus 
the proposed production of HO- radicals from peroxynitrous acid may actually yield a 
species with an as yet undefined structure and reactivity approximately the same as 
hydroxyl radical (Koppenol & Beckman et al., 1992).
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trans-peroxynitrous acid 
N-0-0 bond angle 80“ 
0 - 0  bond length L8A
/  \ nitrate
cis-peroxynitrous acid
Figure 1,6 Proposed formation o f nitrate from peroxynitrous acid. (Adapted from 
Kerwin & Heller et al., 1994)
Another theory based on molecular mechanics calculations is that a potential transition 
state (trans-peroxynitrous acid) accounts for the oxidising power of peroxynitrous acid 
(Koppenol & Beckman et al., 1992), suggesting that the decomposition of 
peroxynitrous acid is not a requirement for its oxidising behaviour. The observation 
that few hydroxyl radical-like products are trapped under optimal trapping conditions 
and that there is a high production of nitrate, can be rationalised from the trans- 
peroxynitrous acid theory which, due to its geometry, is theoretically better suited than 
the c/s-isomer to undergo a concerted rearrangement to form nitrate (Figure 1.6).
1.11 NO: VASODILATION AND NO-DONOR DRUGS
As described in Section 1.8 NO release and dilator tone of arterioles can be enhanced 
by endothelium dependent vasodilators such as ACh and bradykinin. It has been 
recently discovered that nitrates and nitrites such as glycerol trinitrate (GTN) and amyl 
nitrite (see Figure 1.7), which have been therapeutic agents for the treatment of 
angina pectoris and congestive heart failure for over a hundred years (since 1867, after
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Figure 1.7 The dijferent classes of NO donor drugs
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(DEA/NO)
(NOnate)
Sir Alfred Nobel made dynamite from GTN) liberate nitric oxide, which accounts for 
their biological action (Feelisch et al., 1987). This exogenous production of NO, 
which is capable of stimulating guanylate cyclase in the same way as endogenously 
produced NO, implies that organic nitrates are endothelium independent vasodilators, 
and what are now termed as nitrovasodilators. Since this discovery the action of other 
long serving antihypertensive drugs such as SNP (see Figure 1.7) have been better 
understood. Moreover, this discovery has lead to research into other forms of NO- 
donor drugs such as S-nitrosothiols, the molsidomines, NOnates and iron-sulphur 
clusters which may have different or improved pharmacokinetic profiles and uses (see 
Figure 1.7).
There are many drugs with different mechanisms of action for treating hypertension and 
high blood pressure. Beta-blockers, calcium antagonists, diuretics and ACE 
(angiotensin converting enzyme) inhibitors being four of the most important. 
However, rapidly acting nitrates remain the 'gold standard' for treatment of all forms of 
angina pectoris. Relatively new nitrates such as isosorbide dinitrate and its active 
metabolite, isosorbide 5-mononitrate (see Figure 1.7)were developed in the 1940’s 
and 50's and had slightly different and better pharmacokinetic profiles for the treatment 
of angina. The ease with which they can be delivered; chewable tablets, oral spray, 
sublingually or transmucosally, make them very attractive therapeutic agents. The 
major problem with nitrates has been the eventual, and often sustained, tolerance that 
these drugs induce (Needleman et al., 1973), particularly when used frequently, in 
large doses or continuously. The discovery that they act by bioconversion to NO 
which activates guanylate cyclase, has given researchers an insight into how this family 
of drugs can be improved and the fundamental mechanisms which underlie nitrate 
tolerance.
It has been shown that nitrates undergo enzymatic (Chung & Fung, 1990; Feelisch & 
Kelm, 1991b; Kenkare & Benet, 1993) and nonenzymatic (Feelish & Noack, 1987)
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decomposition to produce NO, which is responsible for their vasodilator and 
antiplatelet aggregating effects. Glutathione-S-transferase or cytochrome P4 5 0  
reductases are thought to be responsible for enzymatic decomposition of nitrates in the 
liver and kidney and aorta (Kenkare & Benet, 1993), although they do not appear to be 
involved in the biotransformation of GTN to NO by smooth muscle cells or endothelial 
cells (Chung et al., 1992; Gruetter et al., 1985). The formation of two dinitrate 
metabolites (1,2- and 1,3- glyceryl dinitrates) has been found. This bioconversion 
takes place not only in the liver but also in VSM (Kawamoto et al., 1987) and in human 
plasma (Fung et al., 1986; Fung et û/.,1989) and has been linked to decomposition of 
GTN by glutathione-S-transferases (Kenkare & Benet, 1993). The dinitrate 
metabolites elicit vasodilation and are acted upon to produce NO (Salvemisi & Anggard 
etal., 1993).
Evidence has been presented to suggest that an enzyme-independent pathway for the 
production of NO from organic nitrates is elicited through a common intermediate 
which decomposes to release NO2" and NO (Feelisch & Noack, 1987), Thionitrates 
have been proposed as these intermediates and arise from transestérification between 
organic nitrate and thiol compounds by nucleophillic attack of a thiolate anion on the 
nitrogen atom of the ester group of the nitrate (Feelisch, 1991a).
Certain structural prerequisities of the thiol are thought to account for the finding that 
under physiological conditions only a limited number of sulphydryl containing 
compounds react with organic nitrates to form NO, whereas all thiols decompose 
organic nitrates to N0 2 ”. Thiols such as cysteine are capable of carrying out this 
process (Feelisch & Noack, 1987; Feelisch, 1993). In contrast organic nitrites such as 
amyl nitrite react with all available thiol groups to form S-nitrosothiols which readily 
release NO.
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Nitrate tolerance has been associated with a relative depletion or unavailability of thiol 
groups that are involved in the initial denitration of RONO2. Sulphydryl groups (SH) 
are oxidised during this process. In addition, they are required for the production of S- 
nitrosothiols which are thought to be one of the end products of organic nitrate 
’* metabolism and necessary for guanylate cyclase activation. Many workers have shown 
that exogenous S-nitiosothiols can stimulate GTN tolerant vascular tissue both ex vivo 
and in vivo (Kowaluk et at., 1987; Shaffer et al., 1991; Bauer et al., 1990; Horowitz et 
al., 1983). It has also been shown that exposure of whole animals (rabbits and rats) to 
an infusion of S-niti oso-N-acetyl penicillamine (SNAP) does not bring about tolerance 
(Bauerera/., 1990; Shafferera/., 1991).
Not all the literature is in agreement and many thiol donor studies have been 
unsuccessful in reducing tolerance (Gruetter etal., 1986; Henry etal., 1989; Keith et 
al., 1981). Reasons for this are not clear but variable vascular tissue, sensitivity to 
thiols in different vascular beds and different animal species may explain these 
discrepancies.
The vasodilator action of sodium niuoprusside (SNP) is more difficult to understand as 
tlie only reaction leading to direct release of NO is photochemical decomposition (Wolfe 
& Swinehart, 1975). Experiments using a frogs heart showed that the action of SNP 
t  was greatly^otentiated bv exposure to laser light. (Flitney & Kennovin, 1987). It is 
known that after a multistep process NO is released from SNP on reaction with thiols 
(Butler e/a/., 1988).
Recent evidence from our laboratory supports a proposed theory that S-nitrosothiols are 
intermediates in this process (Greig & Butler, unpublished results). Interestingly, 
evidence has been presented to suggest that SNP is metabolised to nitric oxide in 
vascular smooth muscle (VSM). This process was shown to be catalysed by a 
membrane-associated NO-generating activity which has a molecular weight of
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approximately 4 to llkDa and this activity could be enhanced by the addition of a 
reducing agent such as cysteine or NADPH (Kowaluk et al., 1992).
A relatively new therapeutic agent for the treatment of coronary heart disease is N- 
ethoxycarbonyl-3-morpholino-sydnonimine, which prevents thrombus formation and 
possesses platelet anti-aggregating activity. It is metabolised in the liver to SIN-1 (3- 
morpholinosydnonimine) whereupon the 5-membered ring opens nonenzymatically at 
basic pH, forming SIN-IA (N-morpholino-N-nitrosoaminoacetonitrile), which is 
readily oxidised by oxygen to release NO (Kerwin & Heller, 1994; Figure 1.8).
Molsidomine SIN-1 SIN-IA
NH
OHenzyme
NO
Figure 1.8 The metabolic production of NO from molsidomine (adapted from Kerwin 
& Heller etal., 1994)
A  recently developed group of compounds, the NOnates are claimed to release 
predictable amounts of NO. These compounds are complexes of NO with nucleophiles 
of the general structure Nu-N(0")-N=0, where Nu is a nucleophile such as 
diethylamine or spermidine (Morley & Keefer et al., 1991; see Figure 1.9).
According to Keefer, compounds based on this general stmcture can be readily tailored 
to specific medicinal applications as the rate which they release NO varies dramatically 
from compound to compound depending on the nucleophile present. NOnates 
spontaneously release NO under physiological conditions and therefore do not require
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some sort of metabolic or electron transfer activation, which would limit their utility. 
However, this class of nitrovasodilator has been found to have a mutagenic effect on 
DNA (Wink & Keefer et al., 1991).
Nu^ y  
N— N 
Qo'^ j
RX
^N=N
0 q /  ,
© o^
Nu = Et2N 
TriN
H2N(CH2)3NH(CH2>4iyH
H2N(CH2)3
Figure 1.9 The NOnates (l)which can be alkylated to form NOnate prodrugs (2) and 
which directly release NO under physiological conditions. (Adapted from Kerwin & 
Heller et al., 1994)
As mentioned in Section 1.10 iron-sulphur complexes are thought to be stores of NO 
in vascular tissue and have EDRF-like properties (Mulsch et al., 1991). An iron 
sulphur cluster containing a number of NO ligands in each ion is the anion of Roussins 
Black Salt (RBS; [Fe4S3(NO)7]" see Figure 1.7). This ion decomposes with release 
of NO by both chemical and photochemical routes and ex vivo experiments have shown 
it to be a highly reactive vasodilator. It has been shown to be taken up by endothelial 
cells due to its unusual solubility characteristics which although being ionic, make it 
more soluble in organic solvents than in water. The iron sulphur cluster nitrosyl 
remains in the endothelium for several hours giving a sustained release of NO which 
keeps the vascular tissue in a constant state of vasodilation (Flitney, Megson & Butler, 
1992).
Another class of compounds with EDRF-like properties are S-nitrosothiols. These 
effective, fast acting vasodilators (see Chapters 2 & 5) release NO by a number of
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chemical and physiological mechanisms, and certain S-nitrosothiols such as S-nitroso 
cysteine have a biological action very similar to that of NO itself. This is one reason 
why the controversy surrounding the chemical identity of the EDRF has been so 
difficult to resolve.(Section 1.4)
Biological thiols such as glutathione, cysteine and homocysteine comprise the majority 
of the mammalian fraction of sulphur that exists as free sulphydryl (Jocelyn, 1972) and 
react readily in the presence of NOx under physiological conditions to form S- 
nitrosothiols (Ignarro et a/., 1981a&b; Ignarro et a i, 1989; Stamler et al., 1992a,c; 
Figure 1.10). In addition, S-nitroso serum albumin has been found to be the most 
abundant S-nitrosoprotein in plasma ('-S.SjiM; Stamler et al., 1992b). Non- 
endogenous S-nitrosothiols such as S-nitroso-N-acetyl penicillamine (SNAP; Field et 
al., 1978) and S-nitrosocaptopril (SNoCap; Loscalzo et al., 1989) have been 
synthesised as stable crystalline solids which also show marked biological activity. 
SNoCap acts by producing guanylate cyclase stimulated cGMP and by ACE inhibition 
(Figure 1.10).
The endogenous S-nitrosothiols have been implicated in a number of different 
biological roles. S-nitroso-N-acetyl cysteine and S-nitrosoglutathione have been 
proposed as the endogenous substance released by NANC (non-adrenergic, non- 
cholinergic) nerves in the mouse anococcygeus (Gibson et al., 1992) and rat gastric 
fundus,respectively (Barbier & Lefebvre, 1994). Kerr et a i (1992) have evidence to 
suggest that the Inhibitory Factor (IF), an extract of the bovine retractor penis muscle 
which relaxes smooth muscle, is an S-nitrosothiol. Furthermore, since it has been 
realised that NO is a potent airway smooth muscle relaxant, it has been shown that S- 
nitrosothiols possess the ability to regulate airway tone by NO delivery which activates 
guanylate cyclase and that they are able to preserve the bioactivity of NO in the presence 
of high, ambient concentrations of oxygen and oxygen-derived free radicals (Jansen et 
a i, 1991). In 1985, Loscalso et a i showed that blood platelets incubated with GTN
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Figure 1.10 Some synthetic and natually occuring S-nitrosothiols
produced S-nitrosothiols, indicating that platelets are capable of producing S- 
nitrosothiols by some unknown mechanism, and it has been shown that S-nitrosothiols 
are potent inhibitors of platelet aggregation by many workers (see Section 1.12).
At present, analytical technology with sufficient sensitivity to detect the range of thiols, 
disulphides and S-nitrosothiols that are believed to circulate in plasma is still required. 
High Performance capillary Zone Electrophoresis has been developed (Stamler et aL, 
1992c) and is capable of distinguishing between these three groups of compounds with 
rapidity and specificity (see Chapters 3 & 5). However, at the moment, the method 
lacks the sensitivity that is required for detection of S-nitrosothiols at levels present in 
humans. However, using a Gas Chromatography/High Performance Liquid 
Chromatography-photolysis-chemiluminesence system, Stamler and co-workers have 
been able to calculate the total concentrations of S-nitrosothiols, S-nitrosoproteins and 
free NO in plasma (Stamler et al., 1992b).
The subject of this PhD thesis centres around understanding the mechanisms by which 
S-nitrosothiols release NO in vitro and ex vivo, giving an insight into how this class of 
NO-donor drug may be tailored to release NO at specific sites for specific purposes. 
Further background on S-nitrosothiols is presented in Chapter 2.
1.12 NO: PLATELET AGGREGATION AND NO-DONOR DRUGS
Blood platelets represent the first line of host defence when vessels are injured. Platelet 
adhesion to subendothelium (collagen fibrils, endothelial cell matrix and endothelium 
cell monolayers), aggregation and further platelet recruitment, culminate in 'haemostatic 
plug* formation which is accompanied by the consolidating effect of fibrin deposition 
on and between platelets.
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Proximate endothelial cells possess three protective mechanisms (thromboregulators) 
for limiting the size of the haemostatic plug: Adenosine diphosphatease (ADPase), 
which removes secreted ADP and its prothrombotic effect; Eicosanoid metabolism, the 
major product of which is the prostaglandin PGI2; and EDRF/NO (Table 1.2).
Type Site of action Mode 0  ^action Inhibited by
PGI2 Fluid phase autacoid Elevation of platelet cAMP Aspirin
EDRF/NO Fluid phase autacoid Elevation of platelet cGMP Haemogobin (Hb)
ATPase >AMP + Aden osine Endothelial cell surface Enzymatic removal of secreted ADP ATPase inhibitors
Table 1,2 Inhibitory thromboregulators associated with human endothelial cells 
(adapted from Marcus & Safier, 1993)
The discovery of a role for NO in platelet function occurred in 1981 when it was found 
that NO and other nitrovasodilators inhibited ADP-induced platelet aggregation by a 
cGMP-dependent mechanism (Mellion et al., 1981). It was not until 1986 that a link 
was identified between the actions of NO on platelet aggregation and those of EDRF on 
vascular smooth muscle (Azuma et al., 1986). Subsequently it was shown that EDRF 
itself was capable of inhibiting platelet aggregation ex vivo (Radomski et al., 1987a) 
and in vivo (Hogan et al., 1988). Radomski et al. showed that NO and prostacyclin, 
acting synergistically, had a superior antithrombotic effect (Radomski et al., 1987b) 
and went on to show that both cAMP and cGMP regulated platelet aggregation 
(Radomski et al., 1987c). However prostacyclin, which is a weak inhibitor of platelet 
adhesion, did not synergise with NO, suggesting that NO and consequently cGMP 
regulated platelet adhesion (Radomski et al., 1987c,d).
In 1990, it became clear that platelets also generated NO and that the L-arginine/NO 
pathway responsible acts as a negative feedback mechanism to regulate platelet 
aggregation (Radomski et al., 1990a). Aggregation induced by collagen caused an 
increase in intraplatelet levels of cGMP, which was inhibited by L-NMMA and 
enhanced by L-arginine (Radomski et al., 1990b). The increase in cGMP led to
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increased inhibition of platelet aggregation. L-arginine did not increase the basal levels 
of cGMP in unstimulated platelets, but the enhanced levels found in collagen stimulated 
platelets showed that this NO synthase could utilise exogenous substrate after it had 
been activated. These stimulated platelets possess 100-fold more intracellular Ca^"  ^
than the resting platelet (Ware et al„ 1986) and it is likely that this increased level 
activates the NO synthase. The resulting increases in cGMP cause Ca^+ sequestration 
(Busse et al., 1987) leaving less Ca^+ available for use in platelet aggregation. 
Therefore, as a thromboregulator, NO is produced by platelets from L-arginine and 
from vascular endothelium to inhibit platelet aggregation and adhesion to the cell wall of 
blood vessel. (Figure 1.4)
Endothelial dysfunction in a variety of clinical conditions such as hypercholesterolemia, 
atherosclerosis, hypertension and heart failure, increases the tendency for platelet 
aggregates to form and makes these patients susceptible to thrombotic events. Thus the 
potential clinical role of compounds capable of providing controlled therapeutic 
concentrations of NO could be great. However, the effect of nitrovasodilators on 
platelet aggregation has been poorly understood. It would seem that nitrovasodilators 
which release NO readily such as SNP, SIN-1, S-nitrosothiols and NOnates, are good 
therapeutic agents for the inhibition of platelet aggregation (Radomski et al., 1992; 
Diodati et al., 1993). Radomski et al (1992) have shown S-nitrosoglutathione to be a 
more potent inhibitor than NO itself. Furthermore, S-nitroso-N-acetylpeniciUamine and 
other synthetic S-nitrosothiols have also been shown to be substantially more potent 
than all other classes of NO-donor drugs known to date (Salas, Askew & Radomski et 
al., in press). Diodati et al (1993) has shown that NOnates (Section 1.11) can be 
synthesised with quite different pharmacokinetic profiles for preventing aggregation, 
which correlate with the rates at which they release NO. GTN, on the other hand, is 
almost inactive, suggesting that platelets lack the mechanisms required for the uptake 
and/or conversion of organic nitrates to NO (Gerzer et al., 1988).
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Recent work by Stamler et al. (1993) has shown that S-niti'oso proteins such as S- 
nitroso serum albumin are potent inhibitors of platelet aggregation in vitro, ex vivo and 
in vivo. They are readily formed under physiological conditions (Stamler et al., 
1992a), and release NO at the platelet surface possibly to sulphydryl moieties (Stamler 
et a l 1993). Furthermore, S-nitrosylated proteins can transfer NO to low molecular 
weight thiols to form S-nitrosothiols that can then enter the platelet or facilitate NO 
transfer at the platelet surface to inhibit aggregation (Stamler et al., 1993). These data 
suggest that S-nitrosoproteins may seive as intermediates in the cellular metabolism of 
NO and support the view that S-nitrosothioIs may serve a earner role for NO as 
intermediates in the mechanism of organic nitrate and EDRF action.
1.13 OTHER PHYSIOLOGICAL FUNCTIONS OF NO
THE NERVOUS SYSTEM 
a) Central Nervous System (CNS)
Chemical messengers known as neurotransmitters allow messages to be passed 
between different nerve cells across synaptic contacts. When stimulation of presynaptic 
neurones increases the activity in a postsynaptic neive cell it is known as an excitatory 
synapse. The amino acids glutamate and aspartate are two important excitatory 
neurotransmitters. In 1987, glutamate was shown to elevate cGMP levels in the 
postsynaptic nerve and give rise to an unstable intracellulai* factor (Garthwaite et al., 
1987). This factor was rapidly identified as having properties identical to EDRF or NO 
(Garthwaite et al., 1988). In the following 2 years an isoform of NO synthase, 
dependent on Ca^+Zcalmodulin and similar to that isolated from endothelium and 
platelets, was described, purified and cloned (Knowles et al., 1989; Bredt et al., 1990).
It appears that NO in the brain can act in at least two ways. Firstly it is formed in the 
postsynaptic nerve cell following activation by an amino acid neurotransmitter.
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Stimulation of N-methyi-D-aspartate (NMDA) receptors causes the production of NO 
which diffuses out of the postsynaptic cell, on which it has no effect (possibly because 
high intracellular Ca^+ serves to inhibit guanylate cyclase activity), and acts upon one 
or more neighbouring structures, including the presynaptic nerve cell. For this reason 
NO has been proposed as a retrograde messenger, perhaps involved in the mechanism 
of long term memory (Gaily et al., 1990). However, there are a number of candidates 
for this role and support for NO as a retrograde messenger is speculative. Secondly, 
NO is found presynaptically in the climbing fibres of the cerebellum. The apparent 
effect of NO generated in these fibres is the long term depression of responses in 
Purkinjie fibres, since L-NMMA blocks the depression (Shibuki &Okada., 1991). It 
also seems possible that NO plays some part in the cerebral blood supply and it has 
been suggested that the over-production of NO maybe linked with certain degenerative 
conditions like senile dementia because of its radical nature and ability to generate 
hydroxyl radicals (Butler & Williams etal., 1993).
2) The peripheral nervous system (PNS)
NO synthase has been discovered in a wide variety of tissues within the PNS. NO or a 
related compound such as an S-nitrosothiol (Gibson et al., 1992; Barbier & Lefebvre, 
1994), is now commonly termed a 'non-adrenergic, non-cholinergic’ (NANC) 
neurotransmitter (Bult et al., 1990). It is produced by the vagal nerves supplying 
gastrointestinal smooth muscle and in the corpus cavemosum of the human penis 
(Rajfer et al., 1992). Here, NANC nerves are responsible for relaxing the muscle and 
allowing blood influx which results in the penile erection. There is evidence that the 
arginine to NO pathway is directly involved in this process (Rajfer et al., 1992). NO- 
sensitive NANC nerves have been found in several other tissues including the 
cardiovasculature where they have a role in vasodilation and in the respiratory system. 
In all cases of NANC neurotransmission, competitive inhibitors of NO synthase block 
nerve induced relaxations.
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THE PHYSIOLOGICAL & PATHOPHYSIOLOGICAL ROLE OF 
INDUCIBLE NO SYNTHASE (iNOS)
1) Macrophages
The immune response is the body's reaction to the destruction or neutralisation of 
'foreign matter'. This can be done non-specifically throughout the body by cells 
known as macrophages which non-selectively protect the body against 'foreign 
substances' or cells. To do this substances known as cytokines stimulate the 
macrophage, resulting in the engulfment of the 'foreign matter' (phagocytosis), its 
subsequent neutralisation by cytotoxic substances (NO) injected by tlie macrophage and 
its removal.
The conelation between elevated urinary NO2" and NÜ3“ levels and increased immuno- 
stimulation induced in lipopolysaccaride (LPS)-treated mice, suggested that 
macrophages were the most likely source of NO2" and NO3" (Stuehr & Marietta, 
1985). At about the same time, the cytotoxic capability of activated macrophages 
against tumour target cells was shown to be dependent on the presence of L-arginine 
and accompanied by the production of L-citrulline and NO2" (Hibbs et al., 1987). It 
was subsequently demonstiated that NO synthesised from L-aiginine was indeed the 
precui'sor of the NO2'  and NO3" in these cells (Marietta et al., 1988).
The isoform of NO synthase in the macrophage was only found in the activated cells 
(activated by LPS or LPS and interferon-g (IFN-g); Stuehr & Marietta, 1985) and it 
required protein synthesis for its expression, which meant a time delay of up to 8 hours 
before NO2" and NO3" could be detected (Marietta et al., 1988). This enzyme was 
subsequently found to be NADPH dependent, inhibited by L-arginine analogues, 
Ca^+/calmodulin independent and possess long lasting release of nanomolar quantities 
of NO (Section 1.5).
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As yet the mechanism by which NO produced by macrophage iNOS is cytotoxic is not 
fully understood. Three mechanisms have been proposed. Firstly, the NO radical is 
known to be destructive towards cell membranes and for this reason alone NO is 
cytotoxic. However, Beckman et a i (1990) has proposed that the reaction of NO with 
superoxide to form peroxynitrite, which has the potential to produce the extremely 
destructive hydroxyl radical, accounts for the cytotoxicity of NO (Section 1.10). 
Lastly, NO has been shown to react with enzyme iron sulphur centres necessary for 
metabolic activity to form iron-sulphur cluster nitrosyls (Section 1.10). This can be 
analysed by EPR (Butler et al., 1985).
Whatever the mechanism by which NO produces its cytotoxic action, the large amounts 
of NO produced by the inducible enzyme (iNOS) can result in a dramatic reduction in 
blood pressure this can lead to hypotension when it is induced in the vascular 
endothelium due to infection. This condition is known as septic (or endotoxic) shock 
and can be fatal. The vascular relaxation caused by the over-production of NO and the 
resulting hypotension, is partly due to patient's unresponsiveness to conventional 
vasoconstrictors, such as dopamine and noradrenaline. Inhibition of both the inducible 
and constitutive enzymes by NO synthase inhibitors such as L-NMMA have been 
shown to restore the normal blood pressure and in some cases save lives (Petros et al., 
1991). However, the non-selective behaviour of this drug can be deleterious and 
requires the co-infusion of an NO donor drug such as SNAP to stop potentiation of the 
effects of septic shock in animal models. The NO donor preserves perfusion and 
replaces the vasodilator tone of the arteries (Nava, Palmer & Moncada, 1992; Wright, 
Rees & Moncada, 1992). For more selective behaviour glucocorticoids such as 
dexamethasone have the ability to inhibit the expression but not the activity of the 
inducible NO synthase. This gives them limited therapeutic usefulness in treating 
endotoxic shock (Wright, Rees, Moncada, 1992). In the future, selective inhibitors of 
the inducible enzyme will be more suitable for treating this and other conditions in 
which a similar profile of NO release occurs.
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2) Neutrophils
Another part of the immune system is the collection of cells in blood known as 
leukocytes or white blood cells. Neutrophils are one type of leukocytes which have 
been shown to produce a substance that inhibits platelet aggregation (Salvemini et al., 
1989). Subsequently, it has been shown that neutrophils possess an inducible form of 
NO synthase (McCall et al., 1991).
3) NO and Immunological Responses
Besides the role of NO in immune defence, it may also be involved with inflammatory 
and auto immune-mediated tissue destruction. Since NO, in addition to damaging DNA 
(causing mutagenisis; Wink et al., 1991), is known to be a major cytotoxic effector in 
defence against a number of foreign bodies, bacteria and tumour cells, it is plausible 
that inappropriate or non-specific host cell attack may occur which may lead to 
inflammatory and auto immune response.
NO ’STORES' IN THE VASCULAR SMOOTH MUSCLE
Recently work by Megson et al., (1994) and Venturini, Palmer and Moncada (1993) 
has shown that vascular smooth muscle cells contain a finite store of a photosensitive 
molecule(s) which is capable of releasing NO when irradiated with visible or UV light. 
This store can be exhausted rapidly by exposing vessels to laser light but subsequently 
regenerates in the dark with an absolute dependence upon endothelium-derived NO 
(Megson et al., 1994). The repriming of the store is prevented by L-NMMA or 
haemoglobin and accelerated by NO donor drugs. Venturini et al. proposed that the 
’store' is a nitrosothiol, a nitrosoprotein or an iron-sulphur nitrosyl complex. In 
addition, work by Megson et al. provides evidence that the photosensitive 'store' is a 
nitrosothiol or nitrosoprotein, since it is known that as ethacrynic acid a thiol alkylating 
agent, also prevents repriming of the 'store*.
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NO IN EXHALED AIR OF HUMANS
Endogenous NO has been found to be produced by various cells within the lower 
respiratory tract including inflammatory and epithelial cells and is detectable in the 
exhaled air of normal human subjects. Using a chemiluminescence analyser to detect 
NO, Kharitonov et al. (1994) and Persson et al. (1994) have shown that asthma 
sufferers produce a greater concentration of NO in exhaled air than controls. The peak 
concentration of NO could be significantly reduced by L-NMMA and steroids. These 
observations may reflect induction of NO synthase which is known to be inhibited by 
steroids. Furthermore, Gaston et al. (1993) have shown that S-nitrosothiols can relax 
human bronchial smooth muscle. They suggest that these compounds preserve the 
bioactivity of NO in the airway and could have a potential role in the treatment of 
human bronchospasm.
1.14 THERAPEUTIC MANIPULATION OF THE NITRIC OXIDE
PATHWAY
1) NO donor drugs
As mentioned in Section 1.11, nitrovasodilators based on nitrates are the mainstay of 
therapy in angina, and, to a lesser extent, congestive heart failure. S-Nitrosothiols have 
been discussed in relation to their potential as potent vasodilators and inhibitors of 
platelet aggregation and the newer group of nitrovasodilators, which includes the 
sydnonimines, is likely to expand. SIN-1 has been tested in patients suffering from 
erectile dysfunction and was shown to be dose dependent in its production of an erectile 
response offering an attractive alternative to current auto injection therapies (Kerwin & 
Heller, 1994). Very recently organic nitrates like GTN have been shown to ease uterine 
contractions of pregnant women and prevent premature birth.
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The future development of nitrovasodilators and NO donor drugs lies in specific 
targeting of the site of metabolism in the vasculature or elsewhere, possibly producing a 
different effect or a greater potency of the drug. Reducing the development of nitrate 
tolerance by incorporating sulphydryl groups in its molecular structure could be a way 
to improve the pharmacokinetic profiles of organic nitrates.
2) Agents which stimulate NO synthase
Stimulii to NO release are diverse, from small molecules such as ACh to large peptides. 
Consequently, development of a drug that would increase endogenous production 
should be possible. This may have occurred already, by default, as the development of 
ACE inhibitors increase tissue concentrations of endogenous bradykinin, which is a 
potent stimulant of constitutive NO synthase.
3) Inhaled NO gas
As mentioned in the previous section, endogenous NO is a vasodilator of the 
pulmonary vasculature and inhibition of NO synthesis enhances pulmonary hypoxic 
vasoconstriction. Although NO has the advantage of a short half-life, and is therefore 
less susceptible than other pulmonary vasodilators to systemic hypotension, it can 
provoke respiratory distress syndrome if the tissue is over-exposed. For this reason, 
the therapeutic 'window' for inhaled NO is narrow and therapy requires caution. It 
could however be used to counteract the side effects of pulmonary hypertension caused 
by the use of non-selective NO synthase inhibitors in the treatment of septic shock.
4) L-Arginine administration
The use of exogenous L-arginine as a substrate for NO synthase has proved successful 
in treating patients with hypercholesteroiaemia. It is thought that the added L-arginine 
may compete with endogenous arginine analogue inhibitors, such as L-ADMA 
(Section 1.6), rather than by replenishing low levels of L-arginine in plasma as 
concentrations of this amino acid are high anyway (lO'^M).
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5) NO synthase inhibitors
The consequences of preventing NO synthesis are great, reflecting the diversity of NO 
as an intracellular signal. Consequently research into the synthesis of NO synthase 
inhibitors has been one of the more active fields since the L-arginine to NO pathway 
was discovered. For reasons mentioned in Section 1.13 and 1.6 the search for 
selective inhibitors of the inducible isoforms of the enzyme is paramount and necessary 
for treatment of symptoms like septic shock (Section 1.13). Investigation into 
targeting the many cofactors of the NO synthases is another avenue of research being 
undertaken (Section 1.6).
6 ) Steroids
Glucocorticoids have been found to inhibit the induction of iNOS in both vascular and 
cardiac tissues without effecting the constitutive enzyme. The extent of this effect on 
the anti-inflammatory action of steroids, together with a number of other non specific 
functions this class of compounds posseses, is not yet known. However, 
glucocorticoids exert their beneficial effects only when given as pretreatment before 
enzyme induction is established, which obviously limits their therapeutic usefulness.
7) Superoxide dismutase (SOD) therapy
The use of SOD to remove superoxide anions and potentiate the lifetime and 
consequently the action of NO is another way in which the vasodilator tone arteries and 
other blood vessels could be improved. In other cases however, the use of SOD may 
exacerbate the effects of large amounts of NO produced by iNOS, enhancing the 
cytotoxic effects.
Conclusions
Manipulating the pathway in the right direction at the right time is the key to the future 
therapeutic management of the NO pathway, but the importance of NO biology to
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therapeutics is such that many new approaches to treating patients are likely to come to 
light in the next decade.
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CHAPTER 2
S-NITROSOTHIOLS; 
A NOVEL CLASS OF 
NO-DONOR DRUGS
s o
2.1 INTRODUCTION
S-nitrosothiols or thionitrites were initially discovered as intermediates in the oxidation 
of thiols to disulphides. The fact that S-nitrosothiols are less stable than the 
corresponding oxygen analogues, such as alkyl nitrites, made them difficult to isolate 
and they are consequently less well investigated. Their chemical behaviour is very 
different from the oxygen analogues due to the inherent weakness of the sulphur- 
nitrogen bond compared with the oxygen-nitrogen bond of nitrites. This makes 
thionitrites more reactive and useful in organic synthesis as powerful nitrosating agents.
2.1,1 Nitrosation of thiols
S-nitrosation of thiols occurs more readily than 0 -nitrosation due to the greater 
nucleophilicity of the sulphur atom. Evidence for the existence of S-nitrosothiols was 
reported by Tasker and Jones as early as 1909, when a transient red coloured solution 
(due to the presence of phenyl thionitrite) was seen when benzene thiol was treated with 
nitrosyl chloride. The colour rapidly disappeared due to the formation of diphenyl 
disulfide and NO (1).
PhSH + NOCl ------► [PhSNO] ----- ► PhSSPh + NO (1)
A number of S-nitrosothiols have since been prepared by treatment of thiols with 
nitrosating agents, such as acidified nitrite or nitrous acid, alkyl nitrites, dinitrogen 
tetroxide (N2O4), dinitrogen trioxide (N2O3) and nitrogen dioxide (NO2) (for review 
see Oae & Shinhama, 1983). Until recently it was believed that the best yields of S- 
nitrosothiols were obtained by reacting the thiol with dinitrogen tetroxide N2O4 in 
equimolar amounts at -10'*C, using an inert organic solvent eg hexane, acetonitrile etc 
(Oae et al., 1978). However, Doyle et al. (1983) have shown that S-nitrosothiols can 
be conveniently synthesised using an alkyl nitrite, such as tertiary butyl nitrite, as the
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nitrosating agent. The reaction is carried out in an inert organic solvent and can 
produce quantitative yields of S-nitroso product of tertiary butyl thiol and benzyl thiol.
Nucleophilic catalysis of amine nitrosation and nitrosation of other species is well 
known, and thiols can undergo the same catalysis by halide ions and thiocyanate ion 
(Morris & Williams, 1988) (2).
HNO2 + + X- NOX + H2O (2)
The extent of catalysis is principally governed by the size of the equilibrium constant 
for NOX formation and the well-established trend of reactivity ONCl>ONBr>ONSCN 
is found for the nucleophilic catalysis of thiol S-nitrosation.
The most stable thionitrites appear to be those with bulky substituents eg. t-butyl 
nitrosothiol, triphenyl methyl nitrosothiol and the stable solid, S-nitroso-N-acetyl-DL- 
penicillamine (SNAP), isolated and characterised by Field et al. (1978). Recent work 
by Moynihan & Roberts (1994) has determined the optimum conditions for SNAP 
preparation using a variation of the acidified nitrite nitrosation of acetyl penicillamine 
used by Field. They have also developed syntheseses for bis-thio-nitrosopeniciQamine 
dipeptides which have comparable biological activity to GTN.
S-nitrosation of thiols is a rapid process and requires a fast technique such as stopped- 
flow spectrometry to enable rate constants to be measured. The rate of formation of 
nitrosothiols follows the rate law shown below (3) and applies to the nitrosation of a 
wide variety of substrates, including primary and secondary amines, alcohols etc, 
under certain experimental conditions (Williams, 1985).
Rate = k [Thiol] [H+] [HNO,] (3)
5 2
The nitrosation process can be generally interpreted in terms of a mechanism involving 
rate-limited attack by a positively charged species H2N0 2 "^  or N0+. The high 
reactivity of thiols towards nitrosating agents makes them good scavengers of agents 
such as nitrous acid and they have been used to suppress nitrosamine formation by 
competing with amines for such compounds (Williams et al., 1982).
2,1,2 Reactions of S-nitrosothiols
i) Thermal decomposition
S-Nitrosothiols readily thermally decompose to form the relevant disulphide and NO 
(4).
2RSN0 ----- ► RSSR + 2N0 (4)
Most S-nitrosothiols are unstable at room temperature although others, such as tertiary 
S-nitrosothiols require heating to produce the corresponding disulphide (Field et al., 
1978).
ii) Photochemical decomposition
S-Nitrosothiols have also been shown to decompose upon photolysis to give the 
corresponding disulphide and NO. Barrett et al. (1966) reported that the absorption of 
3650A"-radiation by S-nitrosotoluene resulted in excitation to the extent of 79Kcal/mol, 
which was sufficient to cause fission of the S-N bond. The reaction can be formulated 
as follows (5).
PhCHoSNO ----- ► PHCHoSNO*  ► PhCHoS* + NO2 2  ^ (5)
PhCH^S + PhCHjSNO ----- ► PhCH^SSCH^Ph + NO
iii) Oxidation
Oxidation of S-nitroso-tertiary butyl thiol (t-butylSNO) with fuming nitric acid forms t- 
butyl thionitrate (t-butylSN0 2 ) and the same product can be formed quantitatively by
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reacting tertiary-butyl thiol (t-butylSH) with excess N2O4 (Oae & Shinhama, 1983). 
Subsequent quenching of the reaction with tertiary butanol (t-butOH) leads to the 
formation of the corresponding thiol sulphonate in good yields (RSO2SR). Some S- 
nitrosothiols are also susceptible to air oxidation. With S-nitrosoethane thiol, the 
corresponding disulphide, diethyl disulphide, and N2O4 are obtained after about 3 
hours of exposure to air (Lecher et al., 1926) (6).
2EtSN0 + O2  ► EtSSEt + N2O4 (6)
iv) Reduction
S-Nitrosothiols can be hydrolysed by Hg(II) ions to give the thiol. This reaction was 
used for analysis of SH group concentrations by Saville (1958) and his method has 
since been employed by many researchers to monitor free thiol concentrations in many 
different types of tissue (7).
Hg(ll)Cysteine-SNO + H2O ----- ► cysteine-SH + HNO2 (7)
y) Reactions with thiols or sulphinic acids
The reaction of S-nitrosothiols with thiols or sulphinic acids gives good yields of 
unsymmetrical disulphides and thiolsulphonates respectively (Oae et al., 1977a&b). 
This is the most convenient synthesis of mixed disulphides or thiolsulfonates as their 
preparation can be carried out as a one-pot synthesis by addition of an equimolar 
amount of N2O4 (in CCI4) to an ethereal solution of the thiol. A greenish or reddish 
colour appears due to formation of the corresponding S-nitrosothiol and subsequent 
addition of an equimolar amount of another thiol or sulphinic acid results in the 
formation of the asymmetric product which can be obtained by evaporation of the 
solvents (8 ).
R’SH _  RSSR'
RSNO -----------  (8)
R"SOoH RSSO2R"
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vi) Reaction with amines
Treatment of S-nitrosothiols with cyclic secondary amines produce N-nitrosoamines 
(R2NNO) (Oae et al., 1977b), N-Methylaniline was converted to N-nitroso-N-methyl 
aniline with S-nitrosothiols in a good yield (9).
PhNHMe + t-ButylSNO PhNMeNO (9)3 days, 92%
S-nitrosothiols can also be used to prepare aryl halides in excellent yields by reaction 
with arylamines in the presence of copper (II) halides (Oae & Shinhama, 1983) (10).
C 11X 2ArNH2 + t-ButylSNO------► ArX + N2 + t-ButylSSButyl-t + (t-Butyl)2S3 (10)
0-25'C
CH3CN
2.2 S-NITROSO-N-ACETYL-DL-PENICILLAMINE
(SNAP)
2.2.1 History
SNAP was first synthesised, characterised and its X-ray crystal structure obtained by 
Field et al. in 1978. In the crystalline state, it is the most stable S-nitrosothiol known to 
date, although in solution it decomposes to release NO and form its disulphide (see 
part 2 of section 2.2). It has been shown to be a potent relaxant of vascular smooth 
muscle and consequently a fast acting vasodilator (Ignarro et al., 1981b). Along with 
other S-nitrosothiols, it possesses anticoagulant properties, as it inhibits the aggregation 
of blood platelets and their adhesion to the sub-endothelium (Radomski et al., 1992).
SNAP is a single peptide based on penicillamine. In the solid state SNAP hydrogen 
bonds between the carboxyl and amide groups. It is readily reduced by 
tetrahydroborate to give the disulfide (Field et al., 1978; 11) and undergoes reduction
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by carbon electrodes to form N-acetyl-DL-penicillamine (12) (Takeuchi & Osteryoung, 
1985).
0NSCMe2CH(NHAc)C02H [-SCMe2CH(NHAc)COÿl]2 (11)
RSNO + H+ (RSNO)H+ ; (RSNO)H+ + e- RSH + NO (12)
It can also react with olefins such as methyl methacrylate in the presence of peroxides, 
such as benzoyl peroxide to form hard polymers (13). The same reaction can be 
initiated with UV radiation (Field et al., 1978).
R' R’
RSNO ^  RS ------► RSCH2CH ------► RS(-CH2CH-)„SR (13)
R= -CMe2CH(NHAc)C02H
The parent amino acid, penicillamine, has a strong binding affinity for certain metal 
ions, particularly copper. This property is utilised in the treatment of Wilson's disease, 
where the deposition of excessive amounts of copper causes damage to a wide variety 
of organs and can be fatal without treatment. D-penicillamine, but not L-penicillamine 
(due to its toxicity) is used to chelate the excess copper to treat this disease. If patients 
become tolerant to penicillamine, triethylenetetramine (TETA) is used as a substitute. 
This property of penicillamine could possibly explain why the stability of SNAP, one 
of its nitrosated derivatives, is dramatically affected by copper ions (see Chapter 3).
2.2.2 The chemistry o f SNAP in aqueous solution
i) Results and Discussion
To determine if SNAP, like other S-nitrosothiols previously reported (see reactions 
of S-nitrosothiols), decomposed in aqueous solution to form its disulphide
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(oxidised N-acetyl-DL-penicillamine) and NO, two methods were employed to identify 
the two proposed products.
a) High performance liquid chromatography (HPLC) was used to examine the purity of 
SNAP synthesised by a modified version of the method employed by Field et at. 
(1978) using acidified nitrite (Figure 2,1). HPLC traces of both the starting material  ^
N-acetyl-DL-penicillamine, and the proposed product of decomposition of SNAP, 
oxidised N-acetyl-DL-penicillamine (Figure 2.1), were also obtained. A 5xlO*^M 
solution of SNAP in distilled water was then left to decompose for 3 hours in the dark 
at 30"C (to mimic other experiments carried out on SNAP decomposition described in 
the forthcoming chapters). The HPLC trace of this solution was then obtained and 
compared to that of oxidised N-acetyl-DL-penicillamine synthesised by a method 
described by Field et al. (1978).
The results shown in Figure 2.1 show that decomposed SNAP solution had a similar 
HPLC trace to that of the oxidised N-acetyl-DL-penicillamine, with the appearance of 
two peaks at similar retention times of 21.39 and 22.04 mins to that of 21.59 and 22.26 
mins for oxidised N-acetyl-DL-penicillamine. The slight difference is almost certainly 
due to experimental error caused by manual operation of the detector component of the 
machine. The appearance of two peaks in both cases, is due to the formation of 2 
diastereomers (LD and DL) and 2 enantiomers (DD and LL) present from the use of 
racemic N-acetyl-DL-penicillamine. The symmetry of the shapes and sizes of these 
peaks suggests that the enantiomers have the same retention time which is slightly 
different from tliat of the diastereomers.
b) The Greiss Test - The second product of SNAP decomposition is NO. As mentioned 
in Chapter 1.9, in aqueous solution NO is rapidly hydrolysed to form nitrite (NO2"), 
but no nitrate (NO3"). Consequently the use of the Greiss reagent (which uses 
diazotisation in a colorimetric assay of nitrite concentration) indirectly measures the
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concentration of NO produced. A standard line graph using different concentrations of 
sodium nitrite (NaNOi) in excess quantities of Greiss reagent was constructed, after 
ensuring that the Greiss reagent itself did not change colour over the course of the 
reaction. Subsequently, concentrations of SNAP (from 60-500|iM) were made up in 
distilled water. The solutions were kept in the dark to inhibit photolysis of the 
compound, but they were kept at 50*C to increase the rate of decomposition of SNAP 
(see Chapter 4). After 30 minutes the samples were diluted by a factor of 10 in 
Greiss reagent and the resulting solutions (^-50jxM initial SNAP concentrations) were 
assayed at 549nm after 15 minutes for nitrite concentrations.
SfiI
s
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Figure 2.2 A graph using the Greiss test to show that there is 100% conversion of 
NO to NO2' from SNAP in aqueous solution, using NaNOz as the standard for the 
Greiss test, {open circles) NaNOz y = 0.041x - 0.000, r=l .000.
(closed circles) SNAP y = 0.038x - 0.042, r-1.000.
Figure 2,2 shows that there is a good correlation between the concentrations of nitrite 
expected and those obtained from the decomposition of SNAP. The small differences
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are possibly due to experimental error or a fraction of the nitrite produced being 
oxidised to nitrate.
These two results prove that SNAP, like other nitrosothiols, decomposes to form its 
disulphide with loss of NO, even though initial molecular calculations carried out on 
penicillamine by C.H. Gorbitz (personal communication) suggest that its disulphide is 
unfavourable due to steric hindrance between the two sets of gem-dimethyl groups.
ii) Experimental
a)Syntheses
SNAP
N-acetyl DL penicillamine (5m mol; 0.96g) was dissolved in MeOH (10ml), IM HCl 
(10ml) and conc. H2SO4 (1ml). NaN0 2  (lOmmol; 0.69g) in H2O (10ml) was added 
dropwise over 20 minutes with vigorous stirring at room temperature. After a further 
15 minutes, SNAP was separated off, washed with water and air dried. All the 
solvents were cooled in water before the concentrated H2SO4 was added, to minimise 
the rise in temperature of the solution. The reaction vessel was covered in aluminium 
foil to exclude light from the reaction. On addition of the NaN0 2  a green colour was 
observed and SNAP was filtered off as green crystals with a red reflection. Mpt.l49°C 
(lit. 152-154°C, Field et al, 1978); ÔH (300MHz,CD3 0D), 2.16 (3H,s,COCH3), 2.20 
(3H,s,CCH3), 2.23 (3H,s,CCH3), 5.51 (lH,s,CH); ÔC ( 300MHz,CD3ÜD), 22.56 
(CH3CO), 26.09 (CH3C), 27.54 (CH3C), 59.00 (CH3-C-CH3), 61.46 (CH), 172.49 
(COCH3), 173.50 (CO2H). Found: C, 37.8; H, 5.68; N, 12.6%. C7H 12O4N2S 
O.14H2O requires C, 37.8; H, 5.5; N, 12.3%. miz (FAB) 221.0596 (C7H12O4N2S 
requires 221.0596). One peak only on HPLC see Figure 2.1.
N-acetyl DL penicillamine disulphide (oxidised N-acetyl-DL-penicillamine)
This was formed by refluxing SNAP in MeOH (0.11IM). After approx 2hrs the colour 
disappeared, and the disulphide was obtained by evaporation of the solvent, in 100%
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yield, ÔH (SOOMHz.CD^OD), 1.59-1.62 (12H,4xs,4xCH3>, 2.20 & 2.21 
(6H,2xs,2xCOCH3), 4.72 & 4.75 (2H,2xs,2xCH); ÔC (300MHz,CD3 0 D), 22.61 
(2 XCH3CO), 24.77 (CH3O , 25.00 (CH3C), 27.21 (CH3C), 27.40 (CH3C), 51.96 
(2XCH3-C-CH3), 61.27 (2xCH), 173.13 (COCH3), 173.50 (CO2H), 173.55 (COgH). 
mJz (FAB), 403 (M++ Na), 381 (M++ H).
b) HPLC - The purity of SNAP was examined by reverse phase HPLC at 215 and 
340nm and found to give only one peak for each wavelength at the same retention time. 
0.5mM solutions of the synthesised N-acetyl-DL-penicillamine disulphide and the 
decomposed solution of SNAP were also injected into the machine under the same 
conditions and their HPLC traces were obtained. In addition, the trace of the reduced 
form of N-acetyl-DL-penicillamine was also run to compare the retention time 
differences between the different derivatives of acetyl penicillamine.
Apparatus -The HPLC system contained a Perkin-Elmer LC-235 Diode Array Detector 
and a Perkin-Elmer Series 410 LC pump system linked by a Lichroscorb RP-18 
column (0.46 x 25cm, 10pm).
Conditions - The solvent system consisted of 0.05% trifluoroacetic acid/water (A) and 
0.035% trifluoroacetic acid/acetonitrile (B) using a linear gradient of 90%(A) 10%(B) 
for 10 mins going to 80%(A) 20%(B) over the next 20 mins and then to 70%(A) 
30%(B) over the following 10 mins. The solvent was monitored at 215 and 340nm 
with band widths of 15nm at each wavelength and with a sensitivity setting of 0.1 
absorbance units.
c) Measurement of nitrite concentrations
l)The Greiss Test (developed by Saltzman, 1954)
All reagents were made from analytical grade chemicals and kept in stoppered brown 
bottles in the refrigerator to prolong their stability.
N-(l-Naphthyl)-ethylenediamine dihydrochloride (0.1%) - O.lg of the reagent was 
dissolved in 100ml of water to produce the stock solution.
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Absorbing (Greiss) Reagent - Sulphanilic acid (5g) was dissolved in almost one litre of 
water containing glacial acetic acid (140ml). 0.1% stock solution of N-(l-naphthyl)- 
ethylenediamine dihydrochloride (20ml) was added and the reagent was made up to one 
litre.
2) preparation of standard NaN02  samples
A 0.05M solution of NaNOa (0.345g in 100ml of distilled water) was made up and 
diluted 100 fold to obtain a 500pM stock solution. This was further diluted to make up 
330, 250, 125, and 62.5pM solutions. Subsequently, 0.3ml of these solutions were 
diluted 10 fold in 2.7ml of Greiss reagent in the spectrometer cuvettes. The deep 
purple colour of diazosulphanilic acid, formed by the action of nitrite on sulphanilic 
acid, was allowed to develop to a maximum absorbance value over 15 minutes. The 
maximum absorbance values for aU the NaNOi solutions were recorded and plotted 
against nitrite concentration to give the standard straight line graph shown in Figure 
2 .2 .
3) preparation of SNAP samples
Five separate stock solutions of 500pM SNAP (0.01 Ig in 100ml distilled water) were 
prepared and each one was further diluted to make up 330, 250, 125, or 62.5pM 
solutions of SNAP. These solutions were incubated in the dark at 50“C to increase the 
rate of decomposition of SNAP for 30 minutes until all the SNAP had disappeared. 
0.3ml of these solutions were then added to 2.7ml of Greiss reagent to dilute the 
samples 10 fold in the same way as the NaN0 2  samples. The maximum absorbance 
values for all the concentrations were recorded and the straight line graph of nitrite 
produced versus absorbance was drawn (see Figure 2.2).
As a check, the Greiss reagent containing 0.3ml of only distilled water was left in the 
spectrophotometer for the 15 minute period and the absorbance at 549nm was
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monitored. There was no increase in absorbance with time, indicating that there was no 
detectable nitrite present.
2.3 S-NITROSOGLUTATHIONE (GSNO); AN S-NITROSOTHIOL 
MORE STABLE IN AQUEOUS SOLUTION
2.3.1 History
S-nitrosoglutathione (GSNO) was first synthesised and characterised in 1985 by Hart 
using a modification of a method designed by SaviUe (1958). GSNO is a derivative of 
the tripeptide glutathione (L-y-glutamyl-L-cysteinyl glycine), which is found in 
numerous cellular systems and is considered an essential constituent of all living cells. 
Glutathione is generally the most abundant intracellular non-protein thiol (Meister & 
Anderson, 1983), with a concentration approaching 2-3mM in erythrocytes. 
Consequently, the discovery of EDRF and the suggestion that it is an S-nitrosothiol 
(see Chapter 1.4), together with evidence that the physiological half-life of NO can 
be stabilised by thiols (Ignarro et al., 1980a; Stamler et ai, 1992a; Feelisch et al., 
1994), raises the possibility that S-nitrosoglutathione could be the most important S- 
nitrosothiol synthesised in vivo and involved in numerous physiological processes.
Since 1985, GSNO has been synthesised by other researchers using different methods 
(Park & Means, 1989; Clancy & Abramson, 1992). Clancy and Abramson used a 
column containing red agarose to synthesise GSNO. This was prepared by coupling 
2,2-dithiobis(ethylamine) to Bio-Gel A through an amide linkage and after reduction to 
form reduced thiol using dithiothreitol, the immobilised thiol was treated with NaNOi 
(at pH 2) to form bound S-nitrosothiol. Addition of thiols, such as glutathione,to the 
column produced a transfer of the S-nitroso moiety from the immobilised thiol to the 
fluid phase thiol and stoichiometric amounts of S-nitrosoglutathione were formed.
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GSNO has been shown to be a hypotensive drug as effective as sodium nitroprusside 
(Means & Park, US patent 1989) and a potent inhibitor of platelet aggregation 
(Radomski et al., 1992). Along with SNAP, it is one of the few stable S-nitrosothiois 
in the crystalline state, and, although SNAP is more stable, GSNO kept at 4'C or 
below is stable over a number of months (Park & Means, 1989; Askew, unpublished 
results). A possible reason why pure S-nitrosothiols are so difficult to isolate in the 
solid state could be due to self-decomposition. It has been proposed that they 
decompose spontaneously by second order kinetics (Park, 1988) and so evaporation of 
the solvent leads to increased concentration and more chance of rapid decomposition to 
their disulphides,
A chemical and physiological comparison of the actions of GSNO and SNAP are the 
subjects of a large proportion of this thesis. Interesting and informative data have been 
compiled which gives an insight as to why these two compounds act differently and 
how S-nitrosothiols might be developed in the future to improve their pharmacokinetic 
profiles and target their actions better.
2.3.2 The aqueous chemistry of GSNO compared with that o f SNAP
i) Results and Discussion
Many workers have shown that GSNO decomposes to form NO and oxidised 
glutathione under oxidative conditions (Park & Mean, 1989; Radomski et al., 1992; 
Shaw et al., 1990). However, the rate at which this process occurs in aqueous solution 
is far slower than for SNAP under the same conditions. The main reason for this will 
be discussed in the next chapter, but in repeated experiments following the 
decomposition profiles of SNAP and GSNO at 339nm (the wavelength at which the S- 
NO moiety of S-nitrosothiols absorbs and the A^max of SNAP; see Figure 2.3) 
consistent absorbance profiles were observed for both SNAP and GSNO, with GSNO 
remaining stable over intervals during which SNAP completely decomposed. In fact
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GSNO remains stable in the phosphate buffer (pH7.4) at 30"C for many hours and 
nearly 50% of the nitrosothiol remains after 35 hours under these conditions. Figure
2.4 shows the marked difference in aqueous stabilities of these two S-nitrosothiols.
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Figure 2.4 A graph showing the relative decomposition profiles of GSNO and SNAP 
at 30 V  in phosphate buffer pH7.4,
(open circles) GSNO (OAmM, n=6) (closed circles) SNAP (OAmM, n=ll).
ii) Experimental
GSNO synthesis
To a stirred ice-cold solution of glutathione (1.53g, 5mmol) in water (8ml) containing 
2N HCl (2.5ml) and protected from light by aluminium foil, was added in one portion 
sodium nitrite (0.345g, 5mmol). After 60 minutes at 5'C, the red solution had 
developed into a red sludge and was filtered off and washed, successively, with ice 
cold water (3xlml), acetone (3xlOml) and sodium-dried ether (3x10ml) to afford S- 
nitrosoglutathione (1.28g, 3.8mmol, 76%). (H2O) 335, 545nm. Found: C, 35.2;
H, 4.7; N, 16.3. CioHi60'yN4S O.25H2O requires C, 35.2; H, 4.9; N, 16.4%. m!z
6 6
(FAB) 337 (M++ H). Only one peak was present on the HPLC trace at a retention time 
of 14.9 mins. (for HPLC details see experimental section of Chapter 2.2). The same 
solvent systems as those used for SNAP were used, but a different linear gradient of 
100%(A) for 10 mins going down to 90%(A) 10%(B) over the next 10 mins and then 
to 80%(A) 20%(B) over the following 20 mins. The solvent was monitored at 215 and 
340nm with band widths of 15nm at each wavelength.
Kinetic studies
The kinetics of decomposition of SNAP and GSNO were monitored by following the 
reduction in absorbance at 339nm using a Phillips PU8700 UV/Vis scanning 
spectrophotometer with a Pye Unicam cell temperature control unit. All experiments 
were carried out at 30°C in a phosphate buffer at pH 7.4. A stock solution of the 
buffer was made up from 250ml of 0.1 M KH2PO4 (3.4g) and 195.5ml of O.IM NaOH 
diluted to 500ml with distilled water.
GSNO (0.0135g) was diluted in 10ml of ice cold phosphate buffer (protected from 
photochemical decomposition by aluminium foil) to make up 4mM solution. 0.25ml 
aliquots of this solution were injected into spectrophotometer cuvettes containing 
2.25ml of the phosphate buffer alone at 30*C in the cell programmer carriage, diluting 
the solutions to 0.4mM. Tlie same process was carried out for SNAP using a 4mM 
stock solution (0.0088g in 10ml ice cold distilled water) protected from light. As soon 
as the cuvettes were full (2 for GSNO and 2 for SNAP), which was timed and took 
approximately 1 minute, the computerised timer was started and absorbance readings 
were taken at 10 minute intervals for all the cuvettes using the automated cell 
programmer. The buffer solution alone was used as the standard in the first of the 5 
cuvettes.
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2.4 A COMPARISON OF THE VASODILATOR PROFILES OF GSNO 
AND SNAP ELICITED IN THE RAT TAIL ARTERY
i) Experimental
Preparation
The vasodilator actions of SNAP and GSNO were determined by experiments 
performed on segments of tail artery taken from normotensive adult Wistar rat (250- 
460g) which were killed by cervical dislocation. A length of artery (0.8-1.5 cm) was 
dissected free from connective tissue and overlying skin, cannulated (Portex cannula) 
and transferred to a perspex bath (Figure 2.5).
Apparatus
The cannula (C) forms part of a constant flow perfusion driven by a peristaltic pump 
P(l) (Gilson Minipuls 2). The length of artery (A) was perfused internally (flow rate 2 
ml,min-i). The solution was pre-warmed to 31-33'C by passage through a heat 
exchanger. Drugs were introduced into the lumen of the artery by bolus injection 
(lOjxl) through a side tube (I)). The outer surface of the artery was superfused 
continuously with Krebs solution from a second peristaltic pump (P(2)). The 
temperature of the bath was held at 30-33 °C by adjustment of the flow rate of the 
superfusing solution (ca. 8 mLmin~^). This temperature range was chosen since 
phenylepherine-induced perfusion pressures remained more stable than at 37“C over the 
time periods (up to 8 hours) required to complete the experiments. A differential 
pressure transducer (T; sensym type SCX 150NC Famell Electronic Components, 
Leeds, UK) detected changes in back pressure caused by changes in arterial tone. 
Responses were displayed on a computer and chart recorder.
Experimental Protocol
Arteries were perfused internally with Krebs solution (composition, mM, NaCl 118, 
KCl 4.7, NaHCO] 25, NaH2P0 4  1.15, CaCl2 2.5, MgC^ 1.1, glucose 5.6, gassed
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with O2/CO2 (95%:5%) to maintain pH at 7.4). The initial flow rate was low but was 
gradually increased over 20 min to reach a final value 2 mUnin' .^ The preparation was 
allowed to stabilise for 20-30 min, after which the artery was precontracted by addition 
of phenylephrine hydrochloride to the Krebs buffer ([PE]: mean (± s.e.) = 2.7±0.3|xM 
gave agonist induced perfusion pressure: mean (± s.e.) = 102±2.9mmHg)
Responses to bolus injections of SNAP and GSNO were recorded. All experiments 
were conducted in a darkened laboratory with a red safety light (60 W) as the sole 
means of illumination.
Drugs: use
SNAP & GSNO - lO'^M solutions of SNAP and GSNO were made up in Krebs buffer 
and serially diluted to the concentration required for injection immediately prior to use. 
Both S-nitrosothiols solutions were kept in the dark and on ice at all times to minimise 
any type of decomposition.
N.B. The concentrations of the drugs injected (indicated in the figures) are virtually the 
same as the concentrations which reach the tissue due to the rapid injection time (<0.5 
seconds) and the drug travelling through the narrow bore tubing as a bolus. However, 
a submaximal response produced by 7p.M SNAP administered by perfusion was 
matched by a 3mM Injection of SNAP, This suggests that less than l/400th 
(l/428th) of the drug concentration delivered to the artery by injection (as a bolus) is 
reaching its site of action.
L-phenylephrine hydrochloride - (MW 203.7; Sigma Chemicals). Appropriate volumes 
of a lOmM stock solution were added to internal and external perfusates to produce the 
required concentration which gave the necessary active pressure.
Measurement of drug induced pressure changes for log dose/response 
curves
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The pressure increase Induced by the agonist, PE, was taken to be the active pressure 
(see Figure 2.6). This was calculated by subtracting the total pressure reading 
immediately before each injection of the test drug, from tlie pressure maintained by the 
artery before PE was added (termed the passive pressure). The pressure drop caused by 
the test drug, for each concentration, was measured and expressed as a % of the active 
pressure immediately prior to injection. The mean % relaxation and the standard error 
of the means (s.e.m.) for each concentration were calculated for the number of 
preparations n (indicated in the legends of the figures) and plotted against drug 
concentration (log dose /response curves).
ActivePressure
4 mins
= 3  Passive^4uM P.E.#j Pressure=
Figure 2.6 Pressure recordings showing precontraction with PE. 4pM PE was 
added to the internal and external perfusate reservoirs at the time indicated. The 
pressure maintained by the vessel before PE addition is termed 'passive', whist 
agonist-induced pressure is 'active'. Expt.No 92/311.
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Statistical analysis of data in figures
Statistical analysis on the data was carried out using an unpaired students t test 
* indicates data is significantly different at the P=0,05 confidence level 
** indicates data is significantly different at the P=0.01 confidence level 
*** indicates data is significantly different at the P=0.001 confidence level
ii) Differences between the perfused rat tail artery bioassay and the 
commonly used rabbit aortic ring bioassay.
The perfused rat tail artery as the bioassay system was used as an alternative to the 
commonly used organ bath containing rabbit aortic ring preparation. The apparatus is 
a modified version of that used by Flitney et al. (1992). Compared with the rabbit aorta 
rings system there are a number of important differences of this system. Firstly, the 
test drugs are injected through a side tube (I) located close to the cannula (C) which 
connects the rat tail artery (A). This means the drug passes through the artery, in 
contact with its internal surface, unlike the situation for the rings of rabbit aorta which 
are submerged in physiological buffer in which the test drug is injected. Consequently, 
both internal and external surfaces are exposed to the test drag, which would not be the 
case in vivo. Secondly, the injection of the test drag through into the internal perfusate, 
immediately before the cannula, means the drug reaches the rat tail artery in a matter of 
seconds as a bolus. This results in a larger dose of the drag being required to give the 
same response to that attained in the ring system, as only the small fraction of the bolus 
will be exposed to the tissue (see experimental section). However due to the ‘flow 
through' nature of tlie internal circuit, the higher concentration of drug passes through 
the artery quickly (approx. 0.3 secs) and does not appear to damage the tissue as 
pressure rapidly returns to its pre-injection value (see Figure 2.7). When carrying out 
constant perfusion experiments, in which the artery is continuously exposed to the test 
drug from tlie internal perfusate, lower concentrations of the drug are required for 
maximal relaxation of the artery ( Chapter 7).
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Figure 2j\pressure recordings of responses of the rat tail artery to bolus injections of SNAP
(Top trace) and GSNO (bottom trace) after precontraction with phenylephrine (PE) 4f.tM. 
(SNAP Expt. N^ 91111/9, GSNO Expt. No 9314123). See Experimental section for definitions of 
Passive and Active pressures.
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Hi) Results and Discussion
Both SNAP and GSNO are fast acting and potent vasodilators. As can be seen in 
Figure 2.7 the responses are sharp, appearing soon after injection, and they fully 
recover, in a matter of minutes, to the original precontracted tone of the artery.
When traces like those shown in Figure 2.7 are translated into log/dose response 
curves like those shown in Figure 2.8, it is evident that SNAP is a more effective 
vasodilator. Arteries are approx. 18 fold more sensitive to SNAP than to GSNO with 
an ED50 value of 3.2jxM compared to that of 59|lIM . The differences are statistically 
significant at the 99.9% confidence level, at lOjiM and lOOjiM doses. The log/dose 
response curves are also significantly different at the 95% confidence level for doses of 
lp,M. The possible reasons why SNAP is a better vasodilator than GSNO will be 
discussed in later chapters.
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Figure 2.8 Log [dose]/response cwyes comparing the vasodilator potencies of SNAP 
(closed circles, n=ll’20) and GSNO (open circles, n-6-16).
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2.5 THE SYNTHESIS AND STABILITY OF SOME OTHER S-
NITROSOTHIOLS
The syntheses of a number of other S-nitrosothiols derivatives of penicillamine, 
glutathione and cysteine were attempted using some of the nitrosation methods 
mentioned in Chapter 2.1. Comparisons of their aqueous stability and relative 
physiological properties as inhibitors of platelet aggregation and vasodilators were 
made in an effort to relate their structure differences with activity. Unfortunately the 
syntheses of these compounds proved difficult. Solid, pure, stable products could not 
be obtained in most cases as their disulphides were readily formed, as will be discussed 
later in this chapter. However, impure products containing small amounts of disulphide 
were still potent inhibitors of platelet aggregation (see Chapter 6). Their vasodilator 
action was also tested using rabbit aorta as a bioassay (see Chapter 6).
2.5.1 Syntheses
i) Results and Discussion 
Methods used for S-nitrosation
Two methods were employed to nitrosate the different analogues of cysteine, 
penicillamine and glutathione; acidified nitrite (in an analogous method to that used by 
Hart (1985) and N2O3 produced by the action of concentrated sulphuric acid on sodium 
nitrite.
Nitrosation using acidified nitrite
The addition of sodium nitrite in one portion to an acidified solution of the thiol is 
advantageous for the quick nitrosation and formation of the less stable nitrosothiols as 
this can be conducted with minimal breakdown to the respective dimer. The 
methodology of acidified nitrite nitrosation developed by Field et al, (1978) uses 
sodium nitrite solution which is added dropwise over 20 minutes. This dilutes the 
solution so nitrosothiols that are on the borderline between being soluble and being
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insoluble may not precipitate out of solution. At the same time, for unstable 
nitrosothiols in solution this method takes longer and would result in a less pure 
product. However, the main disadvantage with addition of solid sodium nitrite in one 
portion may lead to some of it remaining undissolved, resulting in contamination of the 
product.
Nitrosation usingN203
It was hoped that this method would give purer products which contained no inorganic 
impurities. Experiments were conducted with the relevant thiol being dissolved in 
water, in ether, or in the solid form. A mixture of NO and NO2 made by adding excess 
H2SO4 , dropwise, to excess sodium nitrite, was carried in a continuous flow of 
nitrogen gas to a vessel containing the thiol on ice. Here, N2O3 is formed and 
nitrosates the thiol. For thiols having a free amine group, the technique seemed to have 
limited use since quantitative production of N2O3 proved difflcult and therefore 
nitrosation of the free amine group was possible.
Penicillamine derivatives
The S-nitrosation of DL-penicillamine and N-formyl-DL-penicillamine were attempted 
using acidified nitrite and N2O3. Equimolar quantities of nitrite and thiol were used for 
nitrosation of the acidified thiol (as used by Hart in the synthesis of S- 
nitrosoglutathione), whereas excess N2O3 was produced by adding concentrated 
sulphuric acid to solid nitrite. Both methods were attempted on both thiols and resulted 
in nitrosation to form green solutions of varying shades. However when concentrated 
solutions were used, green suspensions were obtained which produced solids, in good 
yields, after filtration. Unfortunately the microanalyses of both the nitrosated 
derivatives did not correspond closely with expected values.
Glutathione derivatives
The N-acetyl and N-formyl analogues of glutathione were synthesised and the 
subsequent nitrosations attempted, with the intention of comparing them with the
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penicillamine analogues. The parent thiols were synthesised from glutathione using 
acetic acid and formic acid respectively, in acetic anhydride. Both produced the 
expected products containing small amounts of dimethylformamide (DMF). S- 
Nitrosation of these compounds were carried out using acidified nitrite or N2O3 as the 
nitrosating agent (as above), this resulted in dark pink solutions of S-nitroso-N- 
acetylglutathione and S-nitroso-N-formylglutathione respectively. Both remained pink 
for several days with no signs of decomposition to the disulphide. However, isolation 
of the solid products was not attained as no pink solid precipitated in concentrated 
solutions. When the solutions were freeze-dried, a large portion of the solids formed 
were the respective disulphides.
Cysteine derivatives
The S-nitrosation of several cysteine analogues, N-acetyl-DL-cysteine, N-Boc-cysteine 
and DL-cysteine, using acidified nitrite and N2O3, was attempted. All produced deep 
blood red solutions characteristic of the S-nitrosated derivatives of cysteine. When 
concentrated solutions of the parent thiol were used S-nitrosocysteine produced a bright 
red solid obtained by filtration of the red suspension formed. However, the acetylated 
derivative and the N-Boc derivative only produced red solutions, even in concentrated 
solutions. Use of freeze-drying to isolate a solid produced the disulphide in both cases. 
S-nitrosation of N-Boc-cysteine using N2O3 produced a solid which rapidly 
decolourised to form the disulphide.
Microanalysis of the red solid obtained from S-nitrosation of DL-cysteine showed that 
some disulphide had formed in its isolation as indicated by the high carbon and low 
nitrogen values.
Summary
In most cases it seems apparent that when the solvent is removed to synthesise the solid 
S-nitrosothiol, rapid decomposition occurs, leading to the formation of the relevant
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disulphide. As mentioned in the introduction to Chapter 2.3, a possible reason why 
pure S-nitrosothiols are so difficult to isolate in the solid state could be due to 
spontaneous decomposition. It has been proposed that they decompose by second 
order kinetics (Park, 1988) and therefore evaporation of the solvent would lead to 
increased concentration and more chance of rapid decomposition to their disulphides. 
However our finding that trace metal ions such as copper can catalyse the 
decomposition of S-nitrosothiols (discussed in Chapter 3), would suggest that 
evaporating the solvent merely concentrates these trace metals, promoting more rapid 
decompositon.
When some of these nitrosothiols were synthesised in situ, using equimolar quantities 
of thiol and nitrite (see Section 2.5.2), the resulting solutions were 100% nitrosated 
and in the case of S-nitrosoglutathione produced consistent ^max absorbance values 
when compared to the same compound synthesised as the solid and diluted to the same 
concentration (see Section 2.5.2). It has previously been reported that the reaction 
of thiols with acidified nitrite is essentially irreversible and complete (Aldred et al., 
1982; Byler et al., 1983; Mathews et al., 1993) and it has been suggested that S- 
nitrosation and subsequent decomposition to yield the disulphide occurs only by a base 
catalysed reaction and is much inhibited by reduction of the pH below 4 (Pryor et al., 
1982). It would seem that unstable S-nitrosothiols, or those which have insolubility 
problems when made in concentrated solutions, are best synthesised in situ in acidified 
solutions and the S-nitrosothiols formed then used in subsequent reactions by dilution 
in buffer solutions at the required pH.
ii) Experimental 
Penicillamine derivatives
SNAP
See experimental of Chapter 2.2
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S-nitroso-N-formyl-DL-penîcîllamine (SNFP)
a) Acidified Nitrite
N-formyl D-L penicillamine (0.53g, 3mmol; obtained from the Wellcome Laboratories) 
was added to a solution of water (9ml) and 2N HCl (1.5ml) on ice and the solution 
stirred until the solid dissolved (required heat from steam bath). NaNÛ2 (0.207g, 
3mmol) was added in one portion to the ice cold solution of N formyl D-L 
penicillamine and after 10-15 minutes a green precipitate of nitroso N-formyl D-L 
penicillamine was obtained. Found, C 27.19, H 3.75, N 10.16; C6H 11N2O4S 
requires; C 34.95, H 4.89, N 13.58.
b) Using N2O3
N-formyl D-L penicillamine (0.53g, 3mmol) was added to a volume of water (9ml) in a 
quickfit test tube with a stirrer. The solution was warmed until the N-formyl D-L 
penicillamine dissolved and then the test tube put in an ice/water bath. Excess conc. 
H2SO4 was added dropwise to excess sodium nitrite in a three necked flask and 
nitrogen was passed through the flask, blowing the NO and NO2 produced through to 
the test tube containing the N-formyl D-L penicillamine solution via the third neck of 
the flask linked to the test tube by plastic tubing. The gases were cooled down by the 
ice/water bath to form the deep blue N2O3 solution. A green precipitate of S-nitroso-N- 
formyl D-L penicillamine was obtained.(75% yield). Microanalysis of the nitrosated 
compound did not correspond closely with expected values.
S-nitroso D-L penicillamine (SNPen)
a) Acidified nitrite
To a stirred ice-cold solution of D-L penicillamine (0.746g, 5mmol) in water (8ml) 
containing 2N HCl (2.5ml), was added one portion of sodium nitrite (0.345g, 5mmol). 
After 10 minutes tlie green compound was filtered off and washed with water (lx4ml). 
0.29g (32.6% yield). Found; C 34.39, H 5.68, N 15.14, C5H10N2O3S requires; C 
33.70, H 5.66, 15.72.
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b) Using N2O3
See Synthesis of SNFP. A green compound was formed but microanalysis of the 
nitrosated compound did not correspond closely with expected values.
Glutathione derivatives
SNOG
See experimental section Chapter 2.3
S-nitroso-N-acetylglutathione (SNAG)
a) Synthesis of N-acetyl glutathione
Acetic anhydride (1.5ml) was added to a solution of glutathione (Ig) in acetic acid 
(3ml) at '-40°C. The reaction was followed by thin layer chromatography and was 
complete in 5 hours. A large excess of diethyl ether was added to precipitate the 
product which was separated, washed with ether and left in ethyl ethanoate overnight. 
The crude product was recrystallised from DMF (although absolute ethanol proved to 
be better) and ethyl ethanoate at —20°C (or 0°C for ethanol recrystallisation) 0.31 g 
(28%yield); Found C 42.05, H 5.78, N 12.5, C12H19N3O7S requires; C 41.26, H 
5.48, N 12.03%. The difference was due to C3H7NO (DMF) detected by NMR.
b) Nitrosation of N-acetyl glutathione
Both methods of nitrosation were attempted but no solid product was obtained. The 
final product was a stable deep red solution.
S-nitroso-N-formyl glutathione (SNFG)
a) Synthesis of N-formyl glutathione
Acetic anhydride (1.5ml) was added to a solution of glutathione (Ig) in formic acid 
(3ml) at ~26°C. The reaction, followed by thin layer chromatography, was complete in 
5 hours. A large excess of diethyl ether was added to precipitate the product which was 
separated, washed with ether and left to solidify in ethyl ethanoate overnight. The 
crude product was recrystallised from DMF (although absolute ethanol proved to be
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better) and ethyl ethanoate at —20°C (or O^ C for ethanol recrystallisation). 0.27g 
(24.75%). Found; C 41.39, H 6.41, N 14.01, CnH^^NgO^S requires, C 39.40, H 
5.11, N 12.53%. The difference was due to 1.35moles of DMF (detected by NMR and 
calculated from a microanalysis fit program). ÔH (300MHz, D2O), 1.9-2.3 
(2 H,m,CH2CHNH), 2.45 (2H,t,COCH2CH2CHNH), 2.95 (2H,d,£H2SH), 3.92 
(2 H ,s ,CH.2COOH), 4.36 (H,q,NHGHCH2), 4.57 (H.t.CHCHoSHl. 8.15 
(H,s,NHCHO). ÔC (300MHz, D2O), 26 (CH2SH), 27 (CH2CHNCOOH), 32 
(ÇH2CH2CHNCOOH), 41 (ÇH2COOH), 50 (ÇHCH2SH), 55 (NHCHCOOH), 161 
(NCHO), 170,171,172,173 (2C00H & 2NHC0).
b) Nitrosation of N-formylglutathione
Both methods of nitrosation were attempted but no solid product was obtained, only a 
stable deep red solution.
Cysteine derivatives
S-nitroso-DL-cysteine (SNC)
a) Acidified nitrite
To a solution of cysteine (0.75g, 5mmol) in ice cold water (4ml) and 2N HCl (2.5ml) 
was added sodium nitrite (0.345g, 5mmol) in one portion and the product was isolated 
after 3-5mins giving a red crystalline powder. 0,47g (62.6% yield). Found; C 29.9, H 
5.03, N 11.66, C3H6N2O3S requires; C 24.0, H 4.03, N 18.66%
b) Using N2O3
See Synthesis of SNFP. A red compound was obtained but the microanalysis was a 
poor fit with expected percentages.
S-nitroso-N-acetyl cysteine (SNAC)
a) Acidified nitrite
N-acetylcysteine (1.676g) was dissolved in methanol (20ml), IN HCl (20ml), and 
conc. H2SO4 (2ml). Sodium nitrite (1.38g) was added dropwise over 20 minutes and 
the solution was left to stir for another 15 minutes. A blood red solution was obtained
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but no solid product. Precipitation with acetone gave a white solid which had a melting 
point of 300°C suggesting that tlie dimer had been formed.
b) Acidified nitrite (using acetone and not water as solvent)
To a solution of N-acetylcysteine (1.676g, 8.7mmol) in ice cold acetone (14ml) and 2N 
HCl (4.35ml) was added sodium nitrite (0.60g, 8.7mmol) in one portion and left to stir 
for 25 minutes at 5°C. No solid product was obtained. After removing the acetone 
under vacuum a white solid was formed (mpt. >3(X)°C).
c) Using N2O3
See synthesis of SNFP. This method of synthesis gave a blood red solution which 
was freeze dried to remove the water and afforded a light pink solid. The microanalysis 
indicated that the product was mainly the N-acetylcysteine dimer.
S-nitroso-N-Boc cysteine (SNBC)
a) Acidified niuite
See synthesis of S-nitroso D-L cysteine (SNC). A red solution was obtained and no 
solid product could be isolated.
b) Using N2O3
See synthesis of SNFP. A deep red solution was obtained but no solid product could 
be isolated. Synthesis of the nitrosothiol using the same method but no solvent resulted 
in rapid decolourisation of the red solid formed to the white disulphide.
2.5.2 The aqueous chemistry of S-nitrosothiols synthesised in situ.
1) Results and Discussion
Synthesis of GSNO in situ and measurement of its extinction 
coefficients at different wavelengths
GSNO was synthesised in situ by making up a 12.5mM solution in H2SO4 (0.4M) 
using equimolar concentrations of the tliiol to solid sodium nitrite and 0 .1ml of this
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solution was added to 2.4ml of triple strength (i.e. 0.3M KH2PO4/O.3M NaOH instead 
of O.IM of each solution) buffer at pH7.4. This gave a GSNO solution of 0.5mM with 
an absorbance reading of 0.5 at 339nm. When this was compared to the 0.5mM 
GSNO solution made up from dilution of the solid (synthesised as described in 
Chapter 2.3) in phosphate buffer at the same wavelength, it is evident that the 
absorbance value is the same (0.5; see Figure 2.9). When the same experiments are 
done using SNAP instead of GSNO, equivalent absorbance readings at 339nm of 0.56 
are also attained for both 0.5mM solutions made up from SNAP synthesised in situ or 
from the pure solid (see Figure 2.10 and Figure 2.11 at T=0).
These results support the work of Aldred et al. (1982), Byler et al. (1983), Mathews & 
Kerr (1993) and Pryor et al. (1982), who propose that reaction of thiols with acidified 
nitrite is essentially irreversible and complete and that S-nitrosation and subsequent 
decomposition to yield the disulphide occurs only by a base catalysed reaction and 
reactions are much inhibited by reduction of the pH below 4.
The stability of S-nitroso-D,L-penicillamine (SNPen) and S-nitroso- 
D,L-cysteine (SNC) and their N-acetylated derivatives (SNAP and 
SNAC) in aqueous solution
The above mentioned nitrosothiols were synthesised in situ using equimolar quantities 
of thiol to sodium nitrite and H2SO4 (0.4M) as the acidified solvent. These solutions 
were diluted 25 fold in triple strength phosphate buffer (as above) to form 0.5mM 
solutions of the compounds and the decrease in their absorbance at 339nm were 
monitored (see Figure 2.11).
SNAC proved to be a very stable S-nitrosothiol in solution, far more stable than SNC, 
suggesting that there is a large stabilising effect from the acetyl group. Interestingly, 
SNAP is far less stable than SNAC and also less stable than SNAP synthesised as a 
pure solid and subsequently diluted to a similar concentration (see
83
2 n
1.5-
S
§AI
0.5
0 0.5 1 1.5 2
Concentration GSNO (mM)
□ 299nm e = 369M’W ”^  o  546nm e = 12.7M-^cm-^
■ 386nm e = 283.8M“^ cm"^  #  335nm e = 855.5M"^cm“^
▲ 339nm e = 843.6M'^cm"^ o 407nm e=  119.4M‘ c^m"^
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Figure 2.4). In this case, the SNAP had disappeared over 40 minutes whereas in 
Figure 2.4 the average of 11 runs suggests tliat about 35% of SNAP still remains 
over tlie same time period. The only differences between these two experiments^other 
tlian the method of SNAP syntliesis, is the increased buffer capacity used when making 
SNAP in situ to buffer against the addition of the acidic solution of S-nitrosothiol and 
the slightly higher concentration of nitrosothiol used in this experiment (0.5mM 
compared to 0.4mM). Both of these factors should not account for the large 
differences in SNAP decomposition rates. However, even with this increased rate of 
SNAP decomposition, a trend was evident as SNAP was still found to be more stable 
tlian the non-acetylated SNPen.
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Figure 2,11 The comparative stability of SNC, SNAC, SNPen, SNAP in phosphate 
buffer at pH7A, comparing their absorbance profiles at 339nm. SNC, (closed 
diamond), SNAC (open square), SNPen (open triangle), SNAP (closed circles).
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It seems reasonable to conclude tliat the acetyl group has a stabilising effect on small S- 
nitrosothiols and the reasons why SNAC is more stable than SNAP (synthesised in situ 
or as a pure solid) will be discussed in more detail in Chapter 3.
ii) Experimental
Synthesis of GSNO and the other S-nitrosothiols in situ 
0.4M H2SO4 (5ml) was added to glutathione (0.02Ig) and sodium nitrite (0.0044g) 
crystals in an aluminium foil covered vessel on ice. 0 .1ml of the resulting pink/red 
solution was added to 2.4ml of phosphate buffer (0.3M KH2PO4/  0.3M NaOH) at 
pH7.4 in a spectrophotometer cuvette at SO^’C and the absorbance reading taken.
The same method was used for the other S-nitrosothiols mentioned in this section and 
the changes in absorbance at 339nm were monitored at timed intervals to gain their 
stability profiles in aqueous solution shown in Figure 2.11.
The calculation of extinction coefficients of SNAP and GSNO at 
different wavelengths
l.SmM solutions of SNAP (3.3mg in 10ml) and GSNO (5mg in 10ml) in phosphate 
buffer (O.IM KH2PO4/O.IM NaOH) pH7.4, 30“C, were made up in the presence of 
ImM EDTA (3.7mg in 10ml) to stop metal ion catalysis see Chapter 3. These two 
solutions were diluted down further, using the buffer, to form solutions of 
concentrations 1.125mM, 0.844mM, 0.633mM and 0.399mM and the absorbances of 
the 5 concentrations for both GSNO and SNAP were monitored and recorded at 
299,335 (GSNO only; Imax), 339, 385, 407, 578.5 (SNAP only; Iniax) and 546nm 
(GSNO only; Xmax)-
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CHAPTER 3 
THE
METAL ION-CATALYSED 
DECOMPOSITION 
OF
SNAP & GSNO
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3.1 INTRODUCTION
Much of this work was carried out in collaboration with Prof. D.H.L, Williams's research group at 
Durham University. However any of the figures presented in this section have been constructed from 
data I have obtained.
In chapter 2 it was shown that S-nitrosothiols such as SNAP decompose in aqueous 
solution at physiological pH to produce their disulphide and nitrite (NO2") 
quantitatively (Figures 2.1 & 2.2). If oxygen is vigorously excluded from the 
aqueous SNAP solution then no nitrite is formed and nitric oxide can be detected using 
an NO-probe (Askew & Barnett et al., 1994 in prep). Furthermore, if SNAP is 
allowed to decompose in the presence of N-methylaniline by following the reaction at 
275nm, a quantitative yield of N-methyl-N-nitrosoaniline was obtained (Askew & 
Bamett et al., 1994 in prep). If oxygen was excluded no nitrosamine was formed.
These results can be rationalised in terms of release of nitric oxide, which in the 
presence of oxygen produces a reagent capable of electrophilic nitrosation. This is 
consistent with the mechanism postulated in Chapter 1.9 proposing the formation of 
N2O3 as the nitrosating agent (1).
NO + I/2O2 ------► NO2
(1)NO2 + NO ^  N2O3
As this species would not be formed in the absence of oxygen, it would be expected 
that no electrophilic nitrosation of N-methylaniline would occur. These results imply 
that the reaction of NO2 with NO is much faster than the hydrolysis of NO2, which 
would produce an equal mixture of nitrite and nitrate. As the sole product of SNAP 
decomposition is nitrite, N2O3 is the favoured species. However it has been 
postulated, that an, as yet, uncharacterised species NxOy"’ could be formed and act as 
the nitrosating agent (Wink etaL, 1993).
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Whatever the mechanism by which S-nitrosothiols like SNAP are decomposed to 
produce nitrite at physiological pH, the rate at which it occurs, or more correctly, the 
rate at which NO is released from the SNAP molecule was found to vary dramatically 
from experiment to experiment, under, what seemed the same conditions. Data were 
not reproducible between the two laboratories and the kinetic order was not consistent 
or clear. Occasionally, reasonable first order plots were obtained and at other times 
good half-order plots occurred. This pattern has been recorded in the literature; one 
reporter quoting a second order dependence (Park, 1988).
From the action of metal ions on thiol containing compounds used and studied in 
biochemistry, it was suggested that trace metal ions could be causing this erratic 
behaviour. Consequently, it was decided to investigate this possibility to determine 
whether trace metal ions contained in buffer solutions (or distilled water) could 
contribute to the decomposition of SNAP in aqueous media.
This chapter reports an investigation of the metal ion catalysed decomposition of SNAP 
and some other S-nitrosothiols, particularly concentrating on the effect of copper which 
was found to be the best metal for catalysis.
3.2 COPPER CATALYSIS OF SNAP DECOMPOSITION
3.2.1 Results and Discussion
Due to the strong binding affinity of penicillamine for copper ions, evident in the amino 
acid's use as a chelating agent for copper ions in the treatment of Wilson's disease (see 
Chapter 5), it was decided to investigate whether copper(II) ions had a similar 
binding affinity for SNAP, which may contribute to its decomposition and release of 
NO. By following the decrease in absorbance at 339nm, it was shown that addition of 
increasing concentrations of copper(II) ions to SNAP solutions brought about faster 
rates of decomposition (see Figure 3.1). Furthermore, it was found that the addition
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of small quantities of EDTA (lOpM), which has high formation constants with many 
metal ions, to aqueous solutions of SNAP, dramatically reduced the decomposition rate 
(see Figure 3.1). In another set of experiments, the first order plots of SNAP 
decomposition with increasing concentration of copper (II) ions were obtained and 
showed that there was clearly copper catalysis with good first order correlation (see 
Figure 3.2). The only exception to this was the experiment conducted without 
addition of extra copper (H) ions, over and above those present in the buffer/distilled 
water.
As initial evidence of copper catalysis had been demonstrated, it was decided to 
investigate the possible catalysis of S-nitrosothiol decomposition by other metal ions. 
The effects of iron (II), iron (III), silver and mercury were studied and preliminary 
results are shown in Figures 3.3 and 3.4. It is evident that the addition of extra 
iron(III) and silver to the aqueous SNAP solutions at pH 7.4 had no effect on the 
decomposition rate of SNAP. However, iron(II) and mercury(II) did alter the rate of 
decomposition. Iron(II) was found to be of similar effectiveness as copper(II) at 
decomposing SNAP, whereas the decomposition profile of SNAP in the presence of 
mercury (II) was drastically different to that of the other metal ions tested. Work 
carried out by the Durham group on SNAP has proved that mercury acts differently by 
coordinating to the sulphur group (Hg2+—S) and expelling NO+. No production of 
NO was picked up by an NO electrode and the binding of mercury(II) to SNAP was 
found to be irreversible and non-catalytic (see Figure 3.5). Further work by Bamett 
and Williams and by Neave and Butler, has shown that trace quantities of Zn^+, Ca^+, 
Mg2+, Ni^+, Co2+, Mn2+ and Cr^+ do not effect the rate at which SNAP decomposes.
The catalysis of S-nitrosothiols by iron(II) salts was not investigated in this study and 
this will be the subject of further work in the group. However the concentrations of 
this metal in aqueous aerated buffer solutions would probably be quite small due to
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Figure 3,1 The effect ofCu2-\- ions on the decomposition rate o f SNAP (OAmM) [Cu2+] (open triangles) 5pM, (closedsquares) lOpM, (open squares) 50pM. (closed circles) no added Cu2+, (open crosses) [EDTA] SOpMJOX, KH2PO4 buffer pH 7.4.
Time (mins)
Figure 3.2 The first order plots of increasing copper concentration on SNAP (0.4mM) decomposition rates,
(closed circles) no added Cu '^ ,^ y  = -0.028x - 1.250» r=0.988, =^0.976
(open squares) 5pM y = -0.059x -1.231, r-0.999, =0.997
(closed diamonds) 10[iM Ci?^, y = -0.086x - 1.303, r=0.999, =0.997
(open triangles) 50pM Cu^^, y = -O.lSSx - 1.477, r=0.999, t^=0.999.
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Figure 3,3 The effect of the metal ions copper (II), iron (II) and iron (III) (O.lmM) on the decomposition rate of SNAP (OAmM). (closed diamonds) no added metal ions, (squares with crosses) iron (III), (open circles) iron (II), (closed triangles) copper (II).
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Figure 3,4 The effect of the metal ions mercury (II) and silver(I) (O.lmM) on the decomposition rate of SNAP (0.4mM). (closed triangles) no added metal ions, (squares with crosses) .mercury (Ilf), (open circles) silver (I).
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oxidation to iron(III), which^as has been shown, does not effect the rate of SNAP 
decomposition.
Hg+.2 +
H+ + HONO
Figure 3,5 The mechanism of action o f mercuric salts on S-nitrosothiol 
decomposition
Due to the effect of copper ions on SNAP decomposition, it was decided to calculate 
the metals concenti'ation in the distilled water source and in the buffer constituents used. 
Using atomic absorption it was evident that the trace amounts of copper that were 
proposed to be responsible for the erratic decomposition of SNAP were not coming 
from the distilled water source. This had been the case for initial work conducted by 
the Durham group and reported in our first collaborative paper (McAninley et al.y 
1993). The levels present in the distilled water used for all the experiments discussed 
in this thesis could not be measured on the parts per million (ppm) scale. However, it 
was likely that trace metal ions like copper were present in tlie other buffer constituents 
used. As most of the experiments were conducted at pH 7.4 in a phosphate buffer 
(O.IM KH2PO4/O.IM NaOH), it was decided to measure the total copper content of 
this buffer mixture. Unfortunately due to the high concentrations of sodium hydroxide 
used, atomic absorption could not be carried out on the sample unless ion exchange to
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remove the sodium was done first. It was decided against carrying out this procedure 
due to possible further contamination of the buffer sample with metal ions.
To get an estimate of the maximum concentration of copper ions likely to be present in 
the buffer system, calculations were carried out using the maximum values of the trace 
amounts of copper written on the containers of the buffer constituents, supplied by the 
chemical companies. After taking concentrations and volumes into account, it was 
calculated that 0.03ppm of copper was present in the buffer solution at pH 7.4 (see 
experimental section), which converted into a maximum concentration of 0.47|J.M of 
copper, most of which came from the sodium hydroxide source, as Aristar grade 
phosphate was used. Therefore there will be enough copper ions present to catalyse the 
decomposition of SNAP.
From Figure 3.1 it is evident that complexation of the metal by EDTA dramatically 
reduces the catalysed process. When copper (II) ions were added to solutions of 
SNAP in the presence of EDTA (lOpM), only addition of concentrations of copper ions 
equal to or above the concentration of EDTA resumed the copper ion-catalysed 
decomposition (see Figure 3.6).
A more quantitative examination of the copper catalysed process was undertaken by 
following the decomposition of SNAP as a function of copper (II) ion concentration. 
By increasing the concentration of copper ions with respect to SNAP concentration, a 
'window' of good first order kinetics was obtained. This 'window' varied slightly 
from one sample of SNAP to another. The reason for this is unclear but the kinetics 
did vary between the two laboratories. However, above and below the 'window' of 
good first order behaviour, poor first order fits were obtained. At higher 
concentrations the loss of first order linearity and erratic behaviour could be due to 
complex formation involving copper and the phosphate component of the buffer 
solution which forms an insoluble salt.
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Figure 3.6 The ^ e c t  of increasing the concentration ofCi?^ ions with 
respect to EDTA(lOpM) on the decomposition of SNAP (OAmM). no added 
or EDTA (closed circles), EDTA + no added (open squares), 
EDTA + SjJiM added (closed diamonds), EDTA + lOpM added 
(open triangles), EDTA + lOOpM added (closed triangles) .
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Figure 3.7 The effect o f ions on the decomposition of SNAP, a plot 
of vs [ ( closed circles) = 2 '*^  order rate constatit
calculated ftvm the gradient of the straight line through the 1st order 'window'
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Figure 3.7 shows a graph of increasing copper concentration against kobs for a range 
of experiments following the decomposition of SNAP at 339nm. A 'window' of 1st 
order kinetics was obtained between 5 and lOfxM, which lay on the same straight line. 
The gradient of this line is equivalent to k.2, the second order rate constant and the 
results obtained were consistent with the rate equation (2). The small intercept, which 
was always present for all SNAP samples tested, probably represents the component of 
the reaction catalysed by the residual copper (II) ions present in the buffer system.
Rate = k2 [RSNO] [Cu2+] (2)
This rate equation has been shown to hold for a large range of S-nitrosothiol structures 
(Askew & Bamett et at., 1994, in prep.).
It has also been shown that copper(I) ions can catalyse the decomposition of S- 
nitrosothiols. It is also evident from Figure 3.8 that copper(l) is a better catalyst than 
copper (II). Sodium dithionite was used to reduce copper(II) nitrate to the copper(I) 
salt. When this was carried out in an areated environment a characteristic red colour 
appeared due to the formation of copper (I) oxide (Askew & Barnet et al., 1994 in 
press). This rapidly disproportionates to copper(O) and copper(II). However, 
although disproportionation is favourable in aqueous solution, the low solubility of 
copper(I) in water renders this reaction less important than oxidation to copper(II). 
Therefore, in the graph presented in Figure 3,8, copper(I) was formed by reduction 
of copper(II) nitrate in a deareated environment to prolong the lifetime of the copper(I) 
species. In addition, complex formation notably increases the solubility and the 
stability of copper(I) salts, thus reducing disproportionation. As copper(I) is a soft acid 
it would be expected to readily form complexes with the phosphate buffer used. The 
probable equation for copper(I) formation is shown below.
2Cu2+ + S2O42- + 40H- -4 2Cu+ + 2SO32- + H2O (3)
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Figure 3,8 The effects o f and Cw^ ions on the decomposition rate of SNAP (0.5mM) in phosphate buffer (OJM) pH7A in an oxygen free
environment, (open symbols) Ci?^ (5pM), (closed circles & crossed
diamonds) Cu^ (5pM). fnset; 1st order plots of these samples,
Cu^+ y  = -0.333-0.249x, r = 0.998 & y ^  -0.639-0.147x, r = 0.985;
Cw+y = -I.216-0.537x, r = 0.998 & y = -1.374-0.425x, r = 0.994.
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Figure 3.9 The effects of and Cu'  ^ions on the decomposition rate of 
SNAP (0.4mM) in acetonitrile. (closed circles) no added Cv?^/Cu^, (open 
squares) Cu^^ (IpM), (open triangles) (lOOpM), (closed squares) Cu'^
(IpM), (closed triangles) (lOOpM).
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When the decomposition rates of SNAP by copper(I) and copper(II) ions in acetonitrile 
were compared (used because it is a solvent which stabilises the copper (I) salt by 
forming ligands, such as [Cu(NCMe)4]+), it is noticeable that the two forms of copper 
ion effect the rate, even though the rates of decomposition are much slower in this 
solvent (possibly due to complexation of the metal ions to the solvent, which may stop 
them from acting on the S-nitrosothiol). These results are shown in Figure 3.9.
These findings suggest that copper ions may catalyse the decomposition of S- 
nitrosothiols such as SNAP by some sort of redox reaction, in which the copper 
changes its redox state between 1*^  and 2+ to affect catalysis. Many bioinorganic 
reactions proceed this way and this could explain why copper is one of the only 
transition metal ions to effect catalysis of S-nitrosothiols. The mechanism by which 
copper brings about catalysis of S-nitrosothiols like SNAP is discussed in more detail 
in Chapter 3.4.
3.2.2 Experimental
Chemicals used - Analar grade copper(II) nitrate trihydrate and copper(I) chloride 
and aristar grade potassium dihydrogen orthophosphate were obtained from BDH 
Laboratory supplies, Poole, England. Analar grade iron(III) chloride, iron(II) sulphate 
acetonitrile and sodium hydroxide pellets were obtained from ESA laboratory supplies, 
Loughborough, England. EDTA, mercury(II) chloride and silver(I) chloride were 
obtained from Aldrich Chemicals, Dorset, England. The phosphate buffer was made 
up as described in the experimental section of Chapter 4.3. For experiments 
conducted using 0.3M phosphate buffer the quantities of KH2PO4 and NaOH were 
tripled. SNAP was synthesised as described in experimental section of C hapter 
2 .2 . 2 .
Figure 3.1
A stock solution (6,25mM) of copper (II) nitrate trihydrate was made up (0.0151g in 
10ml water), and diluted by a factor of 10 to form 0.625mM solution. An aliquot of
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this solution (1ml) was equally diluted with water and 0.4ml of this solution were 
added to phosphate buffer (O.IM KH2PO4/O.IM NaOH; 2ml) at pH 7.4. When an 
aliquot (0.1ml) of SNAP solution (0.0IM; 0.01 Ig in 5ml buffer) was added to this 
solution in the spectrophotometer cuvette at 30*“C, the final concentrations of SNAP and 
copper(II) ions in the cuvette were 0.4mM and 50fxM respectively. The other 
concentrations of copper(II) ions were made up in a similar way from further dilution 
of the copper/distilled water stock solutions, always adding a final volume of 0.4mls to 
the cuvette and 0.1ml of the SNAP stock solution. Immediately after addition of the 
0.1ml of SNAP (which had been kept on ice and in the absence of light prior to 
addition), the experiment was started and readings taken at timed intervals against a 
reference cell containing phosphate buffer. For the experiment run in the presence of 
EDTA, the EDTA (10.4|J,M) was made up in buffer (2.4ml) from a stock solution 
(0.0388g in 10ml buffer) which after addition of the stock SNAP solution (0.1ml) 
resulted in the final concentration of EDTA of 10|xM.
Figure 3.2
The first order plots of the effects of increasing copper concentration on the 
decomposition of SNAP were obtained by subtracting the infinity absorbance reading 
from all the other readings of the samples described in Figure 3.1. A plot of In (A(t) 
-A(eo)} with time was constructed.
Figures 3.3
Stock solutions (llmM) of iron(III) chloride (0.0178g in 1ml distilled water), iron(II) 
sulphate (0.0306g in 10ml distilled water), and copper(II) nitrate trihydrate (0.0266g in 
10ml distilled water), were made up and diluted by a factor of 100 (0.1ml in 9.9ml) in 
phosphate buffer pH 7.4 to form 0.1 ImM solutions. Aliquots (2.25mls) of these 
solutions were added to the spectrophotometer cuvette with further addition of the 
SNAP solution (0.25ml of 4mM stock solution) to make up the required concentrations 
of 0.4mM SNAP and O.lmM metal ion. The experiment was carried out as described 
for Figure 3.1 using a reference cell containing the phosphate buffer at pH7.4.
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Figure 3.4
The stock solutions (llmM), of silver (I) chloride (0.0158g in 10ml distilled water), 
and mercury (II) chloride (0.0299g in 10ml) were made up, diluted and used as 
described for Figure 3.3.
Figure 3.6
A stock solution (12.5mM) of EDTA (0.0465g in 10ml buffer) was made up and 
diluted 1000 fold to 12,5pM in phosphate buffer. 2ml of this solution was added to the 
spectrophotometer cuvette at 30“C in the spectrophotometer. A stock solution 
(6.25mM) of copper(II) nitrate trihydrate (0.0151g in 10ml distilled water) was diluted 
by a factor of 10 to form a 0.625mM solution, from which an aliquot (0.4ml) was 
added to the EDTA solution in the cuvette. After addition of an aliquot (0.1ml) of 
SNAP (4mM; 0.01 Ig In 5ml buffer), the final concentrations of SNAP, Cu^+ ions and 
EDTA were 0.4mM, O.lmM and lOp^ M respectively. The other concentrations of 
copper (II) ions were made up by further serial dilution of the stock solution of 
copper(II) nitrate, and for EDTA alone, an aliquot (0.4ml) of buffer not containing 
added copper, was mixed with the EDTA solution. The reference cell contained 
phosphate buffer and EDTA (10|xM).
Figure 3.7
Serial dilution of a stock solution (25mM) of copper (II) nitrate trihydrate (0.0302g in 
5ml distilled water) was used to make up the required concentrations of copper (II) ions 
presented in Figure 3.7. In each case aliquots (0.1ml) of the diluted copper solutions 
were added to the phosphate buffer pH7.4 (2.3ml). Aliquots (0.1ml) of the stock 
SNAP solution (12.5mM) were added to the resulting solutions in the 
spectrophotometer cuvette at 30*C, to make up the final solutions which contained 
0.5mM SNAP. All samples were run against a reference cell containing phosphate 
buffer.
Figure 3.8
A stock solution (5.5mM) of sodium dithionite (0.0048g in 5ml of buffer) was made 
up in oxygen free buffer. An aliquot (0.1ml) was added to a deoxygenated solution
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(9.9ml) of copper(II) niti'ate (50|iM) which was made up by serial dilution from a stock 
solution (5mM; 0.0060g in 5ml deoxygenated buffer). This was carried out to form 
copper(I) ions (50p.M). An aliquot (0.25ml) of this solution was added to 2ml of 
deoxygenated phosphate buffer (0.3M KH2PO4/O.3M NaOH) in the spectrophotometer 
cuvette at 30"C. SNAP (0.25ml; 5mM) was added and the reaction was monitored 
immediately. The same process was carried out without the addition of dithionite to 
directly compare the action of copper(II) ions on SNAP decomposition. Both sets of 
experiments were run with a reference cell containing phosphate buffer (0.3M).
Figure 3.9
Stock solutions (11.ImM) of copper(I) chloride (0.01 Ig in 10ml acetonitrile) and 
copper(B) nitrate trihydrate (0.276g in 10ml acetonitrile) were made up and serially 
diluted in acetonitrile to form 0.1 ImM and l.llp,M solutions. Aliquots (2.25ml) of 
these solutions were added to the spectrophotometer cuvette at 30”C and further 
addition of SNAP solution (0.25ml; 4mM) made up the final concentrations of 
copper(I) and copper(II) ions (O.lmM & IpM) and SNAP (0.4mM). The reference 
cell contained acetonitrile.
Calculation of copper content in 0.3M KH2PO4IO.3 M NaOH buffer pH  
7.4.
Distilled water source = 0 ppm copper 
NaOH source = 0.002% copper s  20 ppm
mass of NaOH in 97.75ml of 0.3M NaOH within buffer solution = 1.173g 
250ml buffer 20 x 1.173/250 = 0,09 ppm of copper from NaOH in buffer
KH2PO4 source = 0.005 ppm
mass of KH2PO4 in 125ml of 0.3M KH2PO4 within buffer solution = 5.10g 
250ml buffer 0.005 x 5.10/250 = 0.1 ppb of copper from NaOH in buffer.
. . Total copper present = 0.0901ppm = 1.4iiM
101
in O.IM KH2PO4/O.IM NaOH; total copper present = 0.47|a.M.
3.3 THE BINDING OF COPPER IONS TO S-NITROSOTHIOLS
3.3.1 Results and Discussion
There was found to be a wide range of second order rate constants for the S- 
nitrosothiols tested, indicating substantial differences in reactivity towards copper(II) 
ions (Askew & Barnet et al., 1994, in pj'ess). Three of the most reactive S- 
nitrosothiols were S-nitrosocysteine (SNC), S-nitrosopenicillamine (SNPen) and S- 
nitrosocysteamine (SNCA). These compounds all have free amine groups. An 
explanation for their fast decomposition in the presence of copper ions is that these ions 
become bidentately complexed with the nitrogen atoms of the nitroso group and the 
amino group, via a six membered ring shown in Figure 3.10.
R' = H or CH 3  
R" = H or CO 2 HR'HC Cu
Figure 3.10 The proposed six-membered ring intermediate formed when copper 
binds to SNPen, SNC and SNCA.
Although the proposed binding stmcture of copper to the amino acids is presented as a 
2 coordinate species, it is veiy likely that 4 or 6 coordination involving water molecules 
(or even the OH group at pH 7,4) occurs. These have not been included for simplicity 
of presentation. The first order dependence upon RSNO concentration argues against 
two molecules of S-nitrosothiol being involved in a four coordinate system.
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The coordination chemistry of copper (II) is dominated by coordination to N and O 
sites (Hathaway, 1987; Stricks & Kolthoff, 1951), although coordination to sulphur 
and other elements is also well known. Much of the bioinorganic chemistry of copper 
(II) involves coordination compounds of this type, eg. with proteins and peptides 
(Pettit et al., 1985).
When amine and acid groups are absent, as in the case for S-nitroso-t-butyl thiol, the S- 
nitrosothiol is very stable and there was no measurable reactivity (Askew & Barnett 
aL, 1994, in prep). Furthermore, increasing the chain length by one methylene group 
(as in S-nitrosohomocysteine) results in a large rate reduction, probably due to 
decomposition via the more unfavourable seven-membered ring intermediate (Askew & 
Bamett et al., 1994, in prep). These variations will inhibit the formation of what seems 
like tlie more favoured six-membered ring intermediate.
Interestingly, when the decomposition rates of S-nitrosocysteine (SNC) and S- 
nitrosopenicillamine (SNPen) (which were made in situ see Chapter 2) were 
compared in the presence of increasing concentrations of EDTA (lOpM-lmM), it is 
evident that EDTA has less of a stabilising effect on SNPen than SNC (see Figures 
3.11 & 3.12). A possible explanation of this result is that the parent amino acid of 
SNPen, penicillamine, has a strong binding affinity for copper, more so than cysteine, 
and it has been shown that penicillamine can compete with EDTA for copper chelation 
(Hanaki & Sago, 1994; & Chapter 5.1). Whether this implies that the nitrosated 
derivative has similar binding affinities for copper has yet to be determined, but the fact 
that even ImM concentrations of EDTA cannot abolish its decomposition, supports this 
theory. This finding may also explain why S-nitroso-N-acetyl cysteine (SNAC) was 
found to be substantially more stable than SNAP (see Chapter 2 Figure 2.12).
Further evidence supporting the theory that the S-nitroso derivatives of penicillamine 
compete better for copper ions in the presence of EDTA than the S-nitroso derivatives
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Figure 3,11 The effect of increasing the concentration of EDTA (10- 
1000fM) on the decomposition rate of S-nitrosopenicillamine (SNPen, 
0.5mM). (diamonds with crosses) lOpM EDTA, (closed circles) lOOpM 
EDTA, (open triangles) lOOOpM EDTA.
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Figure 3,12 The effect of increasing the concentration of EDTA (10- 
lOOOfiM) on the decomposition rate of S-nitrosocysteine (SNC, 0.5mM). 
(diamonds with crosses) lOpM EDTA, (closed circles) lOOfiM EDTA, 
(open triangles) 1000pM EDTA.
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of cysteine is evident in Figure 3.13. SNAC was found to be much more resistant to 
decomposition than SNAP in the presence of EDTA (10|iM) (and no added copper 
ions), having a similar stability to GSNO under the same conditions.
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Figure 3.13 The effect of EDTA (lOM) on the decomposition rates o f SNAP, GSNO 
and SNAC (all 0.5mM). SNAP (open circles), GSNO (diamonds with crosses), 
SNAC (closed triangles).
N-acetylation of the amino group of SNC and SNPen to form SNAC and SNAP has 
been shown to have a dramatic effect on decomposition rates, reducing the reactivity in 
the case of SNAC to virtually unmeasurable levels (see Chapter 2 Figure 2,12) 
This is consistent with the expected large reduction in the electron density on the amino 
nitrogen atom due to its acétylation, which will make coordination with copper much 
weaker. The fact that SNAP does decompose in the presence of copper ions may have 
something to do with the argument presented in the previous paragraph, which could 
relate to the presence of the gem-dimethyl groups of the penicillamine amino acid. 
However, another possible theory is that it decomposes slowly through a seven-
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membered ring Intermediate involving coordination with the nitroso nitrogen atom and 
one of the oxygens of the carboxylate group (see Figure 3.14).
Figure 3 J4  The possible formation o f the more unfavoured seven-membered ring 
when copper forms an intermediate with SNAP.
To complicate the situation further, it is well known that coordination between copper 
(II) ions and carboxylic acids occurs (Hathaway, 1987). Indeed a number of copper 
(II) carboxylates have been isolated and examined structurally (Doedens, 1976). In the 
solid state they are binuclear with four carboxylate bridges (see Figure 3.15).
0 Cu
Figure 3,15 The general binuclear structure of copper binding to carboxylate groups
The nitrosated tripeptide, S-nitrosoglutathione, was found to be very resistant to copper 
catalysis even in the presence of a 50pM concentration of the metal (see Figure 
3.16). From the theory already discussed, this finding is not suprising as the 
appropriate nitrogen atoms are acetylated. Furthermore, there are two carboxylate sites
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in the molecule that will readily bind copper ions, which will reduce the number that 
can act on the 'active site' (the S-nitroso moiety). There is also a free amine group, 
with its substantial electron density, which will attract binding from metal ions such as 
copper, and two amide linkages which are known to have a high binding constants for 
copper (n) ions (Kf -  10 ;^ Pettit et al., 1985).
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Figure 3,16 The effect ofCu^'^ ions on the decomposition rate o f GSNO (OAmM) 
IpM  (closed diamonds), lOfiM (closed squares) ,50fxM (open squares), no 
added (open circles), 30 V, KH2PO4 buffer pH 7.4.
In conclusion, our results are consistent with the formation of a six-membered ring 
intermediate (shown in Figure 3.10), being the most favourable conformation to elicit 
copper ion catalysis of basic S-nitrosothiols, such as S-nitrosopenicillamine and S- 
nitrosocysteine. When structural changes are made to these S-nitrosothiols such as N- 
acetylation, removal of favoured ligands such as amine groups or carboxylates, or 
increasing the chain length between the two ligand binding sites, the stability of the S- 
nitrosothiol increases due to inhibition or reduction of the formation of this six-
107
membered ring intermediate. The larger the peptide chain, and the more carboxylate or 
free amine groups present, but removed from the S-nitroso-moiety, the greater the 
number of binding sites for copper, and the less chance of decomposition of the 
nitrosopeptide with loss of NO. For these reasons GSNO is more resistant than SNAP 
or most other S-nitrosothiols investigated.
3.3.2 Experimental 
Figures 3,11 & 3,12
A stock solution of EDTA was made up and serially diluted to the required 
concentrations (lOmM, ImM and O.lmM). By addition of an aliquot (0.25ml) of these 
solutions to spectrophotometer cuvettes containing 2.15ml of 0.3M KH2PO4/O.3M 
NaOH and aliquots (0.1ml) of the S-nitrosothiol (12.5mM) to be tested, the final 
concentrations of EDTA and S-nitrosothiol were ImM-lOpM and 0.5mM respectively. 
S-nitrosocysteine (12.5mM) and S-nitrosopenicillamine (12.5mM) were made up in 
situ by adding sulphuric acid (0.4M; 10ml) to L-cysteine (0.0151g) and L-penicillamine 
(0.0187g), both containing sodium nitrite (0.0086g). 0.1 mis of these S-nitrosothiols 
were immediately added to the cuvettes containing EDTA and buffer (0.3M phosphate; 
2.4ml). The reference cell contained buffer and the relevant concentrations of EDTA to 
be tested.
Figure 3,13
Stock solutions (12.5mM) of GSNO, SNAP and SNAC were made up by adding 
sulphuric acid (0.4M; 10ml) to glutathione (0.0384g), N-acetyl-DL-penicillamine 
(0.0239g) and N-acetyl-L-cysteine (0.0204g), all in the presence of sodium nitrite 
(0.0086g). Aliquots (0.1ml) of these samples were added to the spectrophotometer 
cuvette containing EDTA (lOpM) in buffer (0.3M phosphate; 2.4ml). The reference cell 
contained buffer and EDTA (lOpM).
Figure 3,16
The same experimental procedure was canied out as described for Figure 3.1 in the 
previous experimental section. Aliquots (0.1ml) of the GSNO stock solution (lOmM;
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0.0168g in 5mls buffer) were added to 2.4ml of O.IM phosphate buffer containing the 
relevant concentration of copper (II) ions. GSNO was synthesised as described in the 
experimental section of Chapter 2.3.2.
3.4 THE MECHANISM BY WHICH COPPER CATALYSES SNAP AND 
OTHER S-NITROSOTHIOL DECOMPOSITION
In this section the decomposition of SNAP by copper is discussed and used as a model 
for all S-nitrosothiols susceptible to copper catalysis.
3.4.1 Results and Discussion
In Chapter 3.2 it was shown that copper(I) is a very effective catalyst of SNAP 
decompostion, and work carried out in the Durham laboratory has shown that this is 
also the case for other S-nitrosothiols (Askew & Bamett et al., 1994 in prep). This 
brought into question whether SNAP decomposition could be catalysed by a redox 
process, in which there would be interconversion of copper between its Cu+ and Cu^ "*" 
states. Many of the bioinorganic reactions proceed this way and this could explain why 
copper is one of the only transition metal ions to effect catalysis of S-nitrosothiols. 
However, Bamett and Williams have examined the possibility of a redox Cu^+ Cu+ 
interconversion by using ESR (Askew & Bamett et al., 1994, in prep) and found no 
evidence for its presence. By following the ESR spectrum of copper(II) during the 
decomposition of SNAP in a static and a flow system, they were unable to detect a 
change in the spectmm during the reaction. In the absence of a buffer they attributed 
the spectmm to Cu(H20)6^+ which was modified in the presence of a dimethylglutaric 
acid buffer system probably to a copper carboxylate species (see Figure 3.15). From 
these results it is possible to eliminate the quantitative conversion of copper (II) -> 
copper (I) and its reappearance by oxidation.
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An alternative possibility is that copper (II) ions coordinate to S-nitrosothiols such as 
S-nitrosocysteine or S-nitrosopenicillamine through the free amine group and the 
sulphur atom of the nitrosothiol moiety. This would result in the formation of a five- 
membered intermediate. As mentioned in Chapter 5 and in Chapter 1, D- 
penicillamine is a well-known complexing agent for free copper (II) ions and is 
believed to be more efficient than EDTA. This is likely to involve a five membered ring 
species. Figure 3.17 (A) shows the visible traces of the absorbances between 438 
and 900nm of the initial mixing and final absorbance after 16 hours of N-acetyl-DL- 
penicillamine (6 .6mM) with copper (II) nitrate (6 .6mM) in distilled water. The 
absorbance at 800nm is due to free copper (II) ions (aq), which have 9 d-electrons. 
Figure 3.17 (B) shows the visible absorbance trace of just copper (II) nitrate 
trihydrate (6 .6mM) in distilled water and the absorbance of 0.085 at 804.8nm relates to 
an extinction coefficient of 12.88M‘lcm'l. It is evident that the absorbance at 800nm 
after initial mixing of N-acetyl-DL-penicillamine is substantially lower than this value at 
just over 0.06, which suggests that some binding of copper is occuring. It was 
noticeable that a rapid colour change transpired, producing a transient purple colour 
which is characteristic of copper-penicillamine complexes (Laurie, 1987). It is known 
that copper can cause the formation of the disulphides of thiols such as penicillamine 
(Laurie, 1987), and when the absorbance was monitored after 16 hours, it had returned 
to roughly the expected absorbance if all the copper was free. As binding of copper(II) 
ions to the disulphide is weak or nonexistent at the disulphide bridge and occurs only 
through the amine or carboxylate groups (Laurie, 1987), it is possible that more of the 
copper would be fi ee and unbound.
Due to the fact that SNAP is N-acetylated and contains an NO group bound to the 
sulphur which is likely to have an adverse effect on the coordinating ability at sulphur, 
it is unlikely that copper(II) binds to form a five-membered ring intermediate. 
Furthermore, it is believed that the mercury(II)-catalysed and also the acid catalysed 
pathways for RSNO decomposition involve Hg2+-S coordination (Saville, 1958) and
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Figure 3 J7  (A) The effect ofN-acetyl-DL-Penicillamine (6,6mM) on free 
copper (6.6mM copper (II) nitrate) absorbance at ^SOOnm in distilled water, (solid line) absorbance at t^O , peak I at 780.8nm; (dotted line) absorbance at 
t = 16 hours, peak 2 at 798.4nm. (B) The absorbance profile o f copper (II) 
nitrate (6.6mM) in distilled water, peak I at 804.8nm
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S-protonation (Al-Kaabi et al., 1982) respectively. Both of which would lead to NO^ 
expulsion and nitrous acid formation. Therefore no nitric oxide would be expected to 
form, contrasting with the copper(II) catalysed decomposition of SNAP in which NO 
was detected using an NO probe by Barnett & Williams (Askew, Barnett et a i, 1994, 
in prep).
When similar experiments as those conducted using equimolar quantities of copper (H) 
nitrate and N-acetyl-DL-penicillamine were carried out with SNAP, some interesting 
results were obtained. Figure 3.18 (A) shows the absorbance between 438 and 
900nm of SNAP (6 .6mM) in EDTA (0.5mM) with no added copper. A peak appears 
at 590nm due to the S-nitroso moiety of SNAP, but no peak appears at ~800nm for free 
copper (II) ions as they will be bound by EDTA. Figure 3.18 (B) shows the 
absorbance of SNAP (6 .6mM) in the presence of copper (II) nitrate (6 .6mM) after 
initial mixing of the two compounds. It is evident that little or no binding of the copper 
(H) ions is occuring as the absorbance at 800nm is around the value of that expected if 
all the copper was free. Figure 3.19 shows the rapid decrease in SNAP absorbance 
at -600nm taken at 2 minute intervals, due to decomposition. It is noticeable that there 
is little change in the free copper (II) absorbance at '^ SOOnm. Therefore if complexation 
is occuring only a small amount of copper is bound at any time.
Having established the structural requirements for NO release from S-nitrosothiols (see 
sections 3.3 & 3.2) and from the work reported in this section, no more can be said, as 
yet, on the mechanistic detail as to the mode of NO release from the proposed cyclic 
intermediates for SNAP, and other S-nitrosothiols susceptible to NO decomposition. 
At this stage it is suggested that spontaneous break up of the ring occurs forming the 
thiol radical (RS ) which yields the disulphide (RSSR), free Cu^+ and NO, although 
the situation may be more complex than this.
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Figure 3.18 (A) The ejfect of EDTA (05mM) on SNAP (6.6mM) in distilled 
water. Peak 1 at 590.5nm is due to SNAP. (B) The absorbance profile o f 
SNAP (6.6mM) in the presence of copper (U) nitrate (6.6mM) in distilled water 
after initial mixing. Peak 1 & 2 at 554.6nm & 5922nm are due to SNAP, Peak 3 
at 799.9nm due to Cu (II) aq.
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!Figure 3,19 The absorbance traces of SNAP (6.6mM) in the presence o f copper (II)
nitrate (6.6mM) taken at 2 minute intervals. Note the decrease in SNAP absorbance at 
590nm and the slight change (increase) in absorbance at'^SOOnm due to free Cu (II) aq 
ions, possibly indicating small amounts of copper complexation.
3.4.2 Experimental 
Figures 3,17 - 3,21
SNAP (0.0145g) and N-acetyl-DL-penicillamine (0.0126g) were added to copper (II) 
nitrate trihydrate (0.0159g) and diluted in distilled water (10ml), to make up 0.0066M 
solutions of the amino acids with the metal. If EDTA (0.5mM; 0.0019g) was required 
this was also added to the 10ml solutions. The visible spectrum between 438nm and 
900nm was measured immediately and in the experiments conducted using SNAP, the 
spectrum was taken continuously at 2 minute intervals.
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CHAPTER 4
OTHER FACTORS 
AFFECTING THE DECOMPOSITION
OF
S-NITROSOTHIOLS 
IN AQUEOUS SOLUTION
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4.1 INTRODUCTION
As well as the effect of trace metal ions present in buffer solutions there are a number of 
other chemical factors which can increase the rate of S-nitrosothiol decomposition to 
NO. These conditions maybe related to, or independent of, the metal ion catalysed 
process. In this chapter SNAP is used as the model S-nitrosothiol and its thermal and 
photochemical decomposition are discussed, together with its decomposition profile 
across a range of pH. In addition, two novel methods for following SNAP 
decomposition by monitoring the production of NO, directly and indirectly, are 
discussed. Finally, in a brief review, other methods of detection of NO and its 
metabolites are covered.
4.2 THE THERMAL DECOMPOSITION OF SNAP
i) Results and Discussion
As was mentioned in Chapter 2, SNAP, along with other S-nitrosothiols, is 
susceptible to thermal decomposition, releasing NO and forming its disulphide. For 
this reason, in all of the experiments carried out using S-nitrosothiols, the solutions 
made up for experimentation were stored on ice until immediately prior to use. 
Experiments carried out on SNAP at temperatures varying from 25*C to 50°C shown in 
Figure 4.1 emphasise the dramatic effect temperature plays on the decomposition rate 
of SNAP. In these experiments, which were carried out before the metal ion catalysed 
decomposition of S-nitrosothiols was known, no precautions were taken to remove the 
trace quantities of metals present in the buffer solutions. This could suggest that it is 
the speed of this process which is enhanced when the temperature is increased. These 
results seem to support the case, as when precautions are taken to remove metal ions 
(using EDTA) there is a marked decrease in the rate of SNAP decomposition (see 
Figure 4.2). However, there is still a substantial difference in the thermal
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Figure 4,1 The effect of increasing temperature on the decomposition rate of SNAP (0.4mM; n^5) in the presence of trace metal ions, 25 V  (closed circles), 30 V  (open circles), 37 V  (closed diamond), 50 V  (open diamond).
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Figure 4,2 The effect of increasing temperature on the decomposition rate of SNAP (0,4mM) in the absence of trace metal ions (removed by EDTA (10-5M), 30 V  (closed circles), 50 V  (open circles).
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decomposition rates over the 20“C range between 30 and 50*C, suggesting that thermal 
decomposition has a role in SNAP, and presumably other S-nitrosothiol's degradation.
ii) Experimental
(see experimental section, Chapter 2.3.2 - kinetics study). For the experiment 
presented in Figure 4.1 the same procedure was carried out as described, with 
adjustment of the temperature setting. In the case of the experiment shown in Figure 
4.2 a 25mM solution of EDTA was made up (0.093Ig in 10ml buffer), diluted 100 
fold to produce 0.25mM solution. An aliquot (0.1ml) of this solution was diluted 25 
fold (lOpM) in the spectrophotometer cuvette, prior to the addition of SNAP (0.25ml, 
0.4mM).
4.3 THE EFFECT OF PH ON SNAP DECOMPOSITION RATES
i) Results and Discussion
There is a dramatic effect of pH on the stability of SNAP. At high and low pH SNAP 
is very stable (see Figure 4.3), whereas at physiological pH the rate of SNAP 
decomposition is dramatically increased (see Figure 4.4). The reasons for these 
observations probably lies with the metal ion catalysed decomposition. The metal, and 
metal ligands, will have different chelating abilities in the protonated and deprotonated 
environments of acid and basic solutions respectively. For instance, at high pH amine 
groups and amide linkages between peptides will be very good ligands for the 
positively charged metal ion like Cu^+ as it will readily deprotonate these species when 
it chelates (Pettit et al., 1985) For these reasons it would be expected that the rate of 
SNAP decomposition would increase, however, in the case of copper catalysis the 
copper ion will be in a different aqueous form than at neutral pH, with a general 
formula C u (O H )x (H 2 0 )y .  It is known that the reaction [Cu(OH2)6l^^ 
[Cu(OH2)5 0 H]+ + H+ has a pK^ of 6 .8 . The stronger binding of OH ligands to Cu^+ 
makes x binding sites on the copper ion unavailable for binding to the peptide, and
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Figure 4.3 A comparison of the rates of SNAP decomposition under highly acidic (pH22) and highly basic (pHlO.2) conditionfat 30 V.pH2.2 - glycine /HCl (closed circles), pH 10.2 - glycinelNaOH (open circles). % SNAP represents a direct comparison to absorbance, with absorbance at t=0 representing 100% SNAP .
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Figure 4.4 A comparison of the rates of SNAP (0.4mM) decomposition at pH7.4 in KH  ^POif.(NaOH (closed circles; n=12) and dimethylglutaric acid (DGA)INaOH (open circles; n==5) at 30 V
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experimental results suggest this probably overrides the fact that the free amine groups, 
or amide linkages are readily available for chelation.
At low pH most of the possible ligands for chelation to copper ions are protonated 
producing electrostatic repulsion between the positively charged copper ion and its 
binding sites. This would be expected to result in little metal ion catalysis and greater 
stability of SNAP. At physiological pH, the aqueous environment of the copper 
species, together with the chelating affinities of its ligands from the S-nitrosothiol, 
seem to be in more amenable forms.
To complicate this study, all buffers will chelate metal ions to different extents at 
different pH's. Therefore, the different binding affinities of the buffer constituents 
must be taken into account, as they may remove or reduce the chelation of the metal 
ions to the S-nitrosothiol. Interestingly, when comparing the buffers KH2P0 4 /Na0 H 
and dimethylglutaric acid (DMGA)/NaOH at the same buffer capacities, little difference 
in the SNAP decomposition rates were seen (see Figure 4.4). However, initial 
evidence from experiments following the decomposition rate of SNAP in tris/HCl 
buffer over increasing pH (see Figure 4.5) suggests that the tris/HCl buffer system 
has less chelating ability at physiological pH than the other two buffer systems. The 
rate of decomposition is faster at'pHT.S for tris/HCl, than at pH7.4 for DMGA/NaOH 
and KH2P0 4 /Na0 H. Figure 4.5 shows the dramatic effect a change of 2 pH units 
(7.1-8.9) has on the decomposition rate of SNAP, without the complication of different 
buffer systems and their different chelating affinities. Figure 4.6 shows that when 
metal ions are removed by EDTA the rates of decomposition of SNAP in the same 
buffer system are dramatically reduced, and are very similar over the first 1000 minutes 
and the same pH range.
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Figure 4.5 The effect of pH on the decomposition rate of SNAP (O.SmM) in the presence of trace metal ions. Tris!HCl buffer, 30 V, pH7.1 (closed circles), pH7.5 (open circles), pH8 (closed diamond), pH8.5 (open diamond), pH8.9 (closed triangle).
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Figure 4.6 The effect of pH on the decomposition rate of SNAP (O.SmM) in the absence of trace metal ions (complexed out by EDTA, 10-5M), Tris I HCl buffer, 30 V, pH7.l (closed squares), pH7.5 (open circles), pH8 (closed circles), pH8.5 (closed triangles), pH8.9 (open squares). (Graph taken from Neave W.E., senior honours project, 1994),
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ii) Experimental
(see experimental section. Chapter 2.3.2 - kinetics study). For the experiments 
presented in Figure 4.3-4.6 the same procedure was carried out as described with 
adjustment of pH and the use of different buffer systems.
Buffer systems used 
KH2P04fNa0H pH7.4
To 50ml of O.IM KH2PO4 (13.60g/l), was added 39.1ml of O.IM NaOH and this was 
diluted to 100ml with distilled water. 
ffp-Dimethylglutaric acid (DMGA)INaOH pH7.4
To 50ml of O.IM p,|3-Dimethylglutaric acid (16.02g/l), was added 46.6ml of 0.2M 
NaOH and this was diluted to 100ml with distilled water.
Glycine/HCl pH 22
To 25ml of 0.2M glycine (15.01g/l), was added 22ml of 0.2M HCl and this was 
diluted to 100ml with distilled water.
GlycinelNaOH pH 10.2
To 25ml of 0.2M glycine (15.01g/l), was added 16ml of 0.2M NaOH and this was 
diluted to 100ml with distilled water.
Tris(hydroxymethyl)aminomethane buffer solutions pH7.1 - 8.9
To 50ml of Tris (12.114g/I), was added xml of O.IM HCl and this was diluted to
100ml with distilled water.
jc = 45.7ml (pH7.1), 40.3ml (pH7.5), 29.2ml (pH8), 14.7ml (pH8.5) & 7ml (pH8.9). 
As the Tris buffer system changes its pH with temperature (Dawson, 1990; dpHfdt ~ 
-0.028pH units/deg) and the values quoted above are set for a temperature of 25'C, 
slight adjustments to the stock solutions of buffer were made to compensate for the 
slight drop in pH by raising the temperature to 30*C.
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4.4 TUE PHOTOCHEMICAL DECOMPOSITION OF SNAP
i) Results and Discussion
As was mentioned in the introduction to Chapter 2j SNAP like other S-nitrosothiols 
is susceptible to photochemical decomposition to form NO and its disulphide. 
Consequently, in all experiments carried out using S-nitrosothiols, solutions were 
protected from light by aluminium foil. Due to the unavailability of a tuneable and 
constant intensity light source, across wavelength, a detailed study of the 
photochemistry of SNAP (and GSNO) was not undertaken. However, in a qualitative 
experiment using daylight as the light source, the decomposition rate of SNAP was 
shown to be photosensitive (see Figure 4.7). The same result was obtained using 
NO chemiluminescence to monitor the production of NO from SNAP, when the S- 
nitrosothiol was exposed to and protected from light (see Figure 4.9). This will be 
discussed in more detail in the next section.
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Figure 4,7 A comparison of decomposition rates o f SNAP (l,5mM) in distilled water in the presence and absence of light (daylight) at 30 V. light (open circles), no light (closed circles), % SNAP represents a direct comparison to absorbance, with absorbance at t-0  representing 100% SNAP,
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ii) Experimental
(see experimental section, Chapter 2.3.2 - kinetics study). For the experiments 
presented in Figure 4.7 the same procedure was carried out as described. However, 
manual rather than automated use of the spectrophotometer was implemented as both 
the test solutions of SNAP in distilled water (one of which was covered in tin foil) were 
kept at 30“C in a water bath exposed to daylight.
4.5 NOVEL METHODS FOR MONITORING NO PRODUCTION FROM 
S-NITROSOTHIOLS SUCH AS SNAP
The experiments described in this section were carried out at the Wellcome 
Laboratories, before the metal ion catalysed process was known. They have been 
included in this section to present other possible methods which could be used to 
follow S-nitrosothiol decomposition in vitro or possibly ex vivolin vivo, by monitoring 
the production of NO (by NO chemiluminescence), or its reaction with 
oxyhaemoglobin, rather than the removal of S-nitrosothiol. In parts 4.5.1 and 4.5.2 
the experimental sections precede the results and discussion for clarity.
4,5.1 Nitric Oxide Chemiluminescence (Downes et at,, 1976)
This technique follows the reaction between NO and ozone (O3) which produces a 
chemiluminescent product of excited NO2, this gives out light when it relaxes to its 
ground state (1).
NO + O3  ^  NO2 + O2
(1)NO2 -------- ► NO2 + light
Many chemiluminescent analysers are now available for quantification of this reaction 
and the technique is highly sensitive (detection limit InM) and linear over a wide range.
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1 to lOOOnM can easily be covered without recalibration of equipment. Analysers are 
rapid and highly reproducible.
i) Experimental
Apparatus - NO chemiluminescence apparatus located at the Wellcome Laboratories and 
the same apparatus used by Palmer et al. (1987).
Procedure
To 149ml of deionised, distilled water in a conical flask, degassed with argon and set at 
pH 7.5, was added 1ml of 1.5mM SNAP solution in the same aqueous medium 
forming a lOjaM concentiation in the flask. This solution was immediately bubbled 
vigorously and continuously with argon to remove NO as it was formed from SNAP 
decomposition, and to keep the pH at 7.5 by not allowing resolvation of acidic gases 
such as CO2. Argon was chosen as the bubbling gas due to its heavier molecular 
weight than nitrogen, allowing it to remain just above the aqueous layer. The conical 
flask was contained in a water bath at 37°C. The same procedure was carried out on 
another conical flask containing the same solution only covered in aluminium foil to 
protect tlie SNAP solution from the daylight.
50pl aliquots of the SNAP solution were removed, at timed intervals, from the stock 
solution for injection into the three necked flask of the chemiluminesence analyser 
(Figure 4.8). The flask contained a strongly heated solution of 75% acetic acid/25 % 
sodium iodide (~80ml). This was done to measure the amount of SNAP remaining. 
Each SNAP molecule was immediately decomposed to produce one NO molecule 
which^when formed, was immediately blown from the acetic acid / sodium iodide 
solution by nitrogen, which is continuously bubbling through the solution at a rate of 
lOOml/min (controlled by a Platon flow meter), through one of the three necks on the 
flask. The NO in the nitrogen gas passes up through a condenser, through a solvent 
ti'ap and into the chemiluminescence analysing chamber. Here it initially reacts with
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excess ozone, formed from an ozoniser supplied with oxygen at a rate of lOOml/min 
(controlled by a Platon flow meter), to form excited NO2 which chemiluminesces to the 
ground state NO2. The chemiluminescence was picked up by a NO chemiluminescence 
photomultiplier system Model MKIA, which was linked to a Gould BS-272 chart 
recorder and a Schimadzu C-R3A chromatopac (integrator). This calculates the area 
under the peak formed from the chemiluminescence due to NO. Both the oxygen and 
nitrogen used were purified by a Supeloo carrier gas purifier.
By injecting into the three necked flask 10,30 and 50ml aliquots of a lOmM solution of 
sodium nitrite, a calibrated linear response was obtained allowing a straight line graph 
of area under the chemiluminescence peak versus moles of NO, to be calculated. The 
peak areas produced by these standard nitrite samples are very reproducible. This was 
used to quantify the number of moles of NO produced from SNAP. The injections of 
SNAP samples were repeated until the peaks being registered on the integrator were too 
small to be measured accurately, as the amount of SNAP remaining was so small.Then 
a graph of ‘moles of SNAP versus time’ was plotted (see Figure 4,9).
Ii) Results and Discussion
Figure 4.9 shows the decomposition profiles obtained by this method in the presence 
and absence of daylight. As in the similar experiment carried out using UV/Vis 
spectrophotometry to monitor the decrease in absorbance of SNAP in the presence and 
absence of daylight (see Figure 4.7), this experiment shows that SNAP is very 
photosensitive. As expected from the unknown light intensities and temperature 
differences, the two decomposition profiles of SNAP exposed to light are different, the 
experiment shown in Figure 4.7, using UV/Vis spectrophotometry to monitor 
decomposition, being the slower. Furthermore, the decomposition profile of SNAP at 
37 "C in the absence of light, monitored by NO chemiluminescence, is significantly 
slower than those obtained at a similar pH and the same temperature, in phosphate 
buffer, monitored by UV/Vis spectrophotometry (see Figure 4.1). A possible
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explanation for the slower rate of decomposition, is that the water used for the 
experiment using the NO chemiluminescence technique was milHQ water which 
contains no detectable metal ions. The only possible metal ions present would come 
from the alkali or acid used to adjust the pH of the water to 7.5. This would suggest a 
slower rate of decomposition of SNAP, compared to the presence of a possible 
concentration of 1.4pM Cu^+ ions in the phosphate buffer used in experiments 
represented in Figure 4.1.
12.5 n
7.5-
2.5-
50 100 150 200 250 3000
Time (Mins)
Figure 4.9 The photochemical decomposition of SNAP (lOM) measured qualitatively 
using daylight as the light source and monitored by NO chemiluminescence. Presence 
of light (open circles); absence of light (closed circles).
Alternatively, if the decomposition of S-nitrosothiols is second order, as proposed by 
Park (1989), the lower concentration of SNAP used in this experiment (40 fold lower) 
compared with that used for the experiments monitored by the UV/Vis 
spectrophotometric method, would suggest a slower rate of decomposition.
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4.5.2 The use o f  oxyhaemoglobin to determine the rate o f decomposition 
o f SNAP
Another spectrophotometric metliod used to monitor NO production involves the use of 
oxyhaemoglobin (Hb0 2 ) and its conversion to methaemoglobin (MetHb) and nitrate in 
the presence of NO (2).
+ NO ---------► MetHb^+ + NGj' (2)
This process is monitored by a dual beam double wavelength spectrophotometer 
monitoring the difference in absorbances at 401 and 421 nm. The conversion is pH- 
dependent and displays the following characteristics at pH7.7, At 421nm, oxy­
haemoglobin absorbs, and its reaction with NO produces a peak at 401nm due to the 
formation of metHb. A representation of the process is presented in Figure 4.10, 
where the isosbetic point at 41 Inm is represented at zero absorbance. This technique is 
very sensitive and can detect picomolar quantities of NO.
I) Experimental
The difference spectium of methaemoglobin versus oxyhaemoglobin, was monitored 
using a double-beam, dual wavelength spectrophotometer (Schimadzu UV 300 with 
temperature control unit TB 95). By continuous recording of the absorbance difference 
between the disappearance of the oxyHb peak at 421 nm and the formation of the metHb 
peak at 40Inm a measure of the nitric oxide development per unit of time can be 
calculated and hence the decomposition rate of SNAP.
Procedure
In these experiments deionised, distilled water was bubbled with argon for about 20-25 
mins to remove any dissolved oxygen/carbon dioxide. The pH was then set at 7.5 at 
37°C, using HCI/NaOH solutions of weak concentrations. 1.1 pi (5mM) of oxygenated
129
absorbance 
+0,05 -1
0 -
401 411 421
-0,05
350 400 450
Wavelengtli (nm)
Figure 4,10 A representation of the disappearance ofoxyHb (peak at 42 Inm ) and the appearance of the metHb (peak at 401 nm) due to reaction with NO (produced fi'om GTN in the presence of cysteine) measured by difference spectrophotometry. An isosbestic point was found at 41 Inm and represented here at zero absorbance, (taken fi om Feelisch & Noack, 1987),
B 0.25 -
0.2 -
0.15“II 0 . 1 -0.05-
100 200 4000 300
Time (mins)
Figure 4.11 A graph showing the formation of metHb from due to 
NO produced from SNAP (0,1 pM) using different concentrations of02Hb. 
(closed triangle) 4,9nM, (open diamond) lOnM, (closed circle) O.lpM
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haemoglobin (see materials for preparation), was transferred to the spectrophotometer 
cuvette by syiinge and 493.9p.l of the argon bubbled water at pH 7.5 and 3 7 was 
added to it. This was then inserted into the spectrophotometer mentioned above and 
allowed to equilibrate for 2-3 mins and then zeroed. 5pl of SNAP solution (10|liM),
made up in the same water, was then immediately added to the vial to make up a final 
concentration of 0.1 |aM SNAP, and the experiment was started. Various 
concentrations of oxyHb were made up at by adjusting the volume of oxyHb added and 
compensating by reducing the amount of water.
Materials
The oxyhaemoglobin solution was prepared as follows: dissolution of haemoglobin 
crystals in neutral distilled water, subsequent gassing with oxygen for 3 minutes, 
reduction with excess sodium dithionite, thereafter gassing with oxygen again for 15 
mins; desalting and purification by passing the solution through a Sephadex G 25 
column. Identification and adjustment were performed spectrophotometrically. Each 
batch prepared was stored at -80°C to avoid contamination.
ii) Results and Discussion
It has been shown that it takes less than 100 milliseconds for the NO radical to react 
witli oxyHb (Kelm & Feelisch et al., 1988) and so the rate of NO production should be 
a good approximation to the rate of SNAP decomposition. Different concentrations of 
oxyHb were used to see if it would effect the rate of decomposition of SNAP by 
scavenging NO from the thiol itself. This did not seem to be the case as Figure 4.11 
shows the rates of NO production were similar across the concentration range studied. 
However at higher concentrations of oxyHb (0.3pM^ in which oxyHb was in excess 
versus SNAP the rate of NO production was very slow and therefore not monitored.
The possible reasons for the overall slowness of SNAP decomposition monitored by 
this technique (possibly even accounting for the very slow decomposition rate at 0.3pM
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oxyHb) are based on the concentration of SNAP used and the metal ion catalysed 
process. Both the experiments carried out using NO chemiluminescence (Figure 4.9) 
and UV/Vis spectrophotometry (Figure 4.1), at similar pH, show faster rates of 
decomposition of SNAP than using this technique. The SNAP concentration of 0.1 jiM 
used in experiments monitored by difference spectrophotometry is 100 fold lower than 
that used in the experiment monitored by NO chemiluminescence and 4000 times lower 
than that used in experiments followed by UV/Vis spectrophotometry shown in Figure 
4.1. A possible explanaion is that if the decomposition of SNAP is second order, as 
proposed by Park (1989), then a much slower rate of NO production from SNAP 
would be expected, as the concentration of SNAP used is lowered. However, in light 
of the discovery of the metal ion-catalysed decomposition of SNAP another possible 
explanation can be put forward. Haemoglobin, being a large protein contains many 
amide bonds which have been shown to have a high formation constant with metal ions 
such as copper (Kf -  1x10^; Pettit et al., 1985). Therefore any metal ions present 
(added in the acid /alkali used to adjust water pH) will have a high chance of being 
complexed and consequently being less available for chelation with SNAP to instigate 
production of NO.
4.6 OTHER TECHNIQUES USED TO DETECT AND MEASURE NO 
DIRECTLY AND INDIRECTLY
NO chemiluminescence and oxyHb detection of NO produced from S-nitrosothiols are 
only two of the sensitive techniques for measuring NO. Both techniques have been 
used to detect NO from liquid samples taken from biological media (Palmer et al., 
1987; Kelm & Feelisch et al., 1988; Meyer et al., 1994 in press).
Chemiluminescence specificity is high in most systems because the majority of other 
molecules potentially able to chemiluminescence with ozone (amines, DMSO etc) are 
not volatile or do not occur in biological systems. This can be demonstrated by passing
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samples through solutions of Fe^+ salts which will remove the NO contribution to the 
signal, or by using low temperature traps (see Figure 4.8) to remove contaminants 
from the sample.
4.6.1 Direct measurements o f NO
NO Probes
Other than chemiluminescence the other main direct measure of NO concentration is the 
NO probe. Two main probe systems have been developed (Shibuki, 1990; Malinski & 
Taha, 1992) which rely on the electrochemical oxidation of NO to generate electric 
current. They can be placed in in vitro systems to determine the exact locality at which 
NO exists. The specificity of these probes depends on their ability to exclude other 
molecules that might give rise to current. Shibuki's probe is a modified oxygen 
electrode, which is robust and sensitive down to 0.5liM. However most versions of 
the probe are several millimeties in diameter and do not allow particularly accurate 
positioning in a cellular system. Malinski has developed a probe which uses a 
polymeric metalloporphyrin to catalyse the electrochemical oxidation of NO. This is 
covered by a thin layer of the cation exchanger Nafion which eliminates anionic 
interference from nitrite. The high sensitivity, small diameter (0.2-l.OpM) and fast 
response time (lOm  ^are necessary features for NO detection in microsystems such as a 
single cell. It also has a detection limit of lOnM and a wide and linear current- 
concentration relationship (10nM-3mM). However, it is very delicate and requires 
considerable technical skill to build and operate.
4.6.2 Indirect measurement o f NO
These techniques aie widely used in the more complex in vivo detection of NO. Often 
a combination of indices are used for more accurate measurement.
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i) Bioassay
The earliest measurement of NO production involved bioassays able to provide units of 
response in particular biological systems. This technique is primarily qualitative. 
Many of the biological parameters regulated by NO are also controlled by other 
molecules and so specificity is a potential problem. However use of drugs which 
inhibit NO production as well as inhibitors of other factors with similar biological 
actions can usually target the cause of a response.
ii) Cyclic GMP
The production of the second messenger cGMP from stimulated guanylate cyclase is a 
possible index of NO production. However many molecules activate guanylate 
cyclase, which will effect the specificity of this technique.
iii) Nitrite & Nitrate
The short lived nature of NO means rapid conversion to a range of breakdown products 
which include nitrite and nitrate. These indices of NO are relatively stable and a wide 
range of techniques have been developed to measure them. Most of these techniques 
work well in oxygenated aqueous solution where the ratio of nitrite and nitrate is 
predictable and other sources of these anions are easily controlled. However, in vivo 
work is more complicated as the ratio of nitrite to nitrate may vary considerably due to 
the reaction of NO with molecules such as haemoglobin, superoxide anions and 
hydroxyl radicals. In addition, other sources of nitrite and nitrate are difficult to control. 
GCMS
Gas chromatography mass spectrometry (GCMS) is a very sensitive and specific 
method for determining nitrite and nitrate levels in plasma. Furthermore, gas 
chromatography combustion isotope mass spectrometry (GCIRMS) is under 
development and has the great advantage of providing isotopic analyses, so that studies 
can be performed on stable isotopes. However, nitroaromatic measurement by mass 
spectrometry is not suitable for routine analyses as nitrite and nitrate levels must be
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measured separately, with nitrite being converted to nitrate and both anions further 
converted to a nitroaromatic. This increases the chances of contamination.
The Greiss Test
This assay can be used to detect nitrite (see Chapter 2)
High Performance Liquid Chromatography (HPLC)
This technique can be used to measure nitrite and nitrate in a single run. However 
extensive pretreatment of samples is required before analysis which risks contamination 
with nitrite and nitrate.
Capillary Zone Electrophoresis (CZE)
Is a rapid and user friendly technique for measuring nitrite and nitrate simultaneously 
with minimal sample preparation, high resolving power, rapid analyses and low sample 
consumption (Leone et al., 1994 in press). Although sensitivity has not been a 
particular strength of this technique there have been recent advances towards improving 
this aspect of the technology. HPCE is performed by application of high voltage (10- 
30kV) across narrow bore fused silica capillaries and samples migrate down the 
capillary at different speeds depending on their charge to mass ratio. This technique is 
used and discussed in more detail in Chapter 5.
iv) Electron spin resonance (ESR)
NO has an unpaired n orbital electron that can be excited by microwave and magnetic 
energy giving rise to a characteristic spectrum on its return to the ground state. This is 
detectable by ESR. NO will, however, react rapidly with oxygen and radicals, so spin 
traps such as nitroxides or haemoglobin are used. The complex formed between NO 
and reduced haem iron (Fell) of haemoglobin has well defined spectroscopic properties 
producing a characteristic 3-line hyperfine pattern which is not seen when Hb binds 
nitrite or other nitrogen containing compounds.
Although Hb has been used as a spin trap and reported to have been able to detect NO 
at 0.1 nM levels (Greenberg et a l, 1990), others have been unable to detect basal
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HbNO in various animal models (Wang et al., 1991). For this reason, together with 
the technical complexity of analyses, the use of ESR as an index of NO detection is 
problematic.
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CHAPTER 5
FACTORS 
EFFECTING NO RELEASE FROM 
S-NITROSOTHIOLS 
EX VIVO
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5.1 INTRODUCTION
In Chapters 1 to 3 the mechanisms of S-nitrosothiols chemical decomposition were 
discussed by examining the stabilities of SNAP and to a lesser extent GSNO under 
different experimental conditions. It was found that GSNO is more stable than SNAP 
at physiological pH and is far less susceptible to metal ion catalysis. In Chapter 1, a 
comparison of the vasodilator effectiveness of SNAP and GSNO on the rat tail artery 
was briefly investigated and experimental results suggested that SNAP is about 18-fold 
more effective than GSNO.
These findings are in line with the theory that guanylate cyclase stimulation by S- 
nitrosothiols is inversely proportional to their stability (Feelisch, 1993; Ignarro & 
Gruetter, 1980a). However, in ex vivo and in vivo situations, many other factors may 
influence NO release from S-nitrosothiols. In this chapter some of these factors are 
investigated. The findings suggest that different modes of NO production may go 
some way towards explaining the relative effectiveness of these two S-nitrosothiols as 
vasodilators and inhibitors of platelet aggregation.
For ease of comprehension, the experimental sections come before the results and 
discussion sections in this chapter.
5.2 SNAP & GSNO; ENDOTHELIUM INDEPENDENT 
VASODILATORS ?
5.2.1 Experimental
The effect ofL-NAME and ferro-haemoglobin on SNAP responses
The trace shown in Figure 5.1 was obtained using the rat tail artery preparation
described in Chapter 2.4. The same protocol was followed. After addition of PE
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(12|iM) to give an active pressure of 115mmHg, SNAP was injected at position I (see 
Figure 2.5) at concentrations of 0.1 and l|iM. L-NAME (lOOjiM) was added to the 
internal perfusate (see Figure 2.5) at the time indicated on the trace in Figure 5.1. 
This solution was continuously perfused through the artery as indicated by the 
horizontal bar, and the SNAP injections were repeated. The system was then washed 
out for 15 minutes with the original Krebs solution (containing 12fxM P.E.) at which 
point ferro-haemoglobin (3ml, ImM) was added to 200ml of Krebs solution 
(containing 12pM P.E.) in the internal perfusate to make up a 15|iM solution, which 
was perfused for the time indicated. Doses of SNAP (O.l-lOpM) were injected and the 
response recorded.
Ferro-haemoglobin (MW 64500) was prepared by reduction of lOOmls of ImM bovine 
haemoglobin using lOmM sodium dithionite. The dithionite was dialysed out of 
solution against 3x2 litre volumes of deareated distilled water at 0-5°C. The stock ferro- 
haemoglobin was then split into 3ml samples and frozen (-10°C). Samples were used 
within 2 weeks.
Responses of rat aortic rings, with and without endothelium, to SNAP and GSNO 
Male Wistar rats (250-300g) were killed by cervical dislocation. The thoratic aorta was 
removed, trimmed free of adhering fat and connective tissue and cut into 4mm rings. 
The endothelium was removed from some rings by gently rubbing the intimai surface 
with a pipe cleaner. The rings were mounted on stainless steel hooks in 20ml organ 
baths containing Krebs buffer. Indomethacin (5pM) was added to the Krebs buffer to 
inhibit the synthesis of cyclo-oxygenase products. The tissues were then subjected to 
an initial tension (l.Og) and allowed to equilibrate (75mins), during which time, the 
Krebs buffer was changed at 15 minute intervals. Responses were measured 
isometrically using Grass FT03 force-displacement transducers and recorded on a 6 - 
channel multipen recorder (Rikadenkil).
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The failure of ACh (1.28jxM) to induce relaxation was taken as an indication that 
removal of the endothelium had been effective and this was confirmed in some 
experiments by scanning electron microscopy. In intact tissues, cumulative relaxation 
curves to ACh were obtained in each ring to assess the integrity of the endothelium. 
Rings showing <65% relaxation were discarded. After washout the tissues were 
allowed to equilibrate for a further 45 minutes during which time the Krebs buffer was 
changed at 15 minute intervals. The tissues were again contracted submaximally by 
addition of PE (approx EC90). When a stable contraction was obtained, SNAP and 
GSNO doses were added to the organ baths.
5.2.2 Results & Discussion
S-Nitrosothiols such as SNAP and GSNO are NO donor drugs which release NO 
readily in tissue environments in a manner which does not require biotransformation, as 
is the case with organic nitrates. An experiment was carried out to show that SNAP 
causes vasodilation by an endothelium-independent mechanism. The responses elicited 
in rat tail artery preparations by bolus injections of SNAP (lO^il) in the absence and 
presence of L-NAME, an NO synthase inhibitor, and the absence and presence of ferro- 
haemoglobin, an efficient NO scavenger, were compared. These were added to the 
internal perfusate (see apparatus Figure 2.5),.
The results are shown in Figure 5.1. In the presence of L-NAME there was no 
significant difference in the amplitude of response caused by 1 and 0.1 pM injections of 
SNAP (0.1 jiM - 34% relaxation, IpM - 52% relaxation) compared with those obtained 
in the absence of L-NAME (0.1 |iM - 36% relaxation, IpM - 52% relaxation). In the 
presence of ferro-haemoglobin the responses to SNAP were dramatically reduced for 
lOpM injections (0.1 |iM & IjiM - 0% relaxation, lOpM - 6%), indicating the liberation 
of NO from the S-nitrosothiol.
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These observations suggests that SNAP induced vasodilation is due to spontaneous 
release of NO and not due to stimulation of NO synthase. Further work carried out at 
Wellcome in collaboration with Rees, using rat aorta rings showed that SNAP and 
GSNO gave enhanced responses in the absence of the endothelium (see Table 5.1). 
Responses may be enhanced because of the supersensitivity of guanylate cyclase to NO 
which develops following a period of NO deprivation (Moncada et al., 1991b).
Compound n ED5o (+E) ED5o (-E) Comments
SNAP 5 0.31+/- 0.15 0.056+/-0.0003 Fast, short acting response, full relaxation.
GSNO 1 0.15 0.074 intermediate rate of onset and duration, full relax.
Table 5,1 A comparison of the vasodilator effectiveness o f SNAP and GSNO on rat 
aorta rings showing that both S-nitrosothiols are endothelium-independent vasodilators. 
(+E)= + endothelium, (-£) = - endothelium.
5.3 SPONTANEOUS/METAL ION CATALYSED RELEASE OF NO
FROM SNAP
5.3.1 Experimental
The preparation, experimental procedure and SNAP sample preparation were carried 
out as described in the experimental section of Chapter 2.4. Two samples of SNAP 
(0.5mM) were prepared in phosphate buffer (O.IM KH2PO4/O.IM NaOH; see 
experimental section Chapter 4.3) and stored on ice at 0“C, protected from light. 
When the artery had stabilised after contraction with PE (about 30 minutes), 0.1ml of a 
solution of copper sulphate (ImM) was added to 9.9mls of one of the SNAP solutions 
to produce a solution containing lOpM of copper (II) ions. The clock was started and 
lOjil of the two SNAP solutions (one with added copper and one without) were 
injected into the artery at timed intervals, allowing full recovery between injections. 
This was carried out until the responses to injection of the SNAP/Cu(II) ion solution 
were minimal and unchanging.
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Control injections of phosphate buffer alone and the phosphate buffer containing lOpM 
copper (II) sulphate were administered. Neither produced a response. Ferro- 
haemoglobin was made up as described in the experimental section of Chapter 5.2.
5.3.2 Results and Discussion
In Chapter 3 it was shown that SNAP, unlike GSNO, is far more susceptible to 
decomposition by metal ion catalysis. Numerous other workers have suggested that S- 
nitrosothiols spontaneously decompose to release NO, and this is responsible for the 
physiological action of these compounds as vasodilators and smooth muscle relaxants. 
The often conflicting results obtained by different research groups have been attributed 
to the different preparations used to test the drugs. However, it is possible that the 
explanation may lie in differing amounts of tracp metal ions present in the physiological 
buffer solutions (such as Krebs), required to keep the tissue viable. The constituents 
of these buffers will contain trace amounts of metal ions which can contaminate the 
perfusate and destabilise certain S-nitrosothiols (see Chapter 3),
Unfortunately, the use of EOT A to chelate metal ions from physiological buffers would 
also complex metal ions required for the essential functioning of the tissue. Therefore, 
quantification of the effect of trace metals on the physiological (vasodilator) responses 
of smooth muscle, to S-nitrosothiols is difficult to obtain and will depend on the time 
the drug is exposed to the buffer before it reaches the tissue.
A series of experiments were undertaken in which the decomposition rate of SNAP was 
compared to its vasodilator response on the rat tail artery, in the presence of trace 
amounts of copper ions (O.lpM-lOOjiM), to see if the presence of copper ions affected 
vasodilator responses. Unfortunately, addition of copper to the internal perfusate 
greatly effected the precontracted (PE-induced) tone of the artery. Injections of 
increasing concentrations of SNAP into the perfusate containing copper did not fully 
recover. The progressive loss of tone after several injections resulted in an active
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pressure which was too low to be physiologically relevant and indicated that continuous 
exposure of the artery to copper ions was possibly toxic for the preparation.
Due to this complication in the experimental protocol, experiments were carried out to 
investigate the effect of addition of copper(II) (lOpM) to SNAP solutions (0.5mM) on 
the vasodilator responses obtained from bolus injection of this solution (lOjiil), at timed 
intervals. Figure 5.2 shows an original trace obtained of vasodilator response versus 
time. The decomposition rate of SNAP was also monitored under the same conditions 
to compare the vasodilator response of SNAP to the rate at which it decomposes. It 
was hoped that this would give an insight into whether SNAP, NO, or both are 
responsible for the vasodilator response.
The results of three experiments are shown in Figures 5.3 and 5.4. Figure 5.3 
shows that when a single concentration of SNAP is stored at pH 7.4 on ice, in the 
presence of only the trace metal ions found in the phosphate buffer, its physiological 
effect hardly changed over the duration of the experiment (-200 mins). If this is 
compared with the decomposition rate of SNAP under the same conditions (on ice), it 
is evident that virtually no SNAP has decomposed over the same time period (Figure 
5.4). This suggests that SNAP, or NO produced from SNAP in the presence of the 
artery, is producing the vasodilator response. However, when copper (II) ions (lOjJ-M) 
are added to the buffer solution containing SNAP (over and above those already present 
from the buffer itself) the vasodilator response of the resulting solution is dramatically 
reduced over the same time period (Figure 5.3). Comparison of this vasodilator 
response profile with the decomposition rate of SNAP under the same conditions 
(Figure 5.4), shows a large discrepancy as SNAP has fully decomposed over 40 
minutes but is still capable of causing approx. 52% vasodilation. The amplitude of this 
response decreases with time but is still present after 150 minutes. These results 
suggest that the decomposition products of SNAP are also giving a response. Ferro- 
haemoglobin abolished most of the response indicating that it is an
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Figure 5.2 A trace showing injections of a solution of SNAP (OJmM) and ions 
(CuS04; lOjjM) kept on ice, with time. B = phosphate buffer only; B + = buffer
+ lOpM ions only; C = control, SNAP (0.5mM) & no added Ci^'^ ions; S = 
sample, SNAP (OJmM) & 10pM Cir'^ ions. Another sample (S) was injected into the 
artery perfused with 15jJM Hb after 13 minutes of incubation with the Cu2-h ions 
(lOpM). (Expt.hP94i4l27,PE25pM)
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Figure 5.3 The effect of copper ions (CuS04; lOpM) on the vasodilator 
action of SNAP (0.5m; kept atOV) over time.(open circles) no added 
Cu(II) ions; (closed circles) lOpM Cu(H) ions added
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Figure 5.4 The effect of copper(II) ions (CuS04; lOpM) on the 
decomposition of SNAP at 0 V. (filled symbols) Cu(II) ions added; (open symbols) no added Cu(II) ions
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NO-mediated response, suggesting that a significant amount of NO survives for long 
enough to cause vasodilation of the artery.
These results suggest that preformed NO from copper ion catalysis, NO produced from 
SNAP in the presence of the tissue, or even SNAP itself can produce vasodilation of 
the rat tail artery. It also demonstrates that metal ions, like copper, can affect the 
vasodilator response of SNAP.
Can metal ion catalysed decomposition o f S-nitrosothiols occur in vivo? 
Copper is the third most abundant heavy metal ion in the human body, at levels of 
between 1.4-2.1 mg/kg body weight (Hughes, 1987; Howard-Lock & Lock, 1987). It 
is an essential metal and is present in trace amounts in all tissues for normal 
metabolism. The highest levels in man are found in the liver, brain, lung and kidney. 
Deficiencies in copper result in increased fragility of bones, aneurysm formation in 
arteries and loss of lysyl oxidase activity in cartilage. These deficiencies are brought 
about by a number of factors;
1) Low intake - due to malnutrition
2) High loss - due to cystic fibrosis and nephrotic syndromes
3) Genetic factors such as Menke's disease
Menke’s disease is an inborn error of copper metabolism leading to a life expectancy of 
less than three years due to low activity of copper-requiring enzymes. The lethal 
deficiency occurs in the brain and a characteristic feature of the disease is 'steely' hair 
structure, due to the presence of free SH groups as lysyl oxidase fails to form 
disulphide links.
At the other end of the scale, an excess of copper, particularly in the liver is a symptom 
of Wilson's disease. Low levels of the copper transport protein ceruloplasmin result in 
excess copper in the liver and progressive liver disease. D-penicillamine or
147
triethyltetramine (TETA) are used as therapeutic agents to chelate excess copper (more 
about chelation is discussed in Chapter 3).
Of the 5mg of circulating copper in human serum approximately 90-95% of it is tightly 
and irreversibly bound to the protein ceruloplasmin (Hughes, 1987; Howard-Lock & 
Lock, 1987), a blue-coloured oxidase enzyme that plays a major role in copper 
transportation. Ceruloplasmin is a single polypeptide chain of molecular weight 
130,GOOD containing 7 copper binding sites (Hughes 1987). These 7 copper ions are 
in different enzymatic sites. Two are in type 1 sites which are responsible for electron 
transfer reactions, the nature of the coordination site ensures a minimal activation 
energy for copper to change between its two oxidation states. One copper ion is in a 
type 2 site, which works in conjunction with the type 1 sites in the overall electron 
transfer process and may represent a substrate binding site. There are also four type 3 
sites which consist of Cu(I) and binuclear coupled Cu(II) ions which are used to bind 
and reduce dioxygen.
The remaining copper in human serum is reversibly bound to the protein albumin or 
histidine, particularly in the gut. Figure 5.5 shows a tripeptide mimic to the Cu(II) 
binding site of albumin (Iyer et al., 1978). It has been postulated that the copper ion 
can be rapidly transferred from albumin to an amino acid eg. histidine, and then to its 
free unbound state (Sarker, 1981). Albumin is thought to be a transporter of copper 
whereas the small size of amino acids like histidine make them membrane diffusible, 
allowing copper to enter cells (Figure 5.5). This mechanism has not been 
satisfactorily proved due to the small amount of copper involved (l|iM ) which is 
difficult to measure experimentally. It is also reasonable to assume that receptor sites 
exist in the various target tissues for copper ions and the possibility of copper release 
by a reductive method from ceruloplasmin or albumin. If this occurs at the cell 
membrane then there may be an intracellular receptor for Cu(I) which, as discussed in 
Chapter 3, also cataiytically decomposes SNAP.
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[Cu (albumin)] Cu (aq) + albumin
amino acid 
(aa) (aa)
Cu (albumin) (aa) [Cu (aa)2j + albumin
Figure 5.5 A model for the copper (H) binding site of albumin by the tripeptide l- 
Gly-L-Asp-L-His and the different environments postulated for copper in the presence 
of albumin and histidine, (adapted from Comprehensive Coordination Chemistry 
chapter 20.2).
Whatever environment the copper ions are in, the quantity required to catalyse the 
decomposition of S-nitrosothiols is very small, in the region of l[iM which as 
mentioned is difficult to detect experimentally. Furthermore, it has not been determined 
if copper bound to albumin or ceruloplasmin or the peptide histidine, can effect 
catalysis of S-nitrosothiols by ligand replacement. It is also possible that one or more 
of the different copper sites on ceruloplasmin could produce NO from S-nitrosothiols. 
These factors must be examined to determine whether trace metal ion catalysis by 
copper ions has a role in the in vivo metabolism of S-nitrosothiols.
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5.4 IS SNAP DECOMPOSED ENZYMATICALLY TO NO EX VIVO
5.4.1 Experimental
a) Synthesis ofD-SNAP (S-nitroso-N-acetyl-D-penicillamine)
The same procedure was followed as for the synthesis of S-nitroso-N-acetyl-DL- 
penicillamine, using N-acetyl-D-penicillamine (see experimental section Chapter 
2.2.2). Mpt. (149°C), [ a ] %  (c=0.088, methanol) = -80.1°
b)Synthesis o f L-SNAP (S-nitroso-N-acetyl-L-penicillamine)
N-acetyl L penicillamine is not available commercially and therefore had to be 
synthesised in the laboratory as follows, 
i). Preparation ofN  methoxydiacetimide
Triethylamine (239mmol, 24.14g) was mixed with methoxyamine hydrochloride 
MeONH2HCl (59.7mmol, 4.98g) in CH^Clg (50ml) with cooling. Acetic anhydride 
(149mmol, 15.2g) was added dropwise over a period of 30 mins. The reaction mixture 
was stirred overnight at room temperature. The salt formed was filtered off and the 
solution washed with 5% bicarbonate (3x35ml), O.IM HCl (2x30ml), H2O (lx30ml) 
and then dried over magnesium sulphate. The solvent was removed under reduced 
pressure to give an oil that was distilled (72-74°C 12mmHg) to give the product as a 
colourless oil. 5.77g (73.7% yield) Vmax (Nujol) 1720cm*l (amide CO), 5H 
(200MHz, CDCI3) 2.31 (s,6H,CH3CO) & 3.74 (s,3H,OCH3), m/z (El) 131 (M+, 
1.92%), 89 (M+H-CH3CO, 38.17%), 43 (CH3CO, 100%),
Ü) Preparation ofN-acetyl-L-penicillamine
To L-penicillamine (Immol, 0.149g) in dioxane (4ml) was added 1 equivalent of 
sodium hydroxide solution (2M, 0.5ml) followed by N-methoxydiacetimide (262mg, 
2mmol). The solution was stirred at room temperature for 27 hours approx. after which 
time the mixture was diluted with H2O (4ml), pH adjusted to 4 with glacial acetic acid 
and extracted with ethyl acetate (3x20ml). The organic phase was dried over MgSO^ 
and the solvent removed under reduced pressure to give a white solid. This solid was
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then suspended in ether, filtered, washed with ether (15ml) and dried to give N-acetyl- 
L-penicillamine as a white solid. 0.067g (35% yield). [a]20jj (c=l, ethanol/water 1:1) 
= -11.28" (lit -10.5±1°, Field et a/., 1978) ÔH (200MHz,û?<î-DMSO) 1.4 
(6H,s,2xCH3), 1.95 (3H,s,OCH3), 4.44 (lH,d,CH), 8.15 (lH,d,NH), Vmax (nujol) 
3600-3200cm-l (OH), 3350 (NH), 1720 & 1640 (C=0). 
in).Preparation of L-SNAP (S-nitroso-N-acetyl-L-penicillamine)
The same procedure as the synthesis of S-nitroso-N-acetyl-DL-penicillamine was 
followed, only using N-acetyl-L-penicillamine. Mpt. (149°C), [a]^0^  (c=0.088, 
methanol) = +75.0"
Physiological Testing
The same procedure was carried out as described in the experimental section of 
Chapter 2.4.
5.4.2 Results and Discussion
Another possible mechanism in which S-nitrosothiols like SNAP can be decomposed 
ex vivo and in vivo is by an enzymatic process. To investigate this possibility, the two 
enantiomers of SNAP (L & D) were synthesised and their pharmacological properties 
compared using the rat tail artery preparation. S-nitroso-N-acetyl-D-penicillamine was 
synthesised directly from N-acetyl-D-penicillamine by nitrosation using acidified nitrite. 
S-nitroso-N-acetyl-L-penicillamine was synthesised from L-penicillamine by 
acétylation using N-methoxydiacetimide for acétylation, and subsequent nitrosation by 
the same method. Optical rotation readings showed that the opposite chirality of the 
two compounds had been retained. The samples made up for testing on the rat tail 
artery were stored on ice for the period of the experiment to minimise metal ion 
catalysed decomposition (see Figure 5.3).Solutions of SNAP (0.1 pM - lOmM) were 
injected into the artery as a bolus. The narrow bore of the cannula, the short time 
period between injection and reaching the tissue, and the bolus nature of drug delivery 
serve to minimise the metal ion catalysed decomposition of SNAP. Therefore, if there
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was an enzymatic process which contributed to SNAP decomposition, a difference 
should be seen in the log dose/response curves. These log dose/response curves are 
shown in Figure 5.6 and compared with those obtained for the racemic mixture of DL 
SNAP, tested on the same arteries. The results show no statistically significant 
difference between any of the SNAP samples tested, suggesting that enzymatic 
decomposition of SNAP is not a factor determining the rate of SNAP decomposition in 
the rat tail artery. Responses were not examined in other physiological models to see if 
this finding was consistent across tissue types.
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Figure 5,6 Log doselresponse curves comparing vasodilator responses elicited in the 
rat tail artery by injections (lOpl) ofDL SNAP (closed circles, n=3-5), D SNAP (open 
circles with crosses, n=3-5), and L SNAP (open squares, n=3-5).
Experiments were also conducted by continuous perfusion of the artery with the 
enantiomers of SNAP (see Chapter 7 for the experimental procedure) and no 
difference in the responses obtained was evident. These results are not shown as 
decomposition of SNAP using this method of delivery is more susceptible to metal ion
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catalysis than that of delivery by bolus injection. This puts the results obtained under 
question.
5.5 THE EFFECT OF y-GLUTAMYL TRANSPEPTIDASE ON GSNO
DECOMPOSITION
5.5.1 Introduction
In Chapters 2 and 3 it was shown that GSNO is a stable S-nitrosothiol in aqueous 
solution at physiological pH and is essentially resistant to trace metal ion catalysis. 
However when exposed to the rat tail artery, ex vivo, it turns out to be a good 
vasodilator. If it is assumed that NO released from GSNO activates guanylate cyclase 
to produce relaxation, then this suggests that the tissue possess the ability to cleave NO 
from the tripeptide. Possible tissue candidates for carrying out this action will be 
discussed in this section and section 5.6.
In section 5.4, experimental evidence suggested that SNAP is not decomposed by an 
enzymatic process. However, SNAP is a synthetic S-nitrosothiol which is not 
endogenous to living cells. GSNO on the other hand, a derivative of the endogenous 
peptide glutathione, has been detected in vivo at concentrations of approximately 
0.25pM in venous plasma and up to 1.2pM in arterial plasma (Stamler et a i, 1992; 
Meyer et al., 1994). Therefore it is more likely that this S-nitrosothiol could be acted 
upon enzymatically to produce NO and vasodilation.
One possible candidate is y-glutamyl transpeptidase (y-GT), a cell surface enzyme 
thought to be of particular importance in the hydrolysis of GSH and GSH conjugates. 
The enzyme is able to catalyse both the hydrolysis of the y-glutamyl group of GSH (or 
other y-glutamyl peptides), autotranspeptidation with glutathione as the acceptor and y- 
glutamyl transfer to other suitable acceptors (see Figure 5.7). Work carried out by 
incubating the purified enzyme with glutathione and a mixture of amino acids, that
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closely approximates the amino acid composition of blood plasma, showed that 
transpeptidation is a significant function of the enzyme. This was determined by 
quantitative measurement of the products formed (Allison & Meister, 1981). At 
physiological pH (7.4), about 50% of the glutathione that was utilised, participated in 
transpeptidation. Studies in which the formation of individual y-glutamyl amino acids 
was monitored showed that L-cystine and L-glutamine are the most active amino acid 
acceptors.
GLUTATHIONE
+
y-GT ENZYME
H2O
cysteinylglycine 
y-glutamyl - enzyme
ammo x  glutathione 
acid
L-glutamate y-glutamyl-amino y-glutamylglutathione 
acid
Figure 5,7 Reaction pathways catalysed by y-glutamyl transpeptidase
The enzyme mechanism
The mammalian y-glutamyl transpeptidases exhibit similar catalytic properties which are 
specific for y-glutamyl compounds. Three separate subsites exhibiting characteristic 
preferences can be distinguished at the active site. Binding of L-y-glutamyl, D-y- 
glutamyl and L-y-(a-methyl) glutamyl compounds occurs at the y-glutamyl binding 
subsite (Griffith & Meister, 1977). On the other hand, the acceptor site, consisting of 
subsites for cysteinyl and glycine moieties, has restricted stereo-specificity in that only 
L-amino acids and dipeptides, in which both amino acids are of L-configuration, serve
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as acceptors (Tate & Meister, 1974). Kinetic and specificity studies indicate that a large 
variety of dipeptide acceptors bind to the Cys-Gly site, interacting with the cysteinyl 
subsite which prefers neutral amino acids such as cystine and glutamine. Kinetic 
studies are also consistent with a ping-pong mechanism involving a y-glutamyl-enzyme 
intermediate (see Figure 5.8) allowing transpeptidation or hydrolysis (Tate & 
Meister, 1974).
N (or O)—a
y-glu-enzyme + Cys-Gly 
(1)
y-glu-acceptor + enzyme
Glutathione + enzyme
y-Glu-enzyme + acceptor 
(2)
Figure 5,8 A schematic representation of the active site o f y-glutamyl transpeptidase
depicting the y-glutamyl-enzyme intermediate (1) and the expected tetrahedral transition 
state intermediate that would deformed during the transfer o f the enzyme bound y- 
glutamyl moiety to the a-amino acid group of the acceptor or to water (2).
y-GT is present on the external surface of certain cell membranes. In most mammals 
the kidney exhibits the highest activity, but the enzyme is found in many different types 
of cells and has been detected in bile, seminal fluid and, more importantly for this 
study, in human blood serum. (Tate & Meister, 1981). It is in contact with many 
amino acids, including glutathione which is translocated across cell membranes.
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Therefore, it would seem that y-glutamyl amino acids must be continually produced and 
transported into cells. The enzyme may also play a role in the extracellular metabolism 
of glutathione.
The subject of this study was to see if y-GT could bring about decomposition of 
GSNO, by the same mechanism of y-glutamyl cleavage. This would form an S- 
nitrosothiol which is likely to have greatly reduced stability, compared with GSNO and 
which could readily release NO. Evidence that this mechanism is possible, may imply 
that this enzyme, or a closely related enzyme such as the y-glutamyl transpeptidase 
related enzyme which has 40% homology to y-GT (Heisterkamp et al., 1991), or a 
number of other members of this gene family (Morris et al., 1993), could be 
responsible, in part, for the biological activity of GSNO.
5.5.2 Experimental
Solution preparation
A y-glutamyl-transpeptidase solution (Sigma, 2.1 mg in 1.5ml distilled water; 
35units/mi) was diluted to the concentrations indicated in Figures 5.10 & 5.11 by 
serial dilution into spectrophotometer cuvettes containing phosphate buffer pH7.4 at 
30“C. An aliquot (0.1ml) of GSNO (0.0168g in 5ml buffer) was added to the cuvette 
to make up a 0.4mM solution. If EDTA (50pM) was required, 2ml of 12.5|iM 
solution in phosphate buffer pH7.4, was used in the cuvette instead of buffer alone. 
When this was diluted to 2.5ml by the enzyme solution and GSNO the required 
concentration of EDTA was attained.
Kinetic studies
The kinetics of GSNO decomposition was monitored by following the reduction in 
absorbance at 339nm using a Phillips PU8700 UV/Vis scanning spectrophotometer 
with a Pye Unicam cell temperature control unit. All experiments were carried out at 
30°C in a phosphate buffer at pH 7.4 (O.IM KH2PO4/ O.IM NaOH) made up using
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distilled water which had undetectable copper and iron content on the ppm (parts per 
million) scale. Therefore, trace metal ions present in the buffer solution must come 
from the buffer system itself.
Enzyme kinetics
The activity of the enzyme y-glutamyltranspeptidase was tested by the use of y - 
glutamyl-p-nitroanilide as the standard substrate and showed expected activity. 
Measured amounts of the enzyme (see Figures 5.10 & 5.11) were then added to 
buffered solutions of GSNO, in the absence and presence of glutamine (0.4mM), and 
the decomposition monitored spectrophotometrically as above.
Capillary Zone Electrophoresis
The apparatus used was a Biofocus 3000 Capillary Electrophoresis System (Bio-Rad, 
Richmond, CA) fitted with a polyacrylamide coated capillary (17 cm x 25|im). 
Electrophoretic separations were detected on-line by computer. The analyses were 
performed at 20°C. To initiate analyses the capillary and electrode reservoirs were 
filled with electrophoresis buffer (0.0IM NagP0 4 /0.03 HCl, pH 2.3, as used by 
Stamler et a i, 1992). The capillary was first flushed with HPLC-grade water 
(Rathbum Chemicals, Walkerbum, Scotland), secondly with capillary wash (Bio- 
Rad), and thirdly by the electrophoresis running buffer. This procedure was carried 
out between each sample run. The voltage field strength was 1 IkV and the polarity of 
the internal power supply was set for migration of cations towards the detector (positive 
polarity). The samples were diluted 1:10 with HPLC water. The detector wavelength 
was set at 200nm. The decomposition of GSNO was also monitored at 335nm (the 
absorption maximum of GSNO).
5.5.3 Results and Discussion
GSNO was incubated with y-glutamyltranspeptidase for 30-60 mins and the resulting 
solution examined by capillary zone electrophoresis (CZE) (Figure 5.9). Peaks were
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Figure 5 S  Capillary Zone Electrophoresis traces for glutathione (GSH), S-nitrosoglutathione 
(GSNO) and oxidised glutathione (GSSG) (all 1 mg/ml), comparing them to the y-glutamyl 
transpeptidase enzyme (3.3 unitslml) digest products of glutathione and S-nitrosoglutathione in 
the presence of the acceptor amino acid glutamine (Imglml). The L-cysteinylglycine (cyslgly) 
fragment of glutathione was also used to spike the enzyme digest of S-nitrosoglutathione and 
glutamine, giving rise to an increase in peaks a &b. It was shown that a & b were the reduced 
and oxidised forms of the cyslgly fragment. Note the complete disappearance of the GSNO peak 
and no formation of the peak corresponding to GSSG. This also indicates that cleavage of the 
glutamyl!cystyl peptide bond has taken place.
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Figure 5,10 The effect of the enzyme y-glutamyl transpeptidase (GGT) on 
the decomposition rate of GSNO (OAmM), in the presence and absence of EDTA, (open circles) GSNO, (open triangles) GSNOIGGT (0,7 unitslml), (closed triangles) GSNOIGGT (2,8 unitslml), (open squares) GSNOIGGT (5,6 unitslml), (black crosses) GSNOIGGT (5,6 unitslml) + EDTA (50pM), Conditions; 30°C, KH2PO4 buffer pH 7,4
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Figure 5,11 The effect of the enzyme y-glutamyl transpeptidase (GGT) on 
the decomposition rate of GSNO (0,4mM) in the presence and absence of an acceptor peptide (glutamine), for the transfer of the glutamyl fragment of GSNO. (open circles) GSNO, (closed triangles) GSNOglutamine (0,4mM), (open squares) GSNOIGGT (2,1 unitslml), (closed squares) GSNOIGGT (2,lunitslml) + glutamine (0,4mM), Conditions; 30 V, KH2PO4 .
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observed at the elution times corresponding to L-cysteinylglycine and the disulfide of 
L-cysteinylglycine. However, no peaks were observed corresponding to GSNO, 
glutathione, and the disulphide of glutathione. The absence of a GSNO peak shows 
that decomposition had occurred. However this appears not to have resulted in release 
of NO from GSNO since such a reaction would have led to formation of the disulphide 
of glutathione. However, if the enzyme had effected cleavage of the cysteine-glutamic 
acid peptide bond to give S-nitroso-L-cysteinylglycine, which then decomposed, 
releasing NO, formation of the disulphide of L-cysteinylglycine would be expected. 
Subsequently, the kinetics of breakdown of GSNO were examined by monitoring the 
disappearance of the absorption peak at 335nm, as a function of enzyme concentration. 
The results are displayed in Figures 5.10 and 5.11. Clearly the rate of GSNO 
decomposition was enzyme dependent and occurred by hydrolysis (Figure 5.10), or 
in the presence of the amino acid acceptor of the glutamyl fragment, glutamine (Figure 
5 .11).
NONO
CHCH glutamate +
glycylglycylglutamyl
NO-cystyl
fragment
CH
glycylglycyl'
Figure 5,12 The proposed mechanism of action o ff  glutamyl transpeptidase on the
decomposition rate of GSNO, postulated from experimental results.
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The results obtained are consistent with the reaction shown in Figure 5.12. One 
would expect the rate of release of NO from S-nitroso-L-cysteinylglycine to be greater 
than from GSNO as the catalysing metal can complex with two favourable binding sites 
in the former (-NH2 and -SNO) while the latter is resistant to metal ion catalysis, as 
discussed in Chapter 3.
Figure 5,10 shows metal ion catalysed NO release from GSNO occurred. Addition 
of EDTA to a mixture of GSNO and y-glutamyltranspeptidase diminished the rate of 
decomposition of the S-nitrosothiol to NO, while having no effect on the action of the 
enzyme (results not shown).
5.6 TRANSNITROSATION (NO TRANSFER) FROM SNAP AND 
GSNO TO OTHER THIOLS
5.6.1 Introduction
The effect of trace metal ion catalysis on the decomposition rate of SNAP, and the 
effect of enzymes such as y-glutamyl transpeptidase on GSNO metabolism, are 
supplemented by possible NO transfer to one or more of numerous sulphydryl 
containing molecules present in vivo. Clearly, the process of transnitrosation can also 
effect the nature and stability of GSNO and SNAP. The sulphydryl groups present in 
vivo are contained in molecules which are either membrane bound, or free, either in the 
intracellular matrix (eg. cysteine, glutathione) or in the plasma (albumin). These 
sulphydryl containing molecules, together with tissue-type plasminogen activator and 
cathepsin B, are susceptible to nitrosation and NO transfer from S-nitrosothiols under 
physiological conditions (Stamler et at., 1992). NO transfer to these proteins or amino 
acids, and the extent to which it happens are likely to depend on a number of factors. 
These include; the relative pK^'s of sulphydryl moieties, the concentration in which 
they are present, and the steric hindrance likely to be caused by the movement of the 
NO group to the acceptor thiol. It has recently been demonstrated that bioactive NO
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equivalents in plasma are bound predominantly to thiol groups of proteins and that this 
reservoir serves a role in modulating vasodilator tone (Stamler et al., 1992a&b).
If transnitrosation occurs from a relatively stable S-nitrosothiol such as GSNO or 
SNAP, to a thiol such as cysteine, which is a relatively abundant thiol in vivo (Jocelyn, 
1972), the formation of the unstable S-nitrosothiol, S-nitrosocysteine, could facilitate 
the release of NO and account in part for the biological action of these S-nitrosothiols. 
This possibility is discussed in this section.
5.6.2 Experimental
Kinetics study
0.25ml of lOmM L-Cysteine (0.0121g in 10ml buffer) was added to phosphate buffer 
pH7.4 (2ml) at 30°C in a spectrophotometer cuvette. An aliquot (0.25ml) of SNAP 
(0.0088g in 10ml buffer; 4mM) was added to the cuvette and the absorbance decrease 
at 339nm was measured as a function of time for the ImM cysteine/0.4mM SNAP 
solution, versus a standard cuvette containing all but the S-nitrosothiol at the same 
concentrations. The same experiment was conducted using S-methylcysteine (0.0135g 
in 10ml buffer; lOmM) substituted for cysteine with SNAP.
Both experiments were repeated using GSNO (0.0134g in 10ml buffer; 4mM) instead 
of SNAP.
Physiological testing
The same procedure was carried out as described in the experimental section of 
Chapter 2.4. Bolus injections of GSNO (0.1|iM - lOmM) were administered to the 
artery via the injection port I  (see Figure 2.5) to obtain a control dose response 
curve. L-cysteine solution (ImM) was then perfused through the artery in the internal 
Krebs buffer supply and the GSNO injections were repeated. The mean response
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amplitudes of nine experiments were obtained for each concentration and statistical 
analysis of the results was carried out.
Statistical analysis of data in figures
Statistical analysis on the data was carried out using an unpaired students t test 
* indicates data is significantly different at the P=0.05 confidence level 
** indicates data is significantly different at the P=0.01 confidence level 
*** indicates data is significantly different at the P=0,001 confidence level
5.6.3 Results and Discussion
Addition of a 20mM cysteine solution to a 20mM solution of GSNO produced a change 
in colour from pink to a red solution, with an absorption spectrum identical to that of 
S-nitrosocysteine (made by the action of acidified sodium nitrite upon cysteine). This 
effect could not be observed visually at 0.4mM concentrations of GSNO but the greatly 
enhanced rate of decomposition (monitored spectrophotometrically) of GSNO in the 
presence of cysteine was evidence that it occurred (Figure 5.13). There was no 
difference in decomposition rate for GSNO, compared with GSNO in the presence of 
ImM S-methylcysteine (Figure 5.13), implying that NO transfer can occur only if 
there is a free thiolate group. A similar effect was seen on the decomposition rate of 
SNAP on addition of cysteine (Figure 5.14). In contrast, addition of S- 
methylcysteine to SNAP caused a small decrease in the rate of NO release. This is 
consistent with the removal of adventitious metal ions in the buffer solution due to 
binding to S-methylcysteine, leaving less available to catalyse the decomposition of 
SNAP (see Chapter 3).
Transnitrosation reactions are known to be rapid (Park, 1988). Therefore, the rate- 
determining step in the cysteine catalysed decomposition of GSNO must be loss of NO 
from S-nitrosocysteine. Formally, transnitrosation may be seen as transfer of N0+ 
from GSNO to cysteine (Figure 5.15) and here the suggestion by Lipton (1993) that
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Figure 5.13 The effect of cysteine (ImM) and S-methylcysteine (ImM) on the decomposition of GSNO. GSNO (open circles, n - 6), GSNO + cysteine (closed triangles, n=4), GSNO+S-methylcysteine (black crosses, n-2). GSNO+cysteine data is significantly different from GSNO and GSNO+S-methylcysteine data atP-0.001 (***) confidence level. Conditions; 30 V, KH2P0 ^ buffer pH 7.4
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Figure 5.14 The effect of cysteine (ImM) and S-methylcysteine (ImM) on the decomposition of SNAP. SNAP (closed circles, n~9), SNAP+cysteine (open triangles, n~7), SNAP+S-methylcysteine (black crosses, n=4). SNAP+cysteine data is significantly different from SNAP and SNAP+ S-methylcysteine data at P-0.01 (**) & atP=0,00I (***) cotfidence level respectively, & SNAP data is significantly different from SNAP+ S-methylcysteine data at P=0.01 (**) confidence level. Conditions; 30 V, KH2PO4 buffer pH 7.4
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NO+, as well as NO, has a role in animal physiology, is acknowledged. However, the 
free nitrosonium ion (N0+) can never exist in an aqueous physiological environment 
due to its rapid conversion to nitrous acid.
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Figure 5J5  The transfer of NO (as NO'^) from GSNO to L-cysteine
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Figure 5 J 6  The effect o f adding cysteine (ImM) to the internal perfusate on the 
vasodilator responses to bolus injections of GSNO. GSNO (open circles, n-5-9), 
GSNOIL-cysteine (closed triangles, n=5-9). ED50 GSNO -  120pM, ED50 GSNOIL- 
cysteine = 19pM.
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The ex vivo vasodilator action of bolus injections of GSNO was enhanced when 
cysteine was allowed to perfuse through the artery via the internal Krebs buffer supply 
(Figure 5.16). The EDgg value for microinjections of GSNO was found to be 
120p-M compared with 19|J,M in the presence of 1 mM cysteine. As GSNO has only 3- 
5 seconds to react with cysteine before reaching the artery, it is reasonable to suppose 
that NO+ transfer to form a less stable thiol occurs rapidly.
5.7 SITES OF NO PRODUCTION EX VIVO BY GSNO AND SNAP
5.7.1 Introduction
S-nitrosothiols are endothelium-independent vasodilators which are susceptible to 
decomposition by a number of mechanisms. The rate of decomposition of SNAP ex 
vivo has been shown to be influenced by trace metal ion catalysis, and also by the 
presence of other thiols such as cysteine, by production of the very unstable S- 
nitrosothiol, S-nitrosocysteine. On the other hand, GSNO is more stable in solution^ 
being more resistant to trace metal ion catalysis, but its decomposition rate is affected 
by the enzymatic action of y-glutamyl transpeptidase (or other possible y-glutamyl 
cleaving enzymes) and by thiols such as cysteine.
The extent to which each of these different mechanisms cause decomposition of S- 
nitrosothiols ex vivo is difficult to ascertain quantitatively. The relative degree of NO 
production from GSNO and SNAP at different sites within or around the tissue, would 
give an indication as to which mechanisms are most important in this process. The use 
of the NO scavenger ferro-haemoglobin (Chies, 1969; Dickson & Chies, 1971; Martin 
et al., 1985) or superoxide dismutase, an enzyme which scavenges superoxide ions and 
consequently prolongs the half-life of NO, added to the internal perfusate of the rat tail 
artery preparation, should give an indication as to whether NO produced from SNAP 
and GSNO is released in solution, in the presence of the tissue, or both.
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5.7.2 Experimental
The same procedure was carried out as described in the experimental section of 
C hapter 2.4. Bolus injections of GSNO or SNAP (0.1 pM - lOmM) were 
administered to the artery via the injection port I (see Figure 2.5) to obtain a control 
dose response curve. Ferro-haemoglobin (15|iM) and superoxide dismutase (150 units 
ml“i; Sigma Chemicals) were then perfused through the artery in the internal Krebs 
buffer supply and the GSNO or SNAP injections were repeated. The meaned response 
amplitudes of experiments were obtained for each concentration and statistical analysis 
of the results was carried out.
Statistical analysis of data in figures
Statistical analysis on the data was carried out using an unpaired students t test 
* indicates data is significantly different at the P=0.05 confidence level 
** indicates data is significantly different at the P=0.01 confidence level 
*** indicates data is significantly different at the P=0.001 confidence level
Drugs: Synthetic procedures and use
SNAP <&. GSNO - 10‘^ M solutions of SNAP and GSNO were made up in Krebs buffer 
and serially diluted to the concentration required for injection immediately prior to use. 
Both S-nitrosothiols solutions were kept in the dark and on ice at all times to minimise 
their decomposition.
Ferro-haemoglobin (Mr 64500) was prepared by reduction of lOOmls of ImM bovine 
haemoglobin using lOmM sodium dithionite. The dithionite was dialysed out of 
solution against 3x2 litre volumes of deareated distilled water at 0-5°C. The stock ferro- 
haemoglobin was then split into 3ml aliquots and frozen (-10°C). Aliquots were added 
to 200ml of Krebs buffer used for the internal perfusate of the artery, immediately prior 
to perfusion, to make up the 15pM concentration required. Samples were used within 
2 weeks.
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5.7.3 Results and Discussion
Exogenous Hb, which binds NO extracellularly, has been used as a classic probe of 
NO generation in the extracellular space (Martin et al, 1985; Ignarro, 1989b). Typical 
traces showing the effect of perfusing ferro-haemoglobin (Hb, 15|liM) through the 
internal circuit, on SNAP and GSNO vasodilator responses are shown in Figures 
5.17 and 5.18 respectively. The vasodilator action of GSNO was substantially less 
affected by ferro-haemoglobin than that of SNAP (see Figures 5.19 & 5.20). 
Ferro-haemoglobin reduced the EDgg value for GSNO by a factor of only 11 whereas 
that for SNAP is reduced by a factor of 73. These results are consistent with the 
finding that SNAP is less stable than GSNO in solution and suggest that SNAP does 
not require tissue to release NO, decomposing, at least in part, in the lumen. The 
vasodilator actions of both SNAP and GSNO are only partially inhibited by 15|J,M Hb. 
This suggests that a significant percentage of each drug reaches the vascular smooth 
muscle cells before releasing NO, probably at the membrane surface (Kowaluk & 
Fung, 1990).
When rat tail artery perfused with Krebs buffer containing superoxide dismutase (SOD, 
150 units ml"l) is given a bolus injection of GSNO there is no potentiation of the 
vasodilator response (Figure 5.21). The ED50 value for GSNO of 17|aM remained 
unchanged in the presence of SOD. This observation is consistent with the view that 
GSNO does not release NO spontaneously in the lumen of the artery but requires tissue 
interaction to effect its release.
On the other hand, the vasodilator action of SNAP was slightly but significantly 
enhanced at lower concentrations by SOD (Figure 5.22). A typical trace is shown in 
Figure 5.23. This further suggests that SNAP releases NO in the lumen, where it 
can then be destroyed by superoxide. Release of NO from SNAP in the lumen could 
be due to the presence of metal ions.
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Figure 5,17 A comparison of pressure recordings of SNAP injections from typical traces 
in the presence and absence of ferro-haemoglobin (Hb,' 15pM) in the internal petjusate aftet 
precontraction with phenylephrine (PE). (SNAP Expt. hP 91/1119,4pM PE, SNAP + Hb 
Expt. NP 93/1115,3.75pM PE).
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Figure 5J8  A comparison of pressure recordings of GSNO injections from typical traces 
in the presence and absence of ferro-haemoglobin (Hb; 15pM) in the internal perfusate aftet 
precontraction with phenylephrine (PE). (GSNO Expt. N° 9314123,4pM PE; GSNO + Hb 
Expt. bP 93HH5,3.75pM PE).
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Figure 5.19 The effect of adding ferro-hemoglobin (I5jjM) to the internal petfusate on the vasodilator reponses to bolus injections of SNAP. SNAP (closed circles, n-20) SNAPIHb (open squares,n=10). ED^O = 3.2pM EDSNAPf Hb  = 230pM
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Figure 5.20 The effect of adding ferro-hemoglobin (I5pM) to the internal petfusate on the vasodilator t eponses to bolus injections of GSNO. GSNO (open circles, ti-l6) GSNOIHb (closed squares,n=8). ED^q GSNO = 59pM ED^q GSNOIHb 660pM
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Figure 5.21 The effect of adding SOD (150 unitslml) to the internal petfusate on the vasodilator response to bolus itijections of GSNO. GSNO(open circles, n=^ 5) GSNOfSOD (crossed squares,n-5)
ED^ O GSNOISOD = I7pM
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Figure 5.22 The effect of adding SOD (150 utntsiml) to the intertial petfusate on the vasodilator t'esponse to bolus itijectiotis of SNAP. SNAP (closed circles, ti-5) SNAPiSOD (crossed squares, ti~5)ED^q sn a p  = 3.2pM ED^q SNAPISOD = 1.5pM
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SNAP comparing typical vasodilator responses in the absence and presence of SOD 
(150 unitslml) in the internal petfusate (Expt. 9411111,2pM),
A  further possibility that cannot be excluded is that GSNO and SNAP enter vascular 
smooth muscle cells and activate guanylate cyclase directly. However, after treatment 
of isolated rat tail artery with ethacrynic acid, a known alkylator of thiol groups, there 
was complete inhibition of the vasodilator action of GSNO and so direct activation 
appears unlikely. Attenuation of responses to authentic' NO also occurred, but this 
was not unexpected as the activation of guanylate cyclase is critically dependent upon 
SH groups (Waldeman & Murad, 1987). This finding suggests that SB groups could 
play a major, if not essential, role in the vasodilator action of GSNO.
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A detailed study carried out by Kowaluk & Fung (1990) on the liberation of NO from 
S-nitrosothiols, found that spontaneous liberation of nitric oxide cannot account for ex 
vivo vascular relaxation by S-nitrosothiols. They found that a range of S-nitrosothiols, 
from the small unstable amino acid, S-nitrosocysteine, to the bulky and polar S-nitroso- 
coenzyme A (MW 797), had similar relaxation potencies on rat aortic rings, even 
though they released NO at different rates. This indicated that entry of intact S- 
nitrosothiols into cells is unlikely to be a requirement for activity. Furthermore, the 
polar, and probably ionised, nature of these compounds at physiological pH, makes it 
unlikely that they would traverse cell membranes readily, which supports this 
hypothesis.
Working on bovine coronary arterial smooth muscle subcellular fractions, they found 
that the tissue exhibited substantial catalytic activity for NO generation from SNAP and 
deduced that this activity might be associated with cellular membranes. This raises the 
possibility that denitrosation of S-nitrosothiols might take place at external vascular 
membranes.
Similar results were obtained by Mathews & Kerr (1993) when they found that 
glutathione and the monoethyl ester of glutathione, which has been shown to enter cells 
much more readily than glutathione, were equipotent in the rabbit aortic ring assay. 
They also showed that the stabilities of the S-nitrosothiols tested had no correlation 
with their potencies on three different test tissues, or with their ability to inhibit platelet 
aggregation in whole blood. The relative potencies were also found to be different on 
the different tissues and blood platelets. They concluded that the R group in RSNO 
determined the biological effectiveness of the S-nitrosothiol and that generation of NO 
at the cell surface, either enzymatically or nonenzymatically, was the most likely 
mechanism of RSNO activity. The differences in effectiveness are possibly due to the 
rate of NO generation at the cell surface, due to differences in the ability of different 
tissues to catalyse RSNO decomposition. Alternatively, the target cell may have a
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transport system that could allow entry of a specific RSNO into the cell making it more 
effective on that tissue than on another tissue in which it is not transported.
Comparing these findings with those of the rat tail artery experiments, in which the 
endothelium was present and intact, there is a question as to whether the endothelium 
can denitrosate S-nitrosothiols. Experiments carried out using the same model tissue 
and the same system with Roussins Black Salt, a potent NO donor drug, which was 
found to be taken up by the endothelium, demonstrated that ferro-haemoglobin 
completely abolished the response of the artery to the drug (0.5mM) by scavenging NO 
(Flitneygr a/., 1992). This suggests that any NO produced from within the endothelium 
will be scavenged by ferro-haemoglobin. Therefore, the responses seen for SNAP and 
GSNO during perfusion of the artery with ferro-haemoglobin are possibly due to 
interaction with the endothelial cells, or smooth muscle cells of the rat tail artery, in 
which NO does not become ’free'. From the work carried out by Kowaluk and Fung 
(1990) it could be hypothesised that it is the external smooth muscle membranes which 
catalyse denitrosation of SNAP and GSNO. However, as the drugs initially come into 
contact with the endothelium this may also play a role in S-nitrosothiol metabolism, 
possibly by removing NO from the drug and transferring it to smooth muscle cells 
without NO becoming free. Catalytic activity at the vascular membranes could be due 
to NO transfer to thiol containing molecules, bound, or located free on the other side of 
the membrane, which transport NO to guanylate cyclase for subsequent activation of 
the enzyme.
In summary, it would seem that SNAP can spontaneously release NO without the 
presence of tissue. Its response is not completely abolished by ferro-haemoglobin and 
a significant percentage of the drug, or 'bound NO' from interaction of SNAP with 
tissue such as the endothelium, reaches the vascular smooth muscle cells. GSNO 
seems to require tissue to be biologically active. As a vasodilator in the rat tail artery 
preparation its action is diminished, but not abolished, by ferro-haemoglobin. Its
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vasodilator effects are less diminished than those of SNAP, suggesting that a greater 
percentage of the drug or 'bound NO' produced from interaction of GSNO with tissue, 
reaches the vascular smooth muscle cells to exert its effect The diminished response in 
the presence of ferro-haemoglobin could be due to 'free' NO release due to reaction at 
the surface of endothelial cells.
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CHAPTER 6
S-NITROSOTHIOLS; 
DISAGGREGATORS 
OF PLATELETS 
AND 
INHIBITORS OF 
PLATELET AGGREGATION
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6.1 INTRODUCTION
As well as being very effective vasodilators, S-nitrosothiols have also been shown to 
be good inhibitors of platelet aggregation (see Chapter 1.12 for background). In 
vitro, S-nitrosation of molecules containing functional thiol groups leads to the 
formation of S-nitrosothiols. Although the biological significance of S-nitrosation in 
vivo is still uncertain, this reaction may result in stabilisation of the chemical and 
pharmacological properties of NO and generation of compounds with NO-donating 
properties (Stamler etal., 1992; Venturini et al., 1993). A recent study has suggested 
that NO may be released from the endothelium in the form of an S-nitrosothiol adduct 
(Myers et at., 1990). Furthermore, sulphydryl groups in proteins represent an 
abundant source of reduced thiol for interaction with NO (or, by way of its derivative 
cation, the nitrosonium ion, N0+ described in Chapter 1.9). and S-nitrosoproteins 
form readily under physiological conditions (Stamler et at., 1992).
It has recently been shown that S-nitrosoproteins such as S-nitroso albumin and S- 
nitroso-tissue type plasminogen activator, like the low-molecular-weight S-nitrosothiols 
such as GSNO (Radomski et a i, 1992), have strong antiplatelet effects with ICgo's in 
the range of 1.5)iM (Simon et aL, 1993). Furthermore it has been postulated that these 
stable adducts release and deliver NO by transfer to low-molecular-weight thiols such 
as cysteine and glutathione (Simon et ai, 1993).
All this evidence suggests that S-nitrosothiols have a possible role as thromboregulators 
controlling platelet aggregation. The subject of this study was to investigate the 
possibility that synthesised exogenous S-nitrosothiols based on penicillamine are also 
potent inhibitors of platelet aggregation. The study includes a comparison of these S- 
nitrosothiols with the platelet action of GSNO, an endogenous S-nitrosothiol, and SIN- 
1, another class of NO-donor drug which has been used as a thromboregulator. The 
pharmacological actions of SNAP and analogues of SNAP, S-nitroso-DL-penicillamine
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(SNPen) and S-nitroso-N-formyl-DL-penicillamine (SNFP; see Figure 6.1), were 
examined on human platelets in vitro. Most of the testing of these drugs was carried 
out by Radomski at the Wellcome Laboratories, although the method described below 
was used by the author in collaboration with Radomski.
NO
SNAP; R = CH3CO 
SNFP; R = CHO 
SNPen; R = H,0H
RHN
Figure 6.1 The structures of the three S-nitrosothiols based on penicillamine
6.2 THE EXPERIMENTAL METHOD USED TO EXAMINE THE 
PHARMACALOGICAL EFFECTS OF S-NITROSOTHIOLS ON 
PLATELET-RICH PLASMA (PRP) AND WASHED PLATELET (WP)
SUSPENSIONS
Two different studies were carried out to examine the effect of S-nitrosothiols on 
human platelets. Firstly, the inhibition of platelet aggregation by these compounds was 
studied and secondly the disaggregation of aggregated platelets by S-nitrosothiols was 
investigated. In both studies the experimental procedure, based on a method developed 
by Bom & Gross (1963), comprised the examination of both optical aggregation, 
following absorbance changes, and looking at ATP release from the aggregating 
platelets, using Luciferin-Luciferase (L.L) (from the fire fly) and monitoring the 
chemiluminescence produced.
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The light beam from the spectrophotometer passed through the sample cuvette 
containing a stirring solution of WP and LL and the absorbance noted. Collagen, 
added to washed platelets, or ADP added to platelet rich plasma, were used to aggregate 
the platelets. This caused a dramatic decrease in absorbance due to reduced light 
scattering by the aggregating platelets. Example traces are shown in Figure 6.2. At 
the same time, aggregation of platelets produces ATP which is monitored using its 
reaction with LL which results in chemiluminescence. Various concentrations of the S- 
nitrosothiol to be tested were injected into the cuvette prior to or after the addition of 
collagen/ADP. If the S-nitrosothiol is added after collagen, an increase in absorbance is 
seen due to dispersion of the aggregates (see Figure 6.2a). Addition of collagen to 
washed platelets, after the S-nitrosothiol, however, produced a slow decrease in 
absorbance depending on the S-nitrosothiol concentration (see Figure 6.2b). The 
chemiluminescence from LL increased with increasing aggregation (Figure 6.2d 
shows a representative trace).
6.3 EXPERIMENTAL
Platelet-rich plasma (PRP) and washed platelet suspensions (WP):
Human blood was collected and PRP and prostacyclin (PGÏ2)-washed platelet 
suspensions were prepared as described before (Radomski & Moncada, 1983).
Platelet aggregation and release of ATP
Platelet aggregation and release of ATP were measured in a platelet-ionised calcium 
lumi-aggregometer. S-nitrosothiols were incubated with WP for I min prior to the 
addition of collagen (l|ig/ml) and their effects on platelet aggregation studied for 3 
minutes. In some experiments, haemoglobin (5|iM) was added 1 min before the S- 
nitrosothiol. In other experiments the compounds (all at IjiM) were incubated for 60 
mins at 37°C.
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Platelet disaggregation
Platelet disaggregation was measured in PRP following initiation of aggregation by 
ADP (3-5}xM). S-nitrosothiols were added 1 minute after ADP and their effects studied 
for 5 mins.
Intraplatelet cyclic GMP levels
Intraplatelet cyclic GMP levels were measured in WP by enzyme immunoassay as 
described previously (Radomski et al., 1992).
i^^I-fibrinogen binding to platelets
125i_fibrinogen binding to platelets was measured as described by Marguerie et al. 
(1979) with some modifications. Washed platelets (lO^ml'l) were incubated with the 
compounds in Tyrode's solution for 15 minutes. Binding was initiated by adding 1251- 
fibrinogen (50jJ,g/ml) and ADP (50|lIM) in a final volume of 500|xl. After 15 minutes 
samples (50^1) of the reaction mixture were layered on 200|o,l of 15% sucrose solution 
and spun for 1 minute at 10,000 x g. The samples were immediately frozen in dry ice 
and the radioactivity associated with the platelet pellet counted in a yoounter.
Release o f NO from S-nitrosothiols
The release of NO from S-nitrosothiols was measured by the method described by 
Feelisch and Noack (1987). The compounds were incubated for 5 mins at 37°C with 
or without intact platelets, platelet lysate, platelet cytosol (100,000 x g for 30 mins 
prepared from 2.5 x 10  ^platelets), reduced glutathione (30|xM), ascorbic acid (30|iM) 
and superoxide dismutase (20Uml“l) and the rate of NO release was measured using a 
dual wave spectrophotometer (Shimadzu; see Chapter 4).
S-nitrosothiols:
SNAP was synthesised by the method of Field et al (1978), and SNPen and SNFP 
were synthesised according to the method of Hart (1985) as described in Chapter 2.
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Reagents
Human haemoglobin was prepared by the method of Paterson et al. (1976). Adenosine 
diphosphate (ADP), adenosine triphosphate (ATP), luciferin-luciferase reagent, 
sucrose, superoxide dismutase, Arg-Gly-Asp-Ser (Sigma), prostacyclin sodium salt 
(Wellcome), L-ascorbic acid (BDH), collagen (Hormon-Chemie), ^25i-fibrinogen 
(Amersham), cyclic GMP enzyme immunoassay (Amersham) and GMP-140 enzyme 
immunoassay (British Biotechnology) were obtained from the sources indicated. 
Solutions of NO gas were prepared as described by Palmer et al. (1987). Briefly, a 
glass bubble was filled with NO (British Oxygen) from a cylinder and sealed with 
silicone rubber injection septa. An appropriate volume was removed with a syringe and 
injected into another gas bulb filled with H2O, which had been deoxygenated by 
gassing with Helium for 1 hour, to give stock solutions of NO of 0.01-1.0% (v/v).
Statistics
Results are mean ± s.e. mean of at least 3 separate experiments. They were compared 
by analysis of variance and p<0.05 was considered as statistically significant.
6.4 RESULTS & DISCUSSION
a) Effects of RSNO on platelet aggregation, ATP release and disaggregation 
Incubation of the S-nitrosothiol derivatives of penicillamine (O.Ol-lOpM) with washed 
platelets resulted in a concentration-dependent inhibition of collagen-induced 
aggregation and ATP release from the platelets (see Figure 6.2 and Table 6.1). 
SNAP and SNFP were significantly more potent than SNPen (p<0.05, n=3-7) as 
inhibitors of platelet aggregation. However there were no significant differences found 
in the action of the three compounds in inhibiting ATP release from the platelets. The 
inhibitory activity of these compounds was reversed by haemoglobin (5|iM) (Figure 
6.2c), indicating the involvement of NO in the process. The addition of the S-
182
a
ADP
IO|iM
3|iM
O.IpM
SNFP Control
Vehicle
SNFP 
Hb I Collagen
i  i 4
SNFP
1|XM
SNFP l(iM  
+ Hb 5)iM
Control'
Collagen
SNFP I
lOflMItlM
O.lUM
0.01|lM
Control
Chemiluminescence from LJL 
due to ATP production
Increased
aggregation
decreasing 
concentration 
of S-nitrosothiol
Figure 6.2 The effects o f SNFP on platelet aggregation, a. stimulation of disaggregation 
of platelets aggregated by ADP (5pM) in PRP, b. Inhibition of collagen (Ipglmlfinduced 
aggregation in WP, c.and its reversal by haemoglobin (5pM), d. A schematic diagram 
showing the increase in chemiluminescence from LJL. due to ATP production by 
aggregating platelets as S-nitrosothiol concentration is reduced.
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nitrosothiol (0.01-10|iM) one minute after induction of platelet aggregation with ADP 
(3-5|xM) in platelet rich plasma resulted in a concentration-dependent induction of 
platelet disaggregation (Figure 6.2a and Table 6.1). The effectiveness of SNAP, 
SNFL and SNPen as inducers of disaggregation was similar. However, in most cases 
higher concentrations of S-nitrosothiols were required than for inhibition of 
aggregation.
When these three compounds are compared with the two S-nitrosothiols, GSNO and S- 
nitrosocysteine, which have been found in vivo, they collate favourably having ICso's 
of the same or similar orders of magnitude, although GSNO appears to be more 
effective over the two test methods (see Table 6.1). When compared with authentic 
NO, only SNPen seems less effective at inhibiting platelet aggregation, and all the S- 
nitrosothiols tested are far more potent (at least six fold) than the other NO-donor drug 
SIN-1 (see Table 6.1).
Compound (n=3-7)
Inhibition of CoUagen-induced aggregation
(IC50,|itM)
Inhibition of Collagen-induced release of ATP
(IC5o,^M)
Stimulation of disaggregation of platelets aggregated
by ADP (IC50,tiM)
SNAP 0.12  ± 0.02 0.18 + 0.11 1.09 ± 0.32
SNFP 0.05 ± 0.01 0.15 ±0.07 0.63 ± 0.21
SNPen 0.38 ± 0.05 0.59 ±0.13 0.25 ± 0.01
GSNO 0.12 ± 0.04 0.09 ± 0.04
SNC 0.11 ±0.05 0.75 ± 0.59
NO 0.36 + 0.10 0.30 + 0.09
SIN-1 2.16 + 0.41 3.41 ± 0.49
Table 6.1 A comparison o f the relative effectiveness at inhibiting platelet aggregation 
and disaggregating platelets of a range of S-nitrosothiols and other NO donors.
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Work carried out by M.W.Radomski
b) Cyclic GMP and I-fibrinogen binding assay
The basal levels of cyclic GMP in platelets were 131 ± 33 fmol/10^ platelets, (n=4). 
Incubation of platelets with SNAP, SNFP and SNPen (O.Ol-lOjiM) caused a 
concentration-dependent increase in intraplatelet cyclic GMP to a maximum of 1643 ± 
133, 1599 ± 123 and 1611 ± 131 fmol/lO^ platelets respectively. These values were 
not significantly different fi*om each other.
All three S-nitrosothiols caused a concentration-dependent inhibition of i^^I-fibrinogen 
binding to the platelets with an ICso's shown in Table 6.2. There was a significant 
correlation between the concentrations of S-nitrosothiol needed for half-maximal 
stimulation of intraplatelet cyclic GMP and those required for inhibition of fibrinogen 
binding (see Table 6.2).
RSNO (n=3-7) Half-maximal stimulation of intraplatelet cGMP
(EC50, |iM)
Inhibition of 
125i-fii)rinogen binding
(IC50, |iM)
Correlation between cGMP and fibrinogen binding 
(r)
SNAP 0.40 0.34 ± 0.07 0.97
SNFP 0.35 0.64 + 0.13 0 .88
SNPen 0.29 0.34 ± 0.07 0.95
Table 6,2 The correlation between cyclic GMP and fibrinogen binding in platelets for 
the S-nitrosothiols based on penicillamine.
There was good correlation between inhibition of fibrinogen binding to platelets and the 
formation of cGMP by S-nitrosothiols, at concentrations that also inhibited platelet 
aggregation and caused disaggregation. This suggests that the platelet-inhibitory 
activity of RSNO depends on cyclic GMP-mediated inhibition of fibrinogen binding to 
platelets. Similar observations have been published recently by Mendelsohn et al. 
(1990) working on S-nitroso-N-acetylcysteine.
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c) Release o f NO
When SNPen was dissolved in Tyrcde's solution, NO was released in a concentration- 
dependent manner (Table 6.3), which was detected at concentrations as low as 
0.1 |iM. However, the release of NO from SNAP and SNFF was not detected at 
concentrations lower than lOpM. The addition of platelet lysate, intact platelets, platelet 
cytosol, reduced glutathione, ascorbic acid or superoxide dismutase did not increase the 
rate of NO release from these compounds at concentrations up to 10|iM (n=3).
In the experiments testing the effects of these three S-nitrosothiols on platelets, there 
was good correlation between NO release from SNPen and the pharmacological effects 
of this S-nitrosothiol. However using the oxyhaemoglobin assay (see Chapter 4 for 
experimental details), NO release was not detected at concentrations below lOfxM, a 
concentration capable of producing both anti-platelet effects and stimulation of 
guanylate cyclase for SNAP and SNFP. Even by the addition of platelet fractions and 
reducing agents known to enhance the rate of NO release from other NO donors 
(Feelisch & Noack, 1987; Radomski et al., 1992), NO could not be detected.
RSNO 
(I4,M, n=4) SNPen
NO release (pmol/min) 
SNFP SNAP
0.01 nd nd nd
0.1 1.29 ±0.02 nd nd
1.0 52.34 ±1.23 nd nd
3.0 253.70 ±2.73 nd nd
10.0 743.00 ±5.60 2.15 ±0.02 5.15 ±0.64
Table 6,3 Release of NO from S-nitrosothiols. nd: not detectable ( < 0.1 pmollmin)
It has also been shown that release of NO from GSNO (10|xM) under the same 
conditions was very low (10 ± 10 pmol/min; Radomski et al., 1992). This rate of NO 
release was enhanced by addition of platelet lysate but not by intact platelets or cytosol.
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6.5 CONCLUSIONS
It is evident that S-nitrosothiols, as a class of NO donor drugs, are very effective at 
inhibiting platelet aggregation and at disaggregating platelets. Whether endogenously 
or exogenously produced, they are far more potent than other commercially available 
NO-donor drugs like SIN-1 and, but for a couple of exceptions, they were found to be 
more potent than NO itself.
The fact that NO could not be detected from SNAP and SNFP in the presence of 
platelets, indicates that either the release of NO from SNAP and SNFP occurs inside 
the platelet, or that this release is not a necessary prerequisite for the stimulation of the 
soluble guanylate cyclase, as the enzyme can also be stimulated directly by these 
compounds. However, the abolished inhibitory effect on platelet aggregation of the S- 
nitrosothiols by ferro-Hb, suggests that NO is the ultimate activator of soluble 
guanylate cyclase in the platelet. On the other hand, NO was found to be produced 
spontaneously from SNPen, even in the absence of platelets, and it was not found to be 
as effective as its formyl or acetyl derivatives. This might indicate that release of NO in 
the platelet is more effective than outside, and that the introduction of formyl or acetyl 
groups to the structure of S-nitroso-DL-peniciUamine leads to a chemical stabilisation of 
the resultant S-nitrosothiols without affecting their pharmacological properties as 
inhibitors of platelet function.
The results obtained by Radomski et al. (1992) which showed that NO release from 
GSNO was low but was significantly enhanced in the presence of platelet lysate, 
suggest that release of NO from GSNO may be catalysed by an enzyme present in 
platelet membranes which become activated following platelet stimulation. This theory 
is consistent with the finding by Kowaluk & Fung (1990) that an enzymatic/protein 
effect rather than spontaneous liberation of NO accounts for the relaxation of rat aortic 
rings by GSNO. Work presented in Chapter 5 showed that GSNO is susceptible to
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enzymatic decomposition by y-glutamyl transpeptidase which has been found in human 
serum (Goldberg, 1980; Rosalki, 1975), although it has not been determined as to 
whether this or a related enzyme is present in platelet lysate.
An alternative explanation is that S-nitrosothiols such as GSNO, SNFP and SNAP, 
release NO at the platelet surface to sulphydryl groups as this is a source of reduced 
thiol equivalents (Simon et al„ 1993). These authors showed that S-nitroso-bovine 
serum albumin, another stable S-nitrosothiol, was susceptible to this mechanism and 
the results discussed here are also consistent with this theory.
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CHAPTER 7
CYCLODEXTRINS; A WAY OF 
STABILISING 
S-NITROSOTHIOLS ? 
AND
A COMPARISON OF 
THE EFFECTIVENESS OF 
S-NITROSOTHIOLS 
WITH OTHER CLASSES OF 
NO-DONOR DRUGS
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7.1 CAN THE STABILITY OF SNAP BE ENHANCED BY 
P-CYCLODEXTRIN ?
7.1.1 Introduction
The main restriction on using S-nitrosothiols as a class of therapeutic agents for the 
delivery of NO is their inherent instability at physiological pH. For therapeutic 
purposes, completely stable drugs are required which can be made to act on a specific 
target site. The instability of most S-nitrosothiols means that NO will be delivered to 
many sites with little specificity for the intended target. SNAP has been shown to be a 
potent vasodilator which produces less pharmacological tolerance than GTN (Bauer & 
Fung, 1991a), but has a short half-life in solution. A paper published by Bauer & 
Fung (1991b) has claimed that SNAP can be stabilised in solution through the use of 
cyclodextrin to form a complex which was found not to affect the pharmacological 
activity of SNAP. The authors investigated the stabilising effects of a variety of 
cyclodextrins, and studied their effects on the physiological activity of SNAP on rat 
aortic rings. They found that the parent cyclodextrin, p-cyclodextrin, had the greatest 
stabilising effect. It was decided to re-investigate the proposed stabilising effects of 
cyclodextrins due to the discovery of trace metal ion catalysis following the same 
conditions used in Bauer & Fung's experiments. The rate of SNAP decomposition 
was monitored, in the presence and absence of copper (II) ions, and at different pH, to 
see if the cyclodextrin stabilisation was affected.
7.1.2 Results and Discussion
Cyclodextrins are cyclicoligosaccharides composed of 7 D-glucose units which are 
known to form inclusion compounds. They are of pharmaceutical interest primarily 
because of their ability to enhance the aqueous solubility of lipophilic compounds (Pitha 
et al., 1988), an improvement which does not require use of cosolvents or structural
modification of the molecule. Improvements in the adsorption, bioavailabüity and drug j
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dissolution rates have all been observed for selected compounds when incorporated 
with cyclodextrins (Pitha et al., 1986; Frijlink et al., 1990).
Evidence has been presented to suggest that SNAP forms an inclusion compound with 
cyclodextrins and seems to do so by a single complexation species, as a linear 
relationship was found between SNAP solubility and cyclodextrin concentration (Bauer 
& Fung, 1991b). Since inclusion complex formation protects the guest molecule from 
the surrounding media, its stability is often improved as well (Golmot et al., 1988).
Due to the discovery of trace metal ion catalysis by metals such as copper, it was 
decided to investigate whether the stabilising effect of cyclodextrin was due to the 
formation of an inclusion compound or whether the cyclodextrin, along with the vehicle 
(5% dextrose) which was used by Bauer and Fung (1991b), stabilised SNAP by 
complexing these metal ions. The use of cyclodextrin in dextrose substantially lowers 
the pH (to ~ 3.5) compared with the physiological pH of 7.4, in which most of the 
cyclodextrin-free experiments were conducted. As has been discussed in Chapter 4, 
pH plays a major role in the rate at which SNAP decomposes and may also play a role 
in the stabilising effect of P-cyclodextrin.
The effect of pH was investigated first, by comparing the decomposition rates of SNAP 
in the presence of P-cyclodextrin and 5% glucose (pH3.5) and in the presence of P- 
cyclodextiin and 5% glucose in phosphate buffer at pH 7.4. This was done by 
monitoring the change in absorbance at 339nm. The results are shown in Figures
7.1 & 7,2 respectively. As can be seen from Figure 7.1, the half-life of SNAP is 
substantially longer in the presence of 5% glucose and enhanced even more by p- 
cyclodextrin when compared with the decomposition rate of SNAP in phosphate buffer 
at pH7.4. The concentration of 1.2mM p-cyclodextrin to 0.4mM SNAP is virtually the 
same ratio of P-cyclodextrin to SNAP which was shown by Bauer & Fung (1991b) to 
stabilise SNAP. It is evident that the increasing ratio of cyclodextrin (0.4-5.0mM) to
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Time (mins)
Figure 7.1 The effect of glucose (5%) and P'Cyclodextrine ( CD ) on the decomposition rate of SNAP (OAmM) at pH 3.5, compared to that of SNAP at physiological pH (7.4). SNAP pH7.4 (closed circles), glucose pH3.5 (squares with crosses), glucose + 0.4mM CD pH 3.5 (closed diamonds), glucose + 1.2mM CD pH 3.5 (open triangles), glucose + 5.0mM CD pH 35  (black stars).
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Figure 7.2 The effect of glucose (5%) and p-cyclodextrine (CD) on the 
decomposition rate of SNAP (0.4mM) at pH 7.4. SNAP pH7.4 (closed circles), glucose pH7.4 (squares with crosses), glucose + 0.4mM CD pH 7.4 (closed diamonds), glucose + 1.2mM CD pH 7.4 (open triangles), glucose + S.OmM CD pH7.4 (black stars).
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SNAP concentration does not dramatically increase the stability of SNAP over and 
above that produced by 5% glucose. Furthermore, when the stabilising effect of p- 
cyclodextrin and glucose are examined at physiological pH (see Figure 7.2), it is 
clear that it is the difference in pH (3.5 compared to 7.4) which accounts for the 
apparent stabilising effect of these two compounds on SNAP.
Tune (mins)
Figure 73 À comparison of the stabilising effect of glucose (5%) and p-cyclodextrin 
(CD) on the decomposition rates of SNAP (OAmM) at pH 3.5 and 74. SNAP pH 3.5 
(open circles) , glucose pH 33  (closed triangles), glucose + CD pH 35  (squares with 
crosses), SNAP pH 7.4 (closed circles), glucose pH 7.4 (open triangles), glucose + 
CD pH 7.4 (diamonds with crosses).
To check whether there was a stabilising effect of glucose and cyclodextrin at pH 3.5, 
the decomposition rates of SNAP in glucose and SNAP in glucose in the presence of p- 
cyclodextrin (5mM), were compared with that of SNAP in distilled water at pH 3.5. 
These decomposition rates were also compared with those of the same constituents at 
physiological pH. The results presented in Figure 7,3 show that there was a
193
stabilising effect of glucose, which was further enhanced in the presence of 
cyclodextiin compared with SNAP in distilled water at pH 3.5. No stabilising effect 
was seen at pH 7.4.
It was decided to determine whether the stabilising effect of p-cyclodextrin at pH 3.5 
was due to binding of trace metal ions, or to formation of the inclusion complex 
postulated by Bauer and Fung (1991b). To test this theory, copper (II) ions (1- 
lOOpM) were added to solutions of SNAP/p-cyclodextrin (1.2mM) at pH 3.5. Figure
7.4 shows that the decomposition rate of SNAP in p-cyclodextrin is dramatically 
increased by copper (II) ions even at pH 3.5. This was also found to be the case at pH
7.4 (see Figure 7.5).
In conclusion, it is apparent that if an inclusion complex of SNAP is formed with 
cyclodextrin, any stabilising effect, such as that described by Bauer & Fung, is solely 
due to the pH of the vehicle solution in which it was examined. Furthermore, whether 
an inclusion compound is formed or not, trace metal ions such as copper can still 
decompose SNAP. It would seem that the slight stabilising effect of P-cyclodextrin on 
SNAP at pH 3.5 is probably due to metal ion complexation. Consequently, it is 
unlikely that cyclodextrins will be useful in delivery systems to prolong and improve 
the pharmacokinetics of S-nitrosothiols like SNAP.
7.1.3 Experimental
Kinetic Studies; Figures 7.1, 7.2 & 7.3.
P-cyclodextrin hydrate (0.1135g) was dissolved in 10ml of O.IM KH2PO4/  NaOH 
buffer or distilled water to make up 0.0IM stock solutions at pH 7.4 and 3.5 
respectively. The required concentrations of P-cyclodextrin (indicated in the figures) 
were obtained by adding different volumes (0.1-1.25ml) of the stock solutions to the 
spectrophotometer cuvette at 30°C, which contained 1.0ml of 12.5% glucose (12.5g in
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Figure 7.4 The ejfect of copper ions on the stabilising properties of 
P-cyclodextrine (l2mM} of SNAP (OAmM) at pH BA. (closed circles) 
SNAP + CD, (squares with crosses) IpM (closed diamonds) 
lOpM (open triangles) lOOpM Cu^^.
Time (mins)
Figure 7.5 The ejfect of copper ions on the stabilising properties of 
p-cyclodextrine (12mM) of SNAP (0.4mM) at pH 7.4, (closed circles) 
SNAP + CD, (squares with crosses) IpM Cu^’*', (closed diamonds) 
lOpM Cu^^, (open triangles) lOOpM
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100ml distilled water). These solutions were made up to 2.25ml in cuvettes with either 
the phosphate buffer or distilled water (depending on the pH required). After 0.25mls 
of SNAP solution (0.0088g in 10ml buffer/distilled water; 4mM) were added to the 
cuvettes, the final concentrations of SNAP, glucose and P-cyclodextrin indicated in the 
figure legends were obtained.
Kinetic Studies; Figures 7.4 & 7.5
P-cyclodextrin hydrate (0.1135g) was dissolved in 10ml of O.IM KH2PO4/ NaOH 
buffer or distilled water to make up 0.0IM stock solutions at pH 7.4 and 3.5 
respectively.
The required concentrations of P-cyclodextrin (indicated in the figures) were obtained 
by adding different volumes of the stock solutions to the spectrophotometer cuvette at 
30"C. These contained 0.25ml of copper (H) nitrate solutions (l-100|iM), obtained by 
serial dilution from a ImM stock solution (0.0242g Cu(N03)2  (Analar grade) in 100ml 
of buffer/distiUed water). These solutions were made up to 2.25ml in the cuvettes with 
either the phosphate buffer or distilled water (depending on the pH required). After 
0.25mls of SNAP solution (0.0088g in 10ml buffer/distilled water; 4mM) were added 
to the cuvettes, the final concentrations of SNAP, copper and p-cyclodextrin indicated 
in the figure legends were obtained.
7.2 A COMPARISON OF THE VASODILATOR RESPONSES OF RAT 
TAIL ARTERY PREPARATIONS TO CONTINUOUS PERFUSION OF 
SNAP, GSNO AND OTHER CLASSES OF NO-DONOR DRUG,
7.2.1 Introduction
SNAP and GSNO are both fast acting and effective vasodilators (Chapters 2 & 5). 
Here, the ex vivo vasodilator action of these S-nitrosothiols on the rat tail artery 
bioassay are compared with the vasodilator profiles of other more established NO-
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donor drugs which have been used clinically. Isosorbide-5-mononitrate (ISMN) was 
chosen as an example of one of the novel nitrate drugs used in the treatment of angina 
as it is a metabolite of isosorbide dinitrate. Comparisons were also made with sodium 
nitroprusside (SNP), a fast-acting vasodilator used clinically, to rapidly lower blood 
pressure. The structures are shown in Figure 7.6.
OH NO
NC ON
NC CN
CN
Isosorbide mononitrate 
(ISMN)
(Isosorbide dinitrate metabolite)
Sodium Nitroprusside 
(SNP)
Figure 7,6 The structures of two clinically used NO-donor drugs
In Chapter 2 the log-dose response curves of GSNO and SNAP are presented 
(Figure 2.8). Similar response profiles have been shown for sodium nitroprusside, 
administered in the same way (Megson, PhD thesis 1993). These responses are longer 
lasting but fully reversible like GSNO and SNAP. Comparatively, isosorbide 
mononitrate produced no responses from the rat tail artery, over concentration (O.lpM- 
ImM) when administered by injection (results not shown). The possible reasons for 
these observations will be discussed in this chapter. However, attention will focus on 
the administration of these drugs by continuous perfusion through the artery. As has 
been discussed previously (Chapter 2.4), administering the drug by this method 
requires much lower concentrations than by bolus injection to elicit responses of the 
same amplitude. A submaximal response produced by 7pM SNAP administered by 
perfusion was matched by a 3mM injection of SNAP. This suggests that less than 
l/400th (l/428th) of the drug concentration delivered to the artery by injection (as a
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bolus) is reaching its site of action. The main reason for administering the drugs in this 
way was to see how it would effect the response elicited by the artery, and to establish 
the vasodilator profile of S-nitrosothiols with the two previously mentioned NO-donor 
drugs.
7.2.2 Experimental
Continuous perfusion
The rat tail artery was dissected, cannulated and prepared for drug testing in the same 
way as previously described in Chapter 2. The test drugs (1ml) of concentrations 
1000 fold greater than that intended for experimentation were added to 1 litre of internal 
perfusate (Krebs buffer). The dmg solution would then pass through the tubes of the 
perfusion circuit at a flow rate of 2mlmin"l to the artery and then on to waste (it was not 
recirculated). When the experiment is complete the artery is washed out with the 
original concentration of PE/Krebs solution used to precontract the artery before the 
experiment began. After a ~30 minute wash-out period, the next drug was tested 
following the same procedure. Chapter 2.4, Figure 2.5 shows the experimental 
set up used and the point of drug addition for continuous perfusion.
Drugs used
Isosorbide-5-mononitrate was obtained from Janssen Chimica, Belgium and sodium 
nitroprusside from BDH Chemicals, Poole, England.
7.2.3 Results and Discussion
Identical concentrations of SNAP, SNP or ISMN were added to the internal perfusate 
(see Chapter 2, Figure 2.5 for the position of administration) to make up a final 
concentration of 0.73pM. The responses of the precontracted rat tail artery were 
compared for these three drugs and an example trace is plotted in Figure 7.7.
The plotted trace shows that SNAP produces the largest initial vasodilation, but that it 
recovers rapidly (-45 minutes) to its precontracted pressure during the period of
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perfusion. However, SNP produces a vasodilation (of smaller amplitude than SNAP) 
which is maintained throughout the period of SNP perfusion (- 3 hours 20 minutes). 
ISMN produces no vasodilator response at this concentration, as was expected from the 
experiments conducted previously using bolus injections.
The responses of the same artery to these NO-donor drugs are markedly different, 
indicating different modes of action. The rapid recovery to SNAP appeared to be due 
to desensitisation of the artery to the drug. Similar vasodilator profiles were seen for 
GSNO, with a rapid recovery towards the precontracted pressure of the artery (see 
Figure 7.8). As GSNO has been shown to be stable in aqueous solution the rapid 
return towards the precontracted pressure cannot be accounted for by thermal or metal­
ion catalysed decomposition of the drug en route to the tissue. In the case of the action 
of SNAP, drug degradation could explain recovery of vasodilator response during the 
perfusion period. In experiments in which the vasodilator profiles of SNAP and 
GSNO were compared (Figure 7.8), there is evidence to suggest that the different 
chemical stabilities of GSNO and SNAP have an effect on their vasodilaton when 
continuously perfused. The plotted traces show that over the sixty minute period 
examined, the artery had fully recovered to its precontracted pressure in response to 
SNAP perfusion, whereas GSNO perfusion still produced a vasodilation of -35% 
relaxation. These results are consistent with the hypothesis that the response profile 
obtained with SNAP perfusions is due, at least in part, to its degradation en route to the 
vessel. However, the profile obtained during GSNO perfusion is likely to be due to 
desensitisation (or 'tolerance') of the vessel to the drug (Needleman et al„ 1973).
The vasodilator response obtained on perfusion of SNP through vessels showed no 
signs of recovery during perfusion but fully reversed on washout. However, all 
experiments were carried out in the dark in Krebs solution buffered to pH 7.4, 
conditions under which SNP is known not to release NO in vitro (Wolf & Swinehart, 
1975; Rucki, 1977) or even ex vivo, when its effects on frog heart muscle contractility
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Figure 7 J  A comparison of the vasodilator responses of the rat tail artery 
to three NO-donor drugs (073pM) delivered by continuous perfusion. 
SNAP (closed circles), sodium nitroprusside (open diamonds) , isosorbide -5-mono-nitrate (open triangles). This is a representative trace of three
experiments. (Expt. N^ 2014192, PE 6pM).
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Figure 7.8 A comparison of the vasodilator responses of the rat tail artery to
continuous perfusion of SNAP (03pM) and GSNO (0.5pM). SNAP (closed 
circles, n=3), GSNO (open circles, n=4).
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were studied (Flitney & Kennovin, 1987). Previous experiments in this laboratory 
using bolus injection of SNP in the absence of light, have shown that SNP-induced 
relaxations are not significantly inhibited by Hb in the rat tail artery preparation 
(Megson, unpublished data). This evidence  ^along with irregularities with regard to the 
amplitude of SNP-induced relaxations and the rise in intracellular cGMP (Feelisch, 
1991a), suggests that SNP may act through mechanisms other than that mediated by 
NO.
In light of this knowledge, the response caused by SNP reported here (Figure 7.7), 
which showed no tendency to recover during the perfusion period, may also indicate a 
different mode of action when compared with both SNAP and GSNO.
ISMN, not surprisingly, in light of results using bolus injections, produces no 
relaxation of the rat tail artery from micromolar quantities of the drug administered by 
continuous perfusion. This is possibly due to the multistep nature of conversion of 
nitrates to NO which has been outlined in Chapter 1.11, requiring several enzymes 
which may not be found in the rat tail artery.
In conclusion, it is evident that prolonged exposure to S-nitrosothiols like SNAP and 
GSNO brings about tolerance or desensitisation of the artery to the drugs. What causes 
this is unknown, but it could be either the depletion of thiol groups which has been put 
forward to explain nitrate tolerance, or down-regulation of guanylate cyclase.
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8.1 CONCLUSIONS
It has been demonstrated in this thesis that S-nitrosothiols are effective NO-donating 
drugs which can elicit vasodilation and disaggregate or inhibit the aggregation of blood 
platelets. Most of this study deals with the chemical mechanisms which decompose 
SNAP and GSNO in aqueous solution and ex vivo, and may contribute to the 
biological effects of these two S-nitrosothiols.
It is evident from the work presented that they are both endothelium-independent, fast- 
acting, and effective vasodilators of the perfused rat tail artery, and decompose to form 
their disulphide and NO (leading to nitrite) in aqueous solution (Chapters 2 & 5). 
GSNO was found to be significantly more stable than SNAP at physiological pH.
In Chapter 3 evidence is put forward to suggest that trace metal ions, such as 
copper(II), present in buffer solutions, are largely responsible for the difference in 
stabilities of these two S-nitrosothiols. This may also be the case in plasma. It is 
postulated that a six-membered ring intermediate (see Figure 3.10) containing a 
copper(II) ion is the most favourable conformation to elicit copper ion catalysis of the 
decomposition of small S-nitrosothiols like SNPen and SNC. Changing the structure 
of these S-nitrosothiols, by, for example, N-acetylation, removal of favourable ligand 
groups such as amines or carboxylates, or increasing the chain length between the two 
ligand binding sites (Askew & Bamet et ai, 1994 in prep) stabilises the S-nitrosothiol 
by reduction or inhibition of the formation of this six membered ring intermediate. This 
theory is supported by the finding that SNAP and SNAC show increased stability 
compared with their analogues SNPen and SNC (Chapter 2). GSNO was found to 
be very resistant to metal ion catalysis possibly due to its increased number of possible 
copper binding sites (i.e. two carboxylates, an amine group and amide linkages) 
removed from the S-nitroso moiety.
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The exact mechanism by which copper catalyses the decomposition of SNAP and other 
S-nitrosothiols (RSNO) is not fully understood, but evidence is presented to suggest 
spontaneous break up of the ring 'intermediate' with the production of NO, the thiol 
radical (RS ), which forms the disulphide (RSSR), and free copper(II).
In Chapter 4 other chemical mechanisms which bring about SNAP decomposition are 
discussed. Evidence is presented to suggest that thermal and photochemical 
decomposition of SNAP are possible. The thermal decomposition of SNAP was found 
to be enhanced by the presence of trace metal ions. pH was also shown to have a large 
effect on the stability of S-nitrosothiols. It is deduced that the effect of pH, which at 
physiological pH (7.4) produces the fastest rate of SNAP decomposition, but stabilises 
the S-nitrosothiol under acid or alkaline conditions, is probably related to the metal ion 
catalysed process. The relative solvated form of the metal (copper) ions or the 
protonation state of the ligands, possibly contribute to reduced coordination under alkali 
or acid conditions.
Results presented in Chapter 5 indicate that copper can reduce the vasodilator action 
of SNAP on the perfused rat tail artery over time, suggesting that the removal of NO 
from the S-nitrosothiol and subsequent oxidation and reaction to form nitrite is the 
cause. Further work on the vasodilator action of SNAP elicited in the rat tail artery 
found no evidence for enzymatic decomposition of the compound, as no significant 
differences were found for the responses of D, L, and DL SNAP. However, chemical 
evidence suggests that SNAP can transnitrosate with other thiol containing compounds 
like cysteine. This supports the theory that transnitrosation may play a role in the 
vasodilator action of SNAP, as it can still elicit a response in the rat tail artery even in 
the presence of ferro-haemoglobin. The same process is possible for GSNO which is 
shown to elicit a significantly increased vasodilator response in the same bioassay when 
injected in the presence of cysteine. Chemical evidence demonstrates that this is due to 
the formation of the significantly more unstable S-nitrosothiol, SNC, by NO-transfer
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from GSNO. As GSNO is far more resistant to copper ion catalysis than SNAP it does 
not readily decompose in buffer solutions which contain the metal. However, the 
enzyme y-glutamyl transpeptidase (y-GT) was shown to decompose the nitrosated 
tripeptide. Evidence is presented to suggest that this decomposition results in the 
formation of an S-nitrosothiol, S-nitrosocysteinylglycine, which would be expected to 
be far more susceptible to metal (copper) ion catalysis and therefore readily produce 
NO. As this enzyme has been found to be present in numerous tissue types (Rosalki, 
1975; Goldberg, 1980) it could present a viable mechanism which would elicit release 
of NO from GSNO.
In Chapter 6 it is shown that these S-nitrosothiols are very effective at modulating the 
behaviour of platelets, by inhibiting their aggregation or disaggregating aggregated 
platelets. As a class of NO-donor drugs, S-nitrosothiols are far more effective than 
other classes of NO-donor drugs, such as the molsidomines (SIN-1), which have been 
reported as effective inhibitors of platelet aggregation (Wautier et al„ 1989). In fact, 
they were found to be equally effective, or even more effective, than 'authentic' NO. 
SNAP and SNFP were found to be more effective than SNPen and yet the production 
of NO was not detected from these two S-nitrosothiols, unlike SNPen. However, the 
effect of ferro-haemoglobin which induced aggregation, even in the presence of SNAP 
and SNFP, suggested that NO was ultimately released, probably within the platelet or 
to sulphydryl groups on the platelet surface (Simon & Stamler et al., 1993). It seems 
that NO released from the S-nitrosothiol in ways similar to these, is more effective than 
spontaneous release of NO outside the platelet, at modulating their behaviour. 
Evidence recently presented has shown that the effective inhibition of platelet 
aggregation by GSNO is enhanced by platelet lysate, suggesting that NO production 
from GSNO is catalysed by the platelet membranes (Radomski et al., 1992). From 
work presented in this thesis and the fact that y-GT is present in human serum (Rosalki, 
1975; Goldberg, 1980), this enzyme, or a related enzyme could be a possible candidate 
for catalysing GSNO decomposition.
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The final chapter investigates the possibility of stabilising these relatively unstable NO- 
donor drugs with cyclodextrins, as a follow up study to one recently done by Bauer 
and Fung, (1991b). This class of compounds has been used to improve the 
pharmacokinetic profiles of other classes of drugs by improving their stability and 
delivery (Pitha et al., 1986; Frijlink et al., 1990). In the experiments carried out it was 
found that there was no enhanced stabilisation of SNAP, and that copper could still 
catalyse its decomposition.
As a class of NO-donor drugs, S-nitrosothiols like SNAP and GSNO were shown to 
be more instantly effective and as fast acting as SNP in the perfused rat tail artery 
bioassay, although their effects were short lived in comparison (Chapter 7).
The findings presented in this thesis are an attempt to understand the mechanisms 
underlying the chemical and physiological properties possessed by the S-nitrosothiols, 
SNAP and GSNO. It can be concluded that although SNAP and GSNO, like other S- 
nitrosothiols, undergo decomposition by similar mechanisms, such as by thermal and 
photochemical means, they are also susceptible to decomposition by NO-transfer 
(transnitrosation) to thiol groups such as cysteine. Furthermore, they can be 
decomposed by different, specific mechanisms. SNAP is very susceptible to copper 
ion catalysis whereas GSNO is not, but GSNO is decomposed by the enzyme y-GT. 
These differences may play a part in explaining their different biological effectiveness 
as vasodilators and modulators of platelet behaviour.
8.2 SCOPE FOR FURTHER WORK
Due to the broad field of study undertaken and reported in this thesis there are many 
areas of work which can be further researched. Some of these are categorised into 
different subjects and discussed below.
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Chem istry
1) Having investigated the effects of Cu(II) ions on the decomposition rates of SNAP 
and GSNO, further investigation of the general mechanism by which this metal brings 
about release of NO from S-nitrosothiols can be undertaken. By synthesising analogues 
of these S-nitrosothiols and varying ligands in close proximity to, or distant from, the 
S-nitroso moiety the effects on metal binding can be compared.
2) Initial results presented in Chapter 2 show that Fe(II) ions also have a dramatic 
effect on the stability of SNAP and presumably other S-nitrosothiols. As iron is 
present in larger concentrations than copper in vivo, a full study on the effect of Fe(II) 
ion on S-nitrosothiols is needed, and a comparison with copper using the same model 
S-nitrosothiols may give an insight into whether the mechanisms by which they act are 
the same.
3) The recent purchase of an NO electrode will allow the study of the decomposition of 
S-nitrosothiols by spectrophotometric techniques, to be supplemented with the 
monitoring of NO production from these compounds. This instrument could be used to 
re-examine the effects of thermal decomposition and pH on S-nitrosothiol 
decomposition and to conduct an in depth study of the photochemical decomposition of 
this class of compounds.
4) The discovery of trace metal ion catalysis, and the subsequent study of the effect of 
copper(II) on different S-nitrosothiols conducted by this laboratory and the Durham 
group, has resulted in the identification of factors which make S-nitrosothiols 
susceptible or resistant to decomposition. The synthesis of di- and tripeptides, which 
have alternative metal ion binding sites away from the S-nitroso moiety, would produce 
more robust S-nitrosothiols which may have improved pharmacokinetic profiles when 
biologically tested. If these peptides incorporate a y-glutamyl group in the structure, 
particularly if it is situated next to the thiol containing amino acid which is nitrosated.
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then t^ '^^ re is the possibility of improved targeting of the S-nitrosothiol to y-glutamyl 
transpeptidases. The resultant cleavage of the y-glutamyl group would leave an S- 
nitrosothiol with a terminal amino acid containing the S-nitroso moiety, susceptible to 
metal ion catalysis. If it is proved that y-GT or a related enzyme is responsible for the 
catalytic decomposition of GSNO in platelet lysate (Radomski et al., 1992; see later for 
experimental determination), then this may present a way to improve and increase 
specificity for the action of this class of NO-donor drugs as modulators of platelet 
behaviour.
5) As all the work conducted and presented in this thesis deals with the decomposition 
rates of S-nitrosothiols like SNAP and GSNO in physiological buffer, the natural 
progression would be to monitor the decomposition of S-nitrosothiols in human blood 
plasma. This would give a better insight into how robust this class of drugs are likely 
to be in the in vivo situation, and whether they are still susceptible to copper catalysis in 
this more complex media.
6) The effect on S-nitrosothiol stability of iron-sulphur clusters in enzymes and proteins 
which are contained in many tissue types, has not been investigated. An initial study 
using model iron-sulphur clusters with a range of S-nitrosothiols, would enable us to 
determine whether this class of compounds has a role to play in S-nitrosothiol 
metabolism and whether a more detailed study is required.
Physiology and Biochemistry
7) It has been shown that GSNO is rapidly decomposed by y-GT (this thesis), and that 
the release of NO from the S-nitrosothiol is significantly enhanced in the presence of 
platelet lysate (Radomski et al., 1992). Therefore, it is necessary to verify whether, or 
not, platelet lysate contains y-GT or a related enzyme and whether this is responsible, at 
least in part, for the release of NO from GSNO. It has been shown that the most
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effective and sensitive method for determining the activity of y-GT in serum or plasma, 
is by the use of y-glutamyl-p-nitroanilide as a substrate, together with glycylglycine as 
the acceptor (Dimov & Kulhanek, 1967). Using this method on platelet lysate would 
prove if a y-GT-type mechanism and therefore y-GT or a related enzyme is present. In 
addition, biochemical techniques such as electrophoresis could be used to separate the 
protein components of the platelet lysate. These could be assayed for activity of y-GT 
enzymes already known, selected marker enzymes such as cytochrome C oxidase, 
NADPH-cytochrome C reductase and others.
7) The use of a more specific alkylating agent than ethacrynic acid for modification of 
thiol groups (protein-bound or free) would give a better insight as to whether NO- 
transfer between S-nitrosothiols like SNAP and GSNO, to thiol containing molecules 
in tissue, plays an essential role in the biological activity of these drugs as vasodilators 
or modulators of platelet behaviour. The blocking of specific thiol groups would 
eliminate or support the relevant thiol containing compound as being involved, 
depending on the biological response. In addition, the use of Ellmans reagent (5,5'- 
dithiobis(2-nitrobenzoic acid), DTNB; Ellman, 1959), can be used to detect the 
concentration of reduced thiol present before and after treatment with an alkylating 
agent by a colourimetric assay. Its only draw back is that it is not specific for 
individual thiols. However, if the thiol is protein bound, methods published by 
Kowaluk et al. (1992) and Kowaluk & Fung, (1990) should allow the determination 
of the site and weight of the protein involved to be determined. Likewise, these 
methods could also be used to determine any catalytic activity existing in vascular 
smooth muscle or endothelial cells, which would bring about decomposition of S- 
nitrosothiols like SNAP and GSNO.
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APPENDIX TO FIGURE 2.7
Below are the peak amplitude (% Active pressure) of responses to lOp.1 injections of
SNAP& GSNO 
SNAP
Expt No lO-^M 1 0 -6 m 10-5m 10-4m 10-3M 1 0 -2 m
91/11/4 7.9 16.0 36.7 43,7 48.2 54.1
91/11/5 8.8 38.8 59.8 61.6 70.0 68.3
91/11/9 0 .0 41.3 53.4 60.4 62.5
91/11/14 5.2 33.7 58.8 65.6 72.0 72.0
93/1/12 2.9 9.5 49.1 57.5 57.2
93/1/131 2.9 6.8 39.6 65.4 74.5
93/1/13Ü 4.1 13.7 34.0 47.0 58.1
93/1/19 9.9 12.3 64.6 64.7 73.5 70.5
93/4/231 0.0 7.1 32.9 55.2 63.3
93/4/23Ü 0.0 7.1 23.6 45.3 54.3
93/4/23iü 0.0 8.6 32.4 46.8 50.4
93/4/23iv 0.0 3,8 22.6 41.5 50.9
93/12/lOi 6.5 10.1 37.4 52.5 59.8 69.3
93/12/1 Oil 4.6 41.4 53.5 65.0 68.9 79.5
94/1/121 3.8 25.8 43.3 49.7 57.9 65.1
94/1/12Ü 4.1 32.2 52.8 57.6 64.1
94/l/12iii 4.2 16.4 40.8 55.8
94/1/131 4.0 32.7 58.1 68.5 76.9 74.4
94/1/13Ü 0 34.9 55.1 60.0 68.0 71.8
94/l/13iii 2.8 9.6 26.0 34.9 36.7 37.2
MEAN 3.6 19.0 43.1 54.6 61.3 65 .9
S .E . 0 .7 2 .9 2 .8 2 .1 2 .4 3 .5
II
GSNO
* = statistically significant from SNAP responses above at P=0.05 confidence level 
*** = statistically significant from SNAP responses above at P=0.001 confidence level
Expt No 10-7m io -6m 10“5m 10-4M 10-3M 10-2m
93/4/231 0.0 0 .0 6.9 26.5 58.7
93/4/23Ü 0 .0 0 .0 5.0 24.4 56.3
93/4/23iii 0 .0 2 .6 4.7 30.5 65.2
93/4/23iv 0,0 0 .0 4.2 26.3 48.7
93/5/271 2.9 5.4 27.0 47.2 64.0
93/5/2711 1.5 3.4 17.9 63.0 64.0
93/5/27iii 3.6 6.4 26.6 50.0 64.0
93/11/511 0.0 3.6 14.9 47.0 61.9
93/ll/5in 33.3 44.9 45.9 45.8 59.2
93/ll/5iv 10.8 14.4 20.6 28.4 68.4
93/11/4Ü 17.6 30.3 49.1 62.2
93/11/4/iii 5.0 23.4 46.7 59.6
93/12/9/ii 3.4 23.3 33.3 62.8 64.7
93/12/9/iii 2.8 7.5 24.0 80.9
93/12/9/iv 6.7 12.8 39.1 60.4 68.9
93/12/711 38.6 59.1
93/12/7in 37.2 64.0
94/1/12 24.4 61.8
MEAN 5.2 7.7* 18.1*** 37.9*** 6 1 .5 6 6 .6
'SE 3.3 2 .9 3 .1 2 .7 1 .4 3 .2
III
APPENDIX TO FIGURE 5.6
Below are the peak amplitude (% Active pressure) of responses to 10)11 injections of 
DL-SNAP, D-SNAP & L-SNAP on the same arteries
DL-SNAP
Expt No lO-^M lO-^M 10-5m 10-4m 10-3m 10-2M
91/11/9 0 38.8 41.3 53.4 60.4 62.5
91/1/13 4.1 13.7 34.0 47.0 58.1
93/1/141 5.2 33.7 58.8 65.6 72.0 72.0
93/1/14Ü 2.9 6.8 39.6 65.4 74.5
93/1/19 9.9 12.3 64.6 64.7 73.5 70.5
MEAN 4.4 21 .1 47 .7 59.2 67 .7 68 .3
SE 1.6 6 .4 5 .9 3 .8 3 .5 2 .9
D-SNAP
Expt No 10-7m lO-^M 10-5m 10-4m 10-3M 10-%M
91/11/9 4.2 11.9 37.1 41.3 61.5 62.0
91/1/13 2.7 50.1 67.8 72.2
93/1/141 3.7 38.3 71.7 76.8 77.0 58.9
93/1/1411 1.0 6.7 76.3 75.7 91.7
93/1/19 3.7 8.2 59.8 72.9 66.1 65.1
MEAN 3 .3 2 3 .0 62.5 6 7 .8 6 8 .2 63 .6
SE 1.2 8 .9 6 .9 6 .7 4 .6 1 .6
IV
L-SNAP
Expt No 10-7m lO-^M 10-SM 10“4m 10-3m 10“2m
91/11/9 5.7 13.4 35.4 54.4 56.2 57.2
91/1/13 3.1 19.6 66.6 73.0
93/l/14i 1.3 57.3 73.8 74.5 78.3
93/1/14Ü 0 .0 27.2 51.4 61.5
93/1/19 6.5 26.0 44.0 73.4 67.0 73.0
MEAN 3.3 28 .7 54 .2 67.4 6 7 .2 65
SE 1.2 7 .6 7 .1 4 .0 6 .8 7 .9
APPENDIX TO FIGURE 5.16
Below are the peak amplitude (% Active pressure) of responses to lOp-l injections of 
GSNO and GSNO with Cysteine (ImM) continuously perfusing through the internal 
perfusate. Experiments were conducted on the same arteries.
GSNO
Expt No lO-^M 10-^M 10-5m 10-4M 10-3M 10-2M
93/4/231 0 .0 0 .0 6.9 26.5 58.7
93/4/2311 0 .0 0 .0 5.0 24.4 56.3
93/4/23111 0 .0 2 .6 4.7 30.5 65.2
93/4/231V 0 .0 0 .0 4.2 26.3 48.7
93/12/91 0.0 3.4 23.3 33.3 62.8 64.7
93/12/911 0 .0 2.8 7.5 24.0 80.9
93/12/9111 0.0 6.7 12.8 39.1 60.4 68.9
93/12/71 38.6 59.1
93/12/711 37.2 64.0
MEAN 0 .0 2 .2 9 .2 31 .5 5 8 .7 6 7 .5
S .E . 0 .0 0 .9 2 .6 2 .3 2 .4 3 .7
GSNO in the presence of Cysteine
* = statistically significant from GSNO responses above at P=0.05 confidence level 
*** = statistically significant from GSNO responses above at P=0.001 confidence level
Expt No lO-^M Io-<5m 10-5m 10-4m 10-3m 10“2m
93/4/231 6 .0 8.3 22.2 42.3 56.3
93/4/2311 0 .0 6 .6 9.6 64.6 74.1
93/4/23111 2.9 6.0 18.9 57.8 60.5
93/4/231V 0 .0 0 .0 11.6 54.5 66.9
93/12/91 3.9 10.0 50,0 53.3 63.0 64.5
93/12/911 0.5 6 .2 11.9 56.2 60.4 73.0
93/12/9111 2 .2 6.4 21.0 55.6 76.6 69.1
93/12/71 72.0 71.7
93/12/711 62.6 71.0
MEAN 2 .2 6.2* 20.7 57.7*** 6 5 .4 6 9 .9
S .E . 0 .9 1 .4 5 .2 2 .8 2 .8 1 .5
VI
APPENDIX TO FIGURE 5.19
Below are the peak amplitude (% Active pressure) of responses to lOpl injections of 
SNAP and SNAP with ferro-haemoglobin (15|xM) continuously perfusing through the 
internal perfusate.Control experiments were not significantly different to the results 
presented in the appendix for Figure 2.7.
SNAP in the presence of Hb
** = statistically significant from SNAP responses (Fig 2.7) at P=0.005 confidence level 
*** = statistically significant from SNAP responses (Fig 2.7) at P=0.001 confidence level
Expt No lO-^M 1 0"6 m 10-5m 10-4m 10-3m io -2 m
93/1/12 0 .0 0 .0 3.3 23.7 64.9 64.8
93/1/13Ü 0 .0 1.7 22.7 45.4 50.0
93/1/141 13.6 33.8 66.7 62.5
93/11/5111 0 .0 6.8 0 .0 12.2 40.8 55.4
93/11/51V 6.7 4.8 6.1 26.3 45.8 51.3
93/11/4Ü 14.0 9.9 44.0 54.5
93/ll/4iv 7.7 6.5 27.6 52.0 57.3
93/12/9Ü 3.2 10.6 11.7 20 .0 35.9
93/12/9iii 1.8 8.0 2.5 13.8 43.1
93/12/9ÎV 2.7 11.7 33.6 46.0
MEAN 1.7 4.1** 6 .6 *** 18.2*** 42.7*** 52.1**
S .E . 1.7 1 .2 1.5 1.5 5 .4 2 . 8
VII
APPENDIX TO FIGURE 5.20
Below are the peak amplitude (% Active pressure) of responses to 10|xl injections of 
GSNO and GSNO with feiTo-haemoglobin (15pM) continuously perfusing through the 
internal perfusate.Control experiments were not significantly different to the results 
presented in the appendix for Figure 2.7.
GSNO in the presence of Hb
** = statistically significant from GSNO responses (Fig 2.7) at P=0.005 confidence level 
*** = statistically significant from GSNO responses (Fig 2.7) at P=0.001 confidence level
Expt No lO-^M I0-<5m lO-^M 10“4m 10-3m 1 0 -2 m
93/11/5Ü 0 .0 3.8 5.1 6.3
93/ll/5iii 5.0 4.4 9.9 17.1 29.1 64.7
93/ll/5iv 7.5 3.6 14.9 11.9 34.2 64.9
93/11/4Ü 9.7 3.3 10.9 37.2 60.7
93/ll/4iv 2.8 0 .0 13.1 48.9 58.6
93/12/9Ü 4.2 2 ,0 10.1 14.4 35.2
93/12/9iii 3.2 3.2 8.2 11.1 26.1
93/12/9iv 0 .0 3.4 14.2 27.4 46.2
MEAN 4.2 4 .0 5.2** 11.5*** 28.9*** 52.6
S .E . 2 .2 1 .0 1.7 1 .2 4 .9 5 .3
VIII
APPENDIX TO FIGURE 5.21
Below are the peak amplitude (% Active pressure) of responses to lOfXl injections of 
GSNO and GSNO with SOD (150 units/ml) continuously perfusing through the internal
perfusate.
GSNO
Expt No lO-^M 10-^M lO-SM 10-4m 10-3m lO-^M
93/11/5Ü 0.0 3.6 14.9 47.0 61.0 68.9
93/ll/5iv 10.8 14.4 20.6 28.4 68.4 81.4
93/11/41 5.4 17.6 30.3 49.1 62.2 58.1
93/11/4Ü 1.0 5.0 23.4 46.7 59.6 60.0
94/1/12 9.4 62.3 61.8
MEAN 5.3 10.2 22 .3 39.1 6 2 .3 6 6 .8
S .E . 2 .2 3 .4 3 .2 5 .2 1 .3 3 .8
GSNO in the presence of SOD
Expt No 10-7m lO-^M lO-SM 10-4m 10-3M 10-2M
93/11/5Ü 7.9 11.3 29.8 52.2 61.9
93/ll/5iii 6.4 14.7 25.0 44.8 53.7
93/ll/5iv 15.7 21.6 21.1 36.1 55.3
93/11/41 7.0 13.2 30.8 54.5 66 .2
93/11/411 2.0 5.2 18.9 44.0 57.1
93/10/12111 1.6 57.5
93/10/121V 9.2 66 .2
94/1/1211 3.7 27.4 36.6 58.5
MEAN 6.7 13.2 25.5 44 .7 5 8 .8 6 0 .7
S .E . 1.6 2 .7 1 .9 3 .1 2 .3 2 .7
IX
APPENDIX TO FIGURE 5.22
Below are the peak amplitude (% Active pressure) of responses to lOpi injections of 
SNAP and SNAP with SOD (150 units/ml) continuously perfusing through the internal 
perfusate.Control experiments were not significantly different to the results presented in the
appendix for Figure 2.7.
SNAP in the presence of SOD
** = statistically significant from SNAP responses (Fig 2.7) at P=0.005 confidence level
Expt No 10-7m lO-^M 10-5m 10-4M 10-3m 1 0 -2 m
93/12/lOüi 3.9 21.4 41.3 54.0 62.2 62.7
93/12/lOiv 11.7 18.0 48.8 70.0 70.5
94/1/12Ü 8.4 27.8 47.4 54.9 60.2 64.3
94/l/12iii 11.6 29.5 40.6 49.4 60.4 65.9
94/l/12iv 14.5 35.6 51.8 60.4 68.3 69.5
MEAN 1 0 26.4 46.0 54.7 64 .2 6 6 .6
S .E . 2 .3 3 .1 2 .2 2.3 2 .1 1.5
X
APPENDICES TO CONTINUOUS PERFUSION GRAPH-FIGURE 7.8
Below are the peak amplitude (% Active pressure) of the responses of the artery to SNAP 
and GSNO at timed intervals (mins) from continuous perfusion of the artery with 0.5pM of
the dnag through the internal perfusate.
SNAP
TIME
(mins)
Expt No
92/5/71
Expt No
92/5/7Ü
Expt No
92/5/7iii
MEAN S .E .
0 0,0 0 .0 0 .0 0 .0 0 .0
1 13.2 17.6 12.8 14.5 1 .5
2 52.9 47.2 41.6 47 .2 3 .3
3 64.5 59.1 56.8 60 .1 2 .3
4 70.2 63.0 62.4 65 .2 2 .5
5 72.9 63.8 64.0 6 6 .9 3 .0
11 69.8 59.9 59.6 63.1 3 .4
19 63.6 51.0 44.0 5 2 .9 5 .7
37 41.3 31.0 15.6 29 .3 7 .5
47 20.7 23.9 0 .0 14.9 7 .5
59 2.1 17.1 0 .0 6 .4 5 .4
67 0.0 13.2 0 .0 4 .4 4 .4
XI
GSNO
TIME
(mins)
Expt No
93/5/5i
Expt No
93/5/5Ü
Expt No
93/5/5iü
Expt No 
93/5/5ÎV
MEAN S .E .
0 0.0 0.0 0.0 0.0 0 .0 0 .0
1 46.9 4.4 4.1 4.2 1 4 .9 10.7
2 70.3 45.7 26.0 26.3 4 2 .1 10.5
3 76.5 61.9 35.7 43.7 5 4 .5 9 .2
4 79.0 61.9 44.9 47.1 5 8 .2 7 .9
10 80.2 68.6 52.0 51.1 6 3 .0 7 .0
15 75.9 61.4 42.9 46.1 5 6 .6 7 .6
20 72.8 56.6 35.2 41.7 5 1 .6 8 .4
30 67.0 51.0 27.6 34.7 4 5 .1 8 .8
40 62.0 45.7 25.0 33.7 4 1 .6 8 .0
50 61.1 41.0 23.5 31.0 3 9 .2 8 .2
60 59.9 27.6 20.4 29.3 3 4 .3 8 .7
65 59.3 21.9 18.6 28.3 3 2 .0 9 .3
XII
